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ABSTRACT OF DISSERTATION 
 
 
NANOCRYSTALS OF CHEMOTHERAPEUTIC AGENTS FOR CANCER 
THERANOSTICS: DEVELOPMENT AND IN VITRO AND IN VIVO EVALUATION 
 
The majority of pharmacologically active chemotherapeutics are poorly water soluble. 
Solubilization enhancement by the utilization of organic solvents often leads to adverse 
side effects. Nanoparticle-based cancer therapy, which is passively targeted to the tumor 
tissue via the enhanced permeation and retention effect, has been vastly developed in 
recent years. Nanocrystals, which exist as crystalline and carry nearly 100% drug 
loading, has been explored for delivering antineoplastic agents. Additionally, the hybrid 
nanocrystal concept offers a novel and simple way to integrate imaging agents into the 
drug crystals, enabling the achievement of theranostics. The overall objective of this 
dissertation is to formulate both pure and hybrid nanocrystals, evaluate their performance 
in vitro and in vivo, and investigate the extent of tissue distribution and tumor 
accumulation in a murine model. Pure and hybrid nanocrystals of several model drugs, 
including paclitaxel (PTX), camptothecin, and ZSTK474, were precipitated by the anti-
solvent method in the absence of stabilizer, and their size was further minimized by 
homogenization. The nanocrystals of PTX, which is the focus of the study, had particle 
size of approximately 200 nm and close-to-neutral surface charge. Depending on the cell 
type, PTX nanocrystals exerted different level of cytotoxicity. In human colon and breast 
cancer xenograft models, nanocrystals yielded similar efficacy as the conventional 
formulation, Taxol, at a dose of 20 mg/kg, yet induced a reduced toxicity. Biodistribution 
study revealed that 3H-PTX nanocrystals were sequestered rapidly by the macrophages 
upon intravenous injection. Yet, apparent toxicity was not observed even after four 
weekly injections. The sequestered nanocrystals were postulated to be released slowly 
into the blood circulation and reached the tumor. Tritium-labeled-taxol, in contrast, was 
distributed extensively to all the major organs, inducing systemic toxicity as observed in 
significant body weight loss. The biodistribution results obtained from radioactive 
analysis and whole-body optical imaging was compared. To some degree, the correlation 
was present, but divergence in the quantitative result, due to nanocrystal integrity and 
limitations associated with the optical modality, existed. Despite their promising 
properties, nanocrystal suspensions must be securely stabilized by stealth polymers in 
order to minimize opsonization, extend blood-circulation time, and efficiently target the 
tumor.  
 
KEYWORDS: nanocrystals, theranostics, poorly water soluble, drug delivery, 
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Chapter 1 - Introduction 
 
1.1.  Current Cancer Therapy and Nanomedicine 
Cancer remains as a leading cause of death worldwide, and the incidence of cancer 
increases every year. Surgical removal is often limited to solid tumors that are confined 
in a limited area. Chemotherapy and some extent of radiotherapy then play important 
roles in inhibiting the growth of residual or metastasized cancer cells and tissues.    
Unfortunately, large proportions of pharmacologically active antineoplastic agents 
emerging from high-throughput drug screening initiatives are poorly water soluble. With 
the current delivery paradigm focusing on solubilizing drug substances prior to the 
intravenous administration, organic solvents and co-solvents are commonly used to assist 
solubilization of an anticancer drug. For instance, Taxol® uses the combination of 
Cremophor EL and ethanol to solubilize paclitaxel, a first-line anticancer drug  [2].  This 
common practice of injecting solubilized drugs in organic solvents or aqueous co-
solvents can potentially yield adverse effects due to the following reasons: (a) the 
inherent toxicity associated with the delivery vehicle (e.g. hypersensitivity reactions, 
nephrotoxicity, neurotoxicity, and neutropenia [3, 4] due to Cremophor); and (b) 
additional toxicities that arise due to the lack of tumor selectivity, which can heavily 
affect the rapidly-growing healthy tissues.  
In an effort to minimize the toxicity, chemotherapeutics have been encapsulated in 
nanovehicles with the intention of increasing the tumor-targeting efficiency. Nano-size 
particles are particularly aimed to take advantage of the enhanced permeation and 
retention (EPR) effect [5-7], which refers to the poorly constructed blood vessels and 
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ineffective drainage of the lymphatic system in solid tumors. Due to their rapid growth, 
tumor vessels are discontinuous, exhibiting abnormal organization, and hierarchical 
branching patterns [8, 9] relative to normal vascular networks. As a result, tumor vessels 
are “leakier”, with relatively slow blood flow. In addition, the lymphatic drainage from 
tumors becomes ineffective as the tumor size increases. This combination of the leakiness 
of tumor vasculature and low clearance from the interstitial space of tumor tissue is 
known as the EPR effect [5-7]. Due to their small size, nanoconstructs can passively 
extravasate into solid tumors through the gaps between the endothelial cells of the 
underdeveloped tumor vasculature (“passive targeting”). More recently, studies have 
shown that as the disease progressed, some receptors or endothelial markers are over-
expressed on the surface of tumor cells [10]. This finding has led to an alternative 
approach of “active targeting”, where the delivery systems are decorated with ligands that 
can specifically bind to the overexpressed receptors. Though the necessity for ligand 
attachment is still controversial, previous studies have shown that the presence of tumor-
targeting ligand does not always result in an increase in tumor accumulation [11-13]. 
These findings suggested that active targeting does not necessarily translate into effective 
delivery to the entire tumor.  
A vast number of drug delivery nanosystems, including liposomes [14, 15], micelles [16], 
solid lipid nanoparticles [17, 18], polymeric nanoparticles [19, 20], and dendrimers [21], 
have been developed in the past decades.  Increasing number of nanoformulations are 
being evaluated in clinical trials, and some have been approved by the U.S. Food and 
Drug Administration (FDA). The current marketed nanomedicines for cancer therapy 
include Doxil® (doxorubicin liposomes), Daunoxome® (daunorubicin citrate liposomes), 
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Abraxane® (amorphous nanoparticles of albumin-bound paclitaxel), Marqibo® 
(vincristine sulfate liposomes), and NanoTherm® (aminosilane-coated superparamagnetic 
iron oxides for magnetic hyperthermia) [22, 23]. Limitations associated with the current 
nanoparticle designs still exist. The solubilization and encapsulation approach, in which 
the drug is dispersed in surfactants, encapsulating polymers and/or solubilizing lipids, 
results in complex constructs. Such multi-component systems could potentially exhibit 
vehicle instability and drug leakage. For liposomes, both drug leakage from the 
formulation and instability have been observed during their preparation, storage, and 
administration [24, 25].  Micellar systems encountered similar problems [26].  
Preparation of such a multi-component system requires multiple, arduous steps of 
synthesis and purification, which make the scale-up for production extremely 
challenging, if not impossible. Furthermore, toxicity concerns, which may sprout from 
the composition of the nanocarriers themselves, are often ignored [27]. More importantly, 
these existing delivery systems have low drug loading. Polymeric micelles, which are 
known to have high drug loading [26], can only contain up to 42.5% drug content [28].  
Considering the fact that no more than 5% of administered nanoparticles can reach and 
accumulate at the tumor [29, 30], drug leakage and low drug loading limit the potential 
benefit of existing nanoparticle designs to cancer patients. Hence, ideal vehicles must 
have high drug loading capacity, low drug loss, and minimum carrier-inherent toxicity 
[27]. The feasibility of large-scale manufacturing also needs to be considered. Nano-sized 
drug crystals, a carrier-free colloidal system, seem to fulfill the aforementioned 
requirements and may potentially offer effective delivery of antineoplastic agents to 
tumors.   
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1.2. Theranostics 
1.2.1 Definition and Purpose 
Nanomedicines are designed with the intent to improve the tumor-targeting efficiency 
and attenuate the toxicity of systemically delivered chemotherapeutic agents. Over the 
past decades, the growth of research in nano-sized drug delivery systems for cancer 
therapy has been substantial, resulting in numerous products in clinical trials and even 
some in the marketed products. Concurrently, the development of nano-size particles for 
diagnostic purposes is also escalating. In recent years, multifunctional systems have been 
developed by either loading imaging probe(s) into the drug delivery systems or 
combining active ingredients into nanomaterials with intrinsic diagnostic capability (e.g. 
gold or iron-oxide-based nanoparticles). The approach to combine the two, therapy and 
diagnosis, is referred to “theranostics”. In a sense, the diagnosis term is not necessarily 
referring strictly to the identification, localization, or staging of a given pathology, but 
rather towards the ability to longitudinally monitor the therapeutic efficacy and predict a 
potential treatment response. Theranostic nanomedicines can be utilized to validate and 
optimize the properties of drug delivery systems and enable personalized medicine via 
pre-screening of treatment in patients in preclinical and clinical settings, respectively 
[31]. When designed properly, theranostic systems are able to provide real-time, yet non-
invasive, information on the tissue distribution and target site (tumor) accumulation of 
the nanoconstructs. This live feedback can be utilized as a tool to optimize the physical 
properties of the delivery system, where improved tumor targeting efficiency, thus 
treatment efficacy, can be achieved with minimal toxicity. In clinics, the post-injection-
data gathered from patients can also be further analyzed to stratify group response to the 
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treatment. Only those that respond well should continue to be treated. Otherwise, 
alternative treatment should be considered. 
 
1.2.2 Imaging Modalities and Probes 
Most of the development and evaluation of cancer theranostic systems still remains in 
preclinical and clinical settings. Imaging probes and their modalities have been 
extensively reviewed [32-36] and will be summarized as follows. 
 
1.2.2.1 Optical Imaging 
The extension of optical imaging techniques from in vitro and ex vivo applications to that 
of non-invasive in vivo imaging has been substantial. The progress has been attributed to 
the development of near-infrared fluorophores, activatable near-infrared fluorochromes, 
bioluminescence probes, and red-shifted proteins [37]. Optical imaging in living subjects 
fundamentally based on the ability to detect light, either from fluorescence or 
bioluminescence emitted from the body. Bioluminescence imaging is used to detect the 
limited numbers of photons that originate from cells that have been genetically 
engineered to express luciferase. It plays a significant role in cancer research, particularly 
in its ability to non-invasively monitor the tumor-cell growth and regression, visualize the 
kinetics of tumor-cell clearance by chemotherapeutics, and track gene expression [36]. 
However, the signals are generated from the cells themselves, not from the theranostic 
agents – thus, it is beyond the scope of this discussion. Fluorescence reflecting imaging 
(FRI) is broadly used in research settings due to its ability to detect low levels of signal 
(photon) and allow rapid testing of proof-of-principle in living experimental models [35]. 
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In addition, it can provide high-throughput imaging because of its ease of operation, short 
acquisition time (i.e. 1 to 60 seconds), and the feasibility to simultaneously measure six 
or more anesthetized living mice [38]. However, limitations, including significant 
background from tissue auto-fluorescence, limited efficiency of light transmission 
through animal tissue (i.e. < 1 cm), and lack of depth information, still exist [35]. The 
imaging information from this system is also surface-weighted, in that anything closer to 
the surface will appear brighter [37]. A newer approach via fluorescence-mediated 
tomography (FMT) allows imaging of deeper structures. With FMT [39, 40], the subject 
is exposed to a continuous wave or pulsed light from different sources, and the detectors 
are spatially and orderly arranged in an imaging chamber to capture the emitted light. The 
algorithm results in a reconstructed tomographic image, with enhanced depth of 
penetration (i.e. < 10 cm, [36]).  
Fluorescence imaging probes are commonly incorporated into theranostic systems 
because they are sensitive [41, 42], relatively inexpensive, and easy to handle (i.e. 
compared to radioactive material) [43].  In vivo imaging of the fluorescence probes is still 
limited due to the light scattering and absorption that occurs in tissue constituents, 
specifically by blood (oxy- (HbO2) and deoxyhemoglobin (Hb)) and water. Near-infrared 
(NIR) fluorophores with wavelength range of 650 and 900 nm are most utilized in optical 
imaging technologies due to their low absorption and auto-fluorescence, minimal 
background interference, and improved tissue depth penetration [37, 44-46]. In the field 
of oncology, the first clinical trials using fluorescence imaging were focused on an 
image-guiding intraoperative method for sentinel lymph node resection [47-51] using 
Indocyanine Green (ICG, emission wavelength of ~ 800 nm), the only FDA approved 
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NIR dye for human use. Based on composition, fluorophores can be categorized into two 
classes: organic and inorganic (quantum dots). Both classes have been extensively used 
in the field of nanotheranostics. 
The organic ones are generally derived from the class of cyanines, squaraines, 
phthalocyanines, porphyrins, and BODIPY [42, 52], while quantum dots (QDs) are 
nanocrystals of semi-conducting materials [53], made from the II-VI (i.e. CdSe, ZnS, 
CdTe), III-V (InP), or IV-VI (PbS, PbSe, PbTe) semiconductors. Organic dyes, due to 
their aromatic structure, generally have low water solubility. Solubility may be increased 
by chemical modification via addition of polar groups, including sulfonate [46, 54] or 
saccharide [55, 56]. Free organic fluorophores are rapidly cleared in vivo. Hydrophilic 
dyes (e.g. fluorescein) are typically cleared by urinary excretion, while lypophilic ones 
(e.g. ICG) are cleared by biliary excretion [43].  Compared to organic fluorophores, QDs 
offer several unique advantages, including significant improvement in the probe 
brightness (i.e. 10-20 times brighter than organic dyes [57]), resistance against 
photobleaching, and enhancement in detection sensitivity (e.g. clearly detectable above 
the tissue auto-fluorescence for animal model) [58]. Despite their advancement as novel 
fluorescent probes for multiplexed tissue and cell labeling, quantum dots still have 
several drawbacks, such as toxicity [59] and clearance by the reticuloendothelial system 
(RES), that still remain unsolved and limit their potential for human clinical applications. 
Specific details of the synthesis, applications, and toxicity of quantum dots have been 
reviewed [58-61].  
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1.2.2.2 Magnetic Resonance Imaging (MRI) 
The MRI signal is based on the difference in nuclear magnetic relaxations of the water 
protons in biological solutions and surrounding solid tissue. During the imaging process, 
subject is exposed to a radio frequency that allows the hydrogen nuclei to have enough 
energy to spin and precess. Upon exposure of strong magnetic field, the nuclei spin back 
in the direction parallel to the field. The relaxation process in which the nuclei return to 
the original aligned state can be exploited into images. The differentiation between 
tissues can be enhanced by using contrast agent to shorten the relaxation parameters (T1 
and T2) of water. MRI is able to provide excellent tissue contrast without ionizing 
radiation, offering high spatial resolution [32-34]. Some of MRI limitations are low 
sensitivity and long acquisition and image processing time, which hinder its use as a high 
throughput modality [34]. Because MRI suffers from low sensitivity, the administration 
of high concentrations of contrast agents is often required to produce a detectable signal 
[32]. Improved signal-to-noise ratio and resolution can also be increased by exposure to 
high magnetic field strength, which may cause physiological effects (e.g. nausea and 
visual abnormalities) [33].  
Common MRI contrast agents, which include the paramagnetic (e.g. gadolinium (Gd) and 
manganese (Mn)) and superparamagnetic (e.g. iron-oxide nanoparticles) substances, are 
commonly incorporated into nano-sized drug delivery vehicles to achieve theranostic 
functions.  Compared to gadolinium-chelates, superparamagnetic iron oxide (SPIO) 
particles are preferred due to their sensitivity and biocompatibility. In addition, their 
physical properties can be manipulated by changing their size [62].  
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1.2.2.3 Radionuclide-based Imaging 
Although the hardware and radioisotopes used for positron emission tomography (PET) 
and single-photon emission computed tomography (SPECT) are different, both 
approaches rely upon the detection of γ-ray emissions arising from radioisotope decay. 
Unlike MRI, radionuclide-based imaging techniques have a nominally low background 
signal and require little signal amplification due to the high energy of gamma rays. 
Compared to SPECT, PET imaging is approximately ten times more sensitive - 
picomolar (10-12 M) concentrations of radiolabel can be readily detected and quantified 
regardless of tissue depth. Although PET imaging is capable to track molecular events, it 
has poor spatial resolution. Thus, generally PET imaging is often hybrided with high 
resolution images from computed tomography (CT) for the event localization. SPECT is 
more widely available than PET, and it is advantageous due to its ability to concurrently 
image multiple radionuclides. Nonetheless, both SPECT and PET are quantitative 
techniques, which are advantageous compared to other modalities, such as MRI and 
optical imaging. For PET imaging, the radiopharmaceuticals utilized generally emit high-
energy γ-ray (e.g. 18F, 11C, 13N, 15O), while low-gamma γ-ray (e.g. 99mTc, 111In, 125I) 
emitting probes are used for SPECT. Radionuclides used for SPECT are simpler to 
prepare and usually have a longer half-life than those used for PET [32].  
 
1.2.2.4 Computed Tomography (CT) 
CT generally provides complementary anatomical information for radionuclide-based 
imaging by measuring the absorption of X-rays as they pass through tissues. Within a CT 
image, one can distinguish the difference between tissues based on the degree of X-ray 
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attenuation, which is determined by the atomic number of the contrast agent and the 
electron density of the tissue.  Absorption differences between bone, fat, air, and water 
produce high contrast images of anatomical structures [63]. CT’s relatively low tissue 
contrast for tumors and surrounding tissue can be enhanced by the use of contrast agent. 
The current CT contrast agent (e.g. iodine) is rapidly extravasated and cleared from the 
system. Prolonged presence in the blood pool may be achieved by developing 
nanoparticles which contain electron dense elements with high atomic number (e.g. 
iodine, bismuth, and gold). Because of gold’s atomic number and electron density [63], it 
provides about 2.7 times stronger contrast per unit weight than iodine. In addition, the 
low toxicity [64], good biocompatibility, and unique physical and chemical properties of 
gold (nanoparticles) make it an ideal contrast agent. More importantly, various shapes of 
the particles can be utilized since the only important parameter in CT imaging is the total 
amount of gold per unit volume (voxel) [65].  The utilization of gold as a contrast agent in 
vivo was first reported in 2006, and it is being continually explored [66]. 
 
1.2.2.5 Ultrasound 
Ultrasound probes typically contain one or more acoustic transducers, which emit high 
frequency sound waves (>20 kHz).  The image is formed based on the sound wave 
echoed back from the internal organs [67]. Contrast enhancement at the molecular level 
can be obtained by introducing gas-entrapped-microbubbles, which have different 
acoustic properties than tissues. Nanoparticle-based contrast agents are currently in 
various stages of development [32].  
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1.2.3 Building Theranostic System 
To form theranostic nanoconstructs, imaging modalities are incorporated in delivery 
systems via various methods, including encapsulation, intercalation, adsorption, or 
covalent-bond conjugation, which may be vehicle-specific [31, 32, 68, 69]. Most relevant 
nanoconstructs, such as vesicles (e.g. liposomes and polymersomes), polymeric 
nanoparticles, micelles, core-shell structures, dendrimers, and carbon nanotubes will be 
reviewed below. 
 
1.2.3.1 Vesicles 
The two main classes of vesicles, liposomes [70] and polymeric vesicles [71], have the 
ability to integrate both hydrophilic and hydrophobic moieties either by covalent and 
non-covalent interaction. The three different approaches to engineer theranostic-based-
liposomes have been reviewed [72]: (i) hydrophobic probes can be embedded in the lipid 
bilayer, (ii) hydrophilic probes can be encapsulated within the internal aqueous-core of 
the liposome, (iii) probes can be physically adsorbed into the surface of the liposome. 
Probes that are popularly being incorporated into liposomes are gold nanoshells and 
nanoparticles, quantum dots, superparamagnetic iron oxide (SPIO) nanoparticles, and 
radionuclides. For instance, Al-Jamal and Kostarelos designed theranostic liposomes by 
loading either doxorubicin or artificially enveloped adenoviruses in the core and 
entrapping the quantum dots into the lipid bilayers [72]. Extended circulation time in vivo 
and minimized non-specific binding were achieved by chemically linking QDs to the 
surface of doxorubicin-loaded actively-targeted anti-HER2-immunoliposomes by PEG-
DSPE [73]. To exemplify the robustness of liposomes as delivery vehicles for both 
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therapeutic and diagnostic agents, multifunctional liposomal system containing 
chemotherapeutic agent and multiple imaging probes, including gadolinium (Gd), near 
infrared fluorescence tracer, or radioisotopes (e.g. 99mTc, 64Cu) have been recently 
developed. The liposome was comprised of DSPC/cholesterol/Gd-DOTA-DSPE/DOTA-
DSPE/IRdye-DSPE with ammonium/ pH gradient, whereby radionuclides such as 99mTc 
and 64Cu, and the antineoplastic, doxorubicin, could be post-loaded to the core [74].  
While liposomes are composed of phospholipids that chemically mimic those in 
eukaryotes, polymersomes result from bilayer self-assembly of a diverse array of 
synthetic amphiphilic block copolymers containing hydrophilic and hydrophobic blocks 
[75]. Similar to liposomes, polymersomes have a large hydrophilic reservoir in the core 
and thick hydrophobic lamellar membranes that are available for functionalization. For 
instance, ultra-small SPIO and doxorubicin were successfully embedded together into the 
membrane of vesicles with one-step nanoprecipitation, creating hybrid polymersomes 
that were able to provide contrast enhancement and a triggered release function in an 
oscillating radiofrequency field [76]. Further use of polymersomes to host 
multifunctional modalities has been reviewed [75]. These vesicle-type delivery vehicles 
are versatile and tunable for the delivery of therapeutic and diagnostic agents. 
Nonetheless, limitations, including production, complexity, and vehicle toxicity [32], 
need to be taken into consideration. 
 
1.2.3.2 Polymeric Nanoparticles 
In polymeric nanoparticles, the hydrophobic portion of the block copolymer self-
associates and concentrates into a semisolid core while the hydrophilic portion of the 
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copolymer forms a coronal layer [77]. Both hydrophobic and hydrophilic moieties can be 
either be encapsulated in the core, adsorbed on the surface, or covalently attached to the 
surface. Superparamagnetic iron oxide nanoparticles and doxorubicin were embedded in 
YCC-DOX polymer nanoparticles, which were composed of poly (ethylene oxide)-
trimellitic anhydride chloride-folate (PEO-TMA-FA) [78]. Compared to conventional 
MRI contrast agent, Resovist®, YCC-DOX showed higher MRI sensitivity to folate 
receptor-positive liver tumor cells. Even more, the nanoparticles showed inhibition of 
tumor growth without inducing adverse side effects. Additional examples of theranostics 
designed from this group of delivery vehicles have been reviewed by the Peppas group 
[79]. 
 
1.2.3.3 Micelles 
Micelles are self-assembled nano-sized colloidal particles with a hydrophobic core and 
hydrophilic shell [16]. Without the aqueous core, imaging agent has to be bound to the 
polymer via conjugation or entrapped within the dense hydrophobic core [80]. Similar 
approaches can be taken to build theranostic systems from polymeric micelles, which 
consist of self-assembled block copolymers with a densely packed hydrophobic core and 
hydrophilic shell [81]. A study reported that doxorubicin and SPIO nanoparticles were 
simultaneously entrapped in the core of a Pluronic F127 micellar system. When tested in 
vitro, the micelles containing SPIO nanoparticles having a diameter of approximately 100 
nm had a substantial advantage in the T2 relaxation and decreased cell toxicity compared 
with Resovist, a commercial SPIO contrast agent [82].  In more complicated 
unimolecular micelles consisting of the amphiphilic multiarm star block copolymer, H40-
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PCL-b-P(OEGMA-Gd-FA), paclitaxel was physically encapsulated within the 
hydrophobic core while a targeting moiety (folic acid) and MRI contrast agent (DOTA-
Gd) were covalently anchored in the hydrophilic outer corona. When tested in a murine 
model, this theranostic nanoconstruct demonstrated conspicuously positive contrast 
enhancement and an extended blood circulation time [83]. 
 
1.2.3.4 Core-shell Nanoparticles 
Nanoparticles (NPs) constructed from inorganic materials (e.g. SPIOs, quantum dots, 
gold NPs, silica NPs) are clustered into this large class of core-shell structures. Advances 
in the development of core-shell structures for theranostics have been extensively 
reviewed by Xie et al. [84]. To link the core-shell structures with other functional 
entities, various techniques, including conjugation, electrostatic surface interactions, and 
adsorption, have been employed [84]. In addition, due to their small size, core-shell-
nanoparticles can also be incorporated into other nanovehicles as diagnostic probes.  
Due to their biocompatibility, inexpensiveness, and superior magnetic properties, SPIOs 
have a vast number of bio-applications, including their use as contrast probes for MRI 
[85-87]. In addition, due to their inherent intrinsic properties, SPIOs can serve dual 
imaging/therapy role. They can be used not only as a contrast enhancer in MRI, but also 
as a transducer in hyperthermia therapy. In the presence of external alternating magnetic 
field (AMF) signal, SPIOs can convert the electromagnetic energy to heat [88, 89]. With 
appropriate coatings, SPIOs can be easily coupled with drug molecules via covalent 
coupling [90-92]. Drug molecules can also be encapsulated in the polymeric matrices, 
15 
 
which typically used as hydrophilic coating [93-95]. Recently, small molecule entity also 
has been successfully loaded into hollow SPIOs [96]. 
Quantum dots (QDs) are semiconductor-based-nanocrystals that have unique and 
unprecedented optical properties, such as improvement in brightness, resistance against 
photobleaching and chemical degradation, enhancement in detection sensitivity, and a 
narrow emission spectrum [84]. Their optical properties can be finely tuned by adjusting 
their size and composition. Modifications of QDs were mostly achieved via the disulfide 
linkage on the surface, but concern regarding the fragility of the disulfide bond still exists 
[97]. However, limitations due to the innate toxicity of QDs have hindered its use in 
clinical trials [97]. QD applications as bioimaging probes may be further extended with 
the recent emergence of less toxic Cd-free QDs [98-100].  
Gold NPs (including gold nanoshells) has a unique surface plasmon feature that enable its 
use for photothermal therapy, where gold NPs can transform light into heat and cause 
ablation to nearby cells. Due to the strong interaction between gold and thiol, surface 
conjugation is mostly done via the addition of thiolated species [101, 102].  
Unlike other core-shell structures, silica nanoparticles do not have an intrinsic diagnostic 
function, but they offer an excellent platform for loading a broad range of therapeutic and 
imaging moieties. Generally, tetraethyl orthosilicate (TEOS) is the precursor for building 
silica NPs. Functional groups can be incorporated into the nanostructures by using 
aminopropyltrimethoxysilane (APS) or mercaptopropylmethoxysilane (MPS) as co-
precursors, which can coagulate with the TEOS matrix and conjugate with amine or thiol 
groups. Besides small chemical entity [103] and drug molecules [104], other small core-
shell structures (e.g. SPIOs, gold NPs, QDs) can be embedded into the silica matrices 
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[105-107]. Additionally, mesoporous silica nanostructures, which consist of hundreds of 
empty channels and large surface areas, are promising candidates for drug vehicles as 
they provide excellent reservoirs for entrapping small molecules [108]. Silica NPs are 
biodegradable, and they are renally cleared within a short period of time [109]. 
 
1.2.3.5 Dendrimers 
Dendrimers are hyper-branched and highly-defined polymer macromolecules 
characterized by large numbers of end-group functionalities and compact molecular 
structures. Their starburst structure enables greater loading efficiency for therapeutics and 
imaging agents [110]. An in vitro study of multifunctional poly(amidoamine) (PAMAM) 
dendrimers conjugated with a chemotherapeutic drug (paclitaxel), imaging agent 
(fluorescein isothiocyanate, FITC), and targeting moiety (folic acid) showed a targeted 
delivery of the therapeutic and imaging agents to specific cancer cells [111]. An 
alternative chemotherapeutic drug, methotrexate, could also be conjugated to the 
multifunctional PAMAM dendrimer [112]. In PAMAM dendrimers, the leading 
dendrimer scaffold in biomaterials, the attachment of therapeutics and imaging probes to 
the amine termini is mainly achieved via a random statistical approach. A more 
controlled strategy was developed recently by creating polyamide-based dendrimer that 
contains nine azide termini, nine amine termini, and fifty-four terminal acid groups [113]. 
The amine termini were reacted with a near infrared cyanine dye, resulting in orthogonal 
functionalization of a multifunctional dendrimer that showed a relatively high quantum 
yield, fluorescence signal, and large Stokes shift with minimal toxicity toward T98G 
human glioblastoma cells. 
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1.2.3.6 Carbon Nanotubes 
Carbon nanotubes (CNTs) are cylindrical carbon allotropes. They can be formed either as 
single-walled or multi-walled, for increased stability [114]. They can be used as 
theranostic platform due to their tunable properties and ability to incorporate multiple 
functionalities. Therapeutic and imaging agents can be linked either covalently via amide 
bonds [115] or non-covalently due to the hydrophobic nature of the surface [116] or 
aromatic (i.e. pi-pi) stacking [117]. Similar to core-shell structures, CNTs have a broad 
excitation profile and high absorption coefficient. One particular study showed that due 
to their unique intrinsic electronic band structures, single-wall carbon nanotubes 
(SWNTs) can have a very high optical absorbance in the NIR regime [118]. In addition to 
their capability to provide optical simulation inside living cells, SWNTs were able to 
cause cell death upon continuous NIR radiation that caused local heating. In order to 
spare the healthy cells, SWNTs were functionalized with a folate moiety that allowed 
selective internalization in cells with overexpressed folate receptor. Thus far, studies on 
multifunctional CNTs are mainly conducted in vitro as cytotoxicity observed from the 
use of CNTs is still debatable [119].  Nonetheless, a recent report on an immunologically 
modified nanotube system utilizing glycated chitosan (GC) as surfactant, showed a 
remarkable ability of SWNTs to induce complete tumor regression and long-term 
survival in a murine EMT6 xenograft model [120]. Upon intratumoral injection, the 
SWNT-GC system maintained its optical properties and was able to be taken up by 
cancer cells. When the subcutaneous tumor (in flank) was irradiated by a laser (980 nm), 
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the SWNTs were able to induce cellular thermal destruction and provide photothermal 
therapy. 
 
In summary, imaging probe(s) can be embedded in the core of nanovehicles, intercalated 
in or be part of the nanovehicle’s shell, or linked to the exterior side by either adsorption 
or a covalent bond (conjugation). Encapsulation, either by the entrapment using 
molecular affinity or covalent conjugation to the material constituting the particle core, 
offers the advantage of protecting probes from direct interactions with biological fluids.  
 
1.2.4 General Considerations for Translation 
In order for nanomedicine to be useful in clinical practice, evidence of sufficient potency 
or payload, reduced toxicity and side effects, biodegradability, and adequate stability 
during formulation, storage, and administration has to be shown. Additionally, 
pharmacokinetics and biodistribution also play important roles in the performance of the 
nanoplatform.  Even with a promising pharmacological response, a nanomedicine that 
cannot reach its target will have no clinical utility. The key factors relevant to the design 
of practical nanomedicines and the regulatory mechanisms to achieve safe and timely 
realization of clinical benefits have been elegantly reviewed by Duncan and Gaspar 
[121]. 
 
  
19 
 
1.3. Nanocrystals 
1.3.1 Introduction 
Over the last few years, nanocrystal formulations have been of considerable interest for 
delivering poorly soluble drugs via oral, parenteral, and other routes [122].  Administered 
directly as nanosized solid particles, drug nanocrystals require no solubilizing and/or 
encapsulating chemicals, thus circumventing side effects that may have stymied many 
existing delivery systems.  More importantly, production of nanocrystals at a large scale 
is feasible due to the simplicity of formulation and absence of solubilizing, encapsulating, 
or conjugating steps. Because no harsh solubilization agents are utilized in the 
nanocrystal formulation, it is expected to offer less toxicity and improved anticancer 
efficacy. 
The term crystal connotes regular, periodic supramolecular structures assembled by 
organic or other types of molecules or atoms.  Characteristically, a crystal shows distinct 
X-ray diffraction patterns and has a specific melting point, density, and solubility, in 
addition to other well-defined physicochemical properties.  Compared with the 
amorphous state, in which molecules are randomly packed, the crystalline state is more 
stable, exemplified by the fact that amorphous materials can readily undergo spontaneous 
phase transitions and recrystallization.  As such, using crystalline materials in a 
formulation assures better physical stability than those amorphous formulations. 
Nanocrystals of poorly soluble drugs can offer several advantages over solubilized and 
encapsulated formulations.  Aside from their physical stability, the dissolution rate of 
nanocrystals can be significantly enhanced – under sink conditions – due to their 
increased surface area.  More importantly, manufacturing at the industrial scale is 
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possible.  Below, major approaches for producing nanocrystals of organic molecules are 
further discussed. The top-down approach produces large crystals that are physically 
reduced in size by comminution; the bottom-up approach yields nanocrystals from 
solution by crystallization. Several review articles have focused on the techniques, 
mainly the top-down approach [122-126]. 
 
1.3.2 Various Approaches to Produce Nanocrystals 
1.3.2.1 Top-down Approach 
There are two basic diminution techniques: wet milling and high-pressure 
homogenization. Wet milling involves mechanical attrition, where drug particles are 
wetted by an aqueous solution of surfactants and subjected to mechanical shearing and 
grinding by, for example, milling balls in a milling container.  The particle size is reduced 
and may reach a few hundred nanometers. The Nanocrystal® technique[127], a wet 
milling process patented by Élan Co., has been employed in several oral products 
including Rapamune®, Emend®, Tricor®, and Megace ES® [128].  One drawback of the 
technique is potential contamination from the erosion of metal milling balls or pearls.  
The amount of contamination is determined by the hardness of drug particles as well as 
the milling time, which can take up to several days [129].  The use of polymeric beads 
(e.g., polystyrene derivatives) may be helpful in minimizing the erosion. 
High-pressure homogenization is another fragmentation technique.  One development is 
based on jet-stream microfluidization [130], in which two fluid streams of particle 
suspensions collide under high pressure in a Y-shaped chamber, leading to particle 
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collision and subsequent particle rupture.  The marketed product Triglide® developed by 
SkyePharma Co. is produced by Insoluble Drug Delivery-Particles (IDD-PTM) 
technology, a microfluidization method [131].  Piston-gap homogenizers are also used to 
produce nanosized solid particles by forcing a suspension of drug particles with a piston 
through a thin gap under high pressure [132].  The combination of cavitations, high shear 
forces, and turbulent flow, fractures the particles into smaller pieces.  The outcome of 
particle fragmentation is influenced by several factors, including the power of 
homogenization, particle hardness, and number of the piston-moving cycles.  Compared 
with wet milling, the homogenization method may yield less contamination during the 
production process [133].  There are currently two patented technologies for nanocrystal 
production that employ the piston-gap homogenization method, DissoCubes® and 
Nanopure®.  In the former, owned by SkyePharma Co., drug powders are dispersed in an 
aqueous solution of surfactants and subjected to homogenization [132]; in the latter, 
previously owned by PharmaSol GmbH and now acquired by Abbott Co., drug particles 
are suspended in either non-aqueous dispersion media (e.g., oils and liquefied 
polyethylene glycol) or aqueous-organic cosolvents (e.g., glycerol-water, and ethanol-
water mixtures) prior to homogenization [132].  These operations require that one start 
with drug particles no larger than 25 μm so that the blockage of the homogenizer can be 
minimized [134]. 
Currently, the top-down approach dominates the production of nanocrystals and is used 
to manufacture several products in the market [126].  Despite its popularity, there are 
inherent drawbacks in this approach, including the high energy input, prolonged 
operation time, possibility of contamination, and decreased crystallinity or stability [135].  
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The stability concern is particularly critical for a nanocrystal system to be considered for 
parenteral drug delivery.  The amorphous content produced during the high-energy 
process can lead to phase instability, which in turn causes uncertainty and potential 
variability in pharmacokinetic behavior which should be tightly controlled. 
 
1.3.2.2 Bottom-up Approaches 
Nanocrystals can be grown directly from solution.  Nucleation and crystal growth thus 
play essential roles in the bottom-up approach.  To induce nucleation, a solution needs to 
become supersaturated.  Cooling, solvent evaporation, and mixing with an antisolvent, 
are among several ways to create supersaturation [136].  Still, a solution can become 
supersaturated to some extent without producing any nuclei.  This is because nucleation 
is energetically unfavorable.  According to the classical nucleation theory [137-139], the 
change in free energy when a nucleus starts to grow includes two energy components, 
one associated with the creation of the new surface, and another with the packing of 
molecules in the bulk crystal.  As depicted in Figure 1.1, the surface-related term, ΔGS, is 
always positive (energetically unfavorable) because creation of a new surface of a solid 
particle requires energy input.  On the other hand, the bulk-related term, ΔGV, is negative 
(energetically favorable) due to the formation of intermolecular interactions between 
molecules in the nucleus.  When a nucleus is small, ΔGS dominates, and the overall free 
energy change is positive so that the development of the nucleus is not spontaneous.  As 
the nucleus grows and surpasses a so-called critical nucleus size (rc), ΔGV becomes 
dominant, and the overall free energy change becomes negative.  Subsequently, the 
nucleus can grow freely as long as supersaturation is maintained. 
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Figure 1.1. Free energy diagram for nucleation. (Adapted from Mullin [1]). 
 
In reality, homogeneous nucleation – nucleation without the aid of substances other than 
the solute molecules – seldom occurs. Foreign materials, impurities, or even the surface 
of the crystallization vessel often help to induce nucleation, which is denoted as the 
heterogeneous nucleation [1].  According to the classical nucleation theory, the presence 
of a foreign surface lowers the ΔGS term for a nucleus to form on the surface.  In other 
words, the nucleus requires less energy for surface creation when it forms on a pre-
existing surface. 
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In order to produce nanosized crystals from solution, it is thus extremely critical to 
control the nucleation process.  It is important not only for controlling the particle size 
but also for the size distribution.  Ideally, nucleation of a large number of crystalline 
embryos must occur concurrently from the supersaturated solution. Rapid depletion of the 
solute molecules from the solution limits further growth of each nucleus so as to achieve 
a nanosize.  Having a large number of nuclei produced at the same time also keeps the 
particle size distribution narrow.  Similar particle sizes are not only preferred for ensuring 
product quality but also important for maintaining the stability of nanocrystals.  A narrow 
distribution of particle size can greatly minimize the so-called Ostwald ripening 
phenomenon, in which larger particles grow at the expense of re-dissolving smaller ones 
because of their differences in surface energy [140].  For this purpose, the induction of 
nucleation needs to be abrupt and homogeneous throughout the growth medium.  One 
common strategy is to mix the solution of a drug compound with an antisolvent, so that 
the supersaturation is reached immediately; at the same time, the mixture is subjected to 
intense sonication and/or mechanical stirring.  It is known that air cavities created by 
sonication may trigger nucleation because of the presence of air-liquid interfaces and 
locally concentrated liquid pockets.  Nevertheless, because nucleation is such a difficult 
process to control [141], subtle changes in growth conditions can result in drastic 
variations in product quality.  For producing nanocrystals, extreme care is particularly 
needed for identifying a suitable set of peripheral conditions [142], which mostly likely 
vary for distinct compounds. 
There are several approaches that have been developed to create supersaturation and 
induce nucleation [125].  They include hydrosols [140], high-gravity controlled 
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precipitation technology (HGCP) [143, 144], confined impinging jets [145], supercritical 
fluid technology (SCF) [146], and sonoprecipitation [147], as further discussed below. 
 
1.3.2.2.1 Hydrosols 
Considered to be a more mature method, hydrosols or aqueous nanosuspensions of poorly 
water soluble drugs have been developed by Sandoz (now Novartis) [148].  The active 
ingredient is dissolved in aqueous-organic miscible cosolvents (e.g., ethanol, isopropanol, 
and acetone), while various peptisers and/or stabilizing agents (e.g., citric acid, gelatin, 
ethyl cellulose N7, lecithin) may be added to the aqueous phase to prevent aggregation. A 
matrix former, generally sugar or sugar alcohol (e.g., mannitol), is also added to the 
solution to prevent agglomeration and aid in the re-suspension process. In the laboratory 
setting, solid nanoparticles can be produced by mechanically mixing the various 
components in a beaker while removing the organic solvent through evaporation. For the 
industrial production, the organic and aqueous phases are pumped into a static mixer and 
forced through an atomizing nozzle, leading to the formation and drying of nanoparticles 
[148-151]. One study reported that spray-dried cyclosporin A contained 38 μm particle 
agglomerates  that were reduced to 120 nm upon re-dispersion in water [149]; the 
nanoparticles produced by this method were nonetheless amorphous [149, 150]. 
 
1.3.2.2.2 High-Gravity Controlled Precipitation (HGCP) 
HGCP is considered to be one of the most promising techniques to produce 
nanoprecipitations at the commercial scale [125].  The key component in HGCP is a 
rotating packed bed (RPB), where two liquid streams are pumped in and mixed together 
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vigorously by centrifugation.  Subsequently, the mixture is spread into thin films and 
ultimately broken into tiny droplets. In addition to using antisolvents, mixing two streams 
of reactants can also produce precipitates chemically in HGCP.  Depending on the 
compound and conditions, a product may be amorphous or crystalline. Nanoparticles of a 
few pharmaceutical compounds, including cephradine [152], danazol [153], and 
salbutamol sulphate [154, 155], have been successfully produced by this method. 
 
1.3.2.2.3 Flash Nanoprecipitation by Confined Liquid Impinging Jets (CLIJ) 
In this technique, two respective jet streams of a drug solution and an antisolvent are 
forced together by opposing nozzles that are mounted in a small chamber to create 
localized, intensified mixing.  The mixing causes precipitation of nanoparticles within the 
residence time of mixing.  The velocity, drug concentration, and volume ratio of the two 
streams are considered to be the factors determining the particle size distribution of a 
product.  CLIJ has been utilized in the production of salbutamol sulphate, ibuprofen, 
cyclosporin A, and amphotericin B [156-158]. GRAS (Generally Regarded as Safe) 
additives may be added to assist the production. 
 
1.3.2.2.4 Supercritical Fluid (SCF) Technology 
This method takes advantage of the unique physical properties of supercritical fluids, 
including low density and viscosity as well as high diffusivity of solute molecules to 
attain rapid mixing. In addition, quick and easy removal of a SCF without excessive 
drying can greatly facilitate the precipitation of nanoparticles. Supercritical carbon 
dioxide (SCO2) is mostly used and considered green or environmentally friendly for 
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processing most pharmaceuticals. Depending on the solubility of a compound in SCO2, 
production can be accomplished by allowing the drug/SCO2 mixture to expand under 
ambient conditions (method called Rapid Expansion of Supercritical Solution or RESS 
[159]) or by using SCO2 as the antisolvent when the drug is poorly soluble in SCO2 (a 
process called Supercritical AntiSolvent, or SAS [159]).  In the both methods, it is critical 
that other solvents used are miscible with SCO2; water is actually immiscible. 
Amoxicillin, ampicillin, and rifampicin nanoparticles were successfully produced by the 
SCF approach [160]. 100-500 nm nanoparticles of insulin, rhDNase, lysozyme, and 
albumin were precipitated from aqueous ethanol solution by using ethanol as the co-
solvent [161]. 
 
1.3.2.2.5 Sonoprecipitation 
Ultrasonic waves can create cavitations that subsequently collapse, releasing shock waves 
that may assist in rapid and more uniform nucleation [162]. Ultrasound can also reduce 
particle agglomeration by minimizing particle contacts [147]. Drug microparticles were 
reportedly produced by the sonocrystallization method [163-165]; it was also shown that 
the method could produce nanoparticles of amorphous cefuroxime axetil [166].  Factors 
that influence the quality of a final product include: (i) ultrasound frequency, intensity, 
and power, (ii) sonication probe size and immersion depth, (iii) solution volume, and (iv) 
duration.  Although the experimental setup appears to be straightforward, this technology 
has not been adopted for commercial production. 
The quality of nanocrystals produced by the bottom-up approach is expected to be 
superior to that by the top-down method.  Particle size and morphology can be better 
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controlled, and it is possible to produce pure nanocrystals with little or no amorphous 
content.  Shorter production time, less energy consumption, and reduced contamination 
also make the precipitation techniques desirable.  Clearly, the bottom-up approach holds 
great promise for developing nanocrystals for parenteral delivery, which demands 
uncompromised quality and stability.  Although no such product is currently in the 
market, there is certainly a growing interest and need in this field.  Challenges remain in 
controlling nucleation and subsequent crystal growth, so that batch-to-batch 
reproducibility can be achieved.  It is certain that, among various methods that are being 
developed, ones that are simple, reproducible, and yet cost-effective for production scale-
up should have  great potential in commercial production [140]. 
 
1.3.2.3 Combination Approach 
There have been efforts to combine the two aforementioned approaches.  The 
NanoEdgeTM patent by Baxter claims that nanocrystals, ranging from 400 nm to 2μm, can 
be prepared by crystallization followed by high pressure homogenization [167].  Our 
research group used an antisolvent approach to grow nanocrystals by rapidly precipitating 
anticancer drugs under intense stirring and sonication [168, 169]. To further reduce the 
size, the nanocrystal suspension can subsequently be homogenized. Nanocrystals with an 
average particle size ranging from 200 to 800 nm have been successfully produced in our 
laboratory.  The second step of homogenization breaks down larger crystals and, 
particularly, aggregates, achieving a much narrower particle size distribution. 
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1.3.3 Particle Stabilization 
Nanocrystals and nanoparticles of drugs, whether prepared by the top-down or bottom-up 
approach, often require surfactants to be physically attached to the surface of each 
particle in order to prevent the particles from aggregation during the preparation, storage, 
and administration.  Particle aggregation mutually facilitates Ostwald’s ripening and 
eventually becomes irreversible, leading to larger particles and precipitates.  Surfactant 
usage is particularly necessary when the surface of nanocrystals is uncharged.  In general, 
polymeric surfactants are commonly used to introduce steric repulsion between particles; 
electrostatic repulsion also promotes particle segregation when ionic surfactants are used. 
Povidones, pluronics, and cellulosics are the most commonly used surfactants.  Natural 
biological molecules, such as lecithins and cholic acid derivatives, are utilized as well 
[170]. 
Finding a suitable surfactant for a particular drug is experimentally demanding [171].  A 
stabilizer obviously needs to have sufficient affinity for the particle surface and the 
amount used should provide sufficient steric and/or electrostatic repulsion between the 
particles[172]. Excess surfactant does not always lead to better coverage due to the 
tendency of surfactants to form micelles when the concentration surpasses the critical 
micelle concentration (CMC)[173, 174].  A recent study of the effects of 13 stabilizers 
during wet milling of nine drug compounds [175] concluded that the semi-synthetic 
polymers, including hydroxypropylmethylcellulose (HPMC), methylcellulose (MC), 
hydroxyethylcellulose (HEC), hydroxypropylcellulose (HPC), carboxymethylcellulose 
sodium salt (NaCMC), and alginic acid sodium salt (NaAlg), yielded rather poor 
stabilizing performance, likely due to their high viscosity. Less viscous stabilizers, 
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including linear synthetic polymers (PVP K30 and K90) and synthetic copolymers 
(poloxamer 188 and Kollicoat IR®) showed better stabilizing capabilities, especially at 
higher concentrations. Tween® 80 and TPGS (D-α-tocopherol polyethylene glycol 1000 
succinate) gave the best stabilizing performance.  Moreover, the timing of surfactant 
addition may affect particle properties. Stabilizers are commonly added along with the 
starting microcrystalline materials for wet milling or homogenization. However, the 
addition of a stabilizer prior to crystallization may alter the nucleation and subsequent 
crystal growth outcome.   
Because the surfaces of nanocrystals undergo consistent dynamic changes due to 
dissolution and surface recrystallization, albeit at a slow rate, surface coating by 
surfactants may not be able to sustain stability of nanocrystals for long-term storage. 
Alternatively, nanocrystal products can be post-processed by freeze-drying, spray drying, 
or pelletization [124].  In the absence of solvents, the surface dynamics and Ostwald 
ripening are greatly minimized.  Water soluble sugars such as mannitol, trehalose, and 
dextran are commonly added as matrix formers prior to drying [176]. Nanosuspensions 
for intravenous use can be sterilized by  terminal heat and gamma irradiation [177] as 
well as filtration [178] and stored as liquid suspensions or lyophilized solids. 
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1.3.4 Physical Characterization of Nanocrystals 
Nanocrystals need to be fully evaluated to determine their: (i) particle size and size 
distribution, (ii) surface charge, (iii) crystallinity, and (iv) dissolution rate [123, 134, 176, 
179].   
1.3.4.1 Particle Size 
When a formulation is intended for intravenous delivery, it is essential to ensure that the 
particle size is smaller than the smallest blood capillary (a few micrometers) so that  
potential capillary blockade or emboli formation can be avoided [134]. For rapid and 
non-invasive determination of the mean particle size and size distribution, photon 
correlation spectroscopy (PCS) or dynamic light scattering (DLS) is mostly used for 
particles ranging from 3 nm to 3 μm.  The size distribution is indicated by the 
polydispersity index (PI), which is a cumulant-method-derived-parameter that is used for 
determining the width of the particle size distribution. When particle size population is 
assumed to follow the Gaussian distribution, the PI relates the standard deviation (σ) and 
the intensity-weighted average hydrodynamic size (ZD) of particles in the following 
equation: 
?? ? ? ?
??
?
?
                                                            (1) 
PI value of 0.1-0.25 suggests that the size distribution is fairly narrow, while a PI value 
greater than 0.5 indicates a very broad distribution. To achieve long-term stability, it is 
important to maintain the PI parameter as low as possible.   
The first order output of DLS is intensity distribution of particle size, which is weighted 
according to the intensity of light scattered by the particle. Using the Rayleigh 
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approximation, the relative contribution of particles is proportional to the (diameter)6. 
Thus, generally it is difficult to measure the presence of small particles (e.g. 10 nm) in a 
population that is dominated by larger particles (e.g. 1000 nm) because the total scattered 
light generated by the large particles overshadows that of the small ones. Intensity-
weighted output is ideal for identifying the presence of aggregates in the sample.  
The intensity distribution can be converted to volume-weighted distribution when the 
following assumptions are accepted: (a) all particles are spherical, (b) all particles are 
homogeneous, (c) particle’s optical properties are known (e.g. refractive index), and (d) 
no error in the intensity distribution [180]. In volume-weighted distribution, the 
contribution of each particle in the distribution relates to the volume of particle, which is 
proportional to (size)3. Laser diffractometry (LD), which generates volume-based 
distribution, is suitable for measuring particle size greater than 3 μm. This technique 
works well for spherical particles; for nanocrystals, which tend to have large aspect ratios 
(i.e., length/width), the size results often deviate significantly from those determined by 
electron microscope imaging. For non-spherical particles, LD may overestimate the 
particle size distribution [181, 182]. Over-prediction of the median diameters is also 
observed [183]. Thus, caution is needed when measuring and reporting particle size of 
irregular-shape particles [184].  
A coulter counter, which yields the absolute number of particles per volume unit of 
different size classes, can be used as an additional method, for example, to quantify any 
contamination from microparticles. In instruments that generates a number-weighted 
distribution, each particle is given equal weighting irrespective of its size [180]. 
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1.3.4.2 Surface Charge 
Surface charging is important for the stability of nanocrystals in solution.  According to 
the Derjaguin, Verwey, Landau, and Overbeek (DLVO) theory, the stability of a colloidal 
system depends on the balance between two counteracting forces, attractive (van der 
Waals) and repulsive (electrical double layer) [185]. The electrical double layer 
surrounding a particle consists of an inner region (Stern layer), where counter-ions are 
strongly bound to the particle, and an outer region (diffuse layer), where counter-ions are 
loosely associated. Within the diffuse layer, there exists a notional boundary, named the 
slipping plane, which separates counter-ions that move along with the particle and those 
that stay with the bulk fluid. The electric potential difference at the slipping plane versus 
a point in the bulk medium is defined as the zeta potential. It can be measured by using 
light scattering to monitor the electrophoretic mobility when the colloidal system is 
subjected to an electric field. In addition to the sample’s surface chemistry, pH of the 
medium, conductivity of the fluid, and concentration of additives can influence the 
distributions of counter-ions surrounding the interface and thereby the zeta potential. To 
resist flocculation and aggregation, particles need to have sufficiently high repulsion 
forces.  It is generally recognized that a specific value of zeta potential can be useful in 
predicting the physical stability of a nanosuspension formulation. ±30 mV or larger 
(absolute value) is desired for an electrostatically stabilized suspension. For particles with 
smaller zeta potentials, surfactants may be needed to provide further steric and/or 
electrostatic repulsions [186]. Numerous studies have shown that surface potential can 
have a drastic influence on cellular uptake or even tumor targeting of nanoparticles [187-
191].  One study of cationic and anionic polymeric nanoparticles with similar particle 
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size (90-100 nm) reported that anionic nanoparticles were transited through the 
degradative lysosomal pathway within the cell, while the cationic particles were 
transcytosed and accumulated at the basolateral membrane [188]. On the other hand, 
positively charged micelles caused higher hemolytic activity – due to strong electrostatic 
interaction between the particles and the anionic erythrocyte membrane – and 
accumulated in the liver proportionally to the positive charge density; in contrast, 
negatively charged micelles were not hemolytic [191].  Highly charged nanoparticles had 
a much higher opsonization rate than neutral or slightly charged nanoparticles of the 
same size [191, 192]. Thus, it is necessary to balance the surface charge in order to 
achieve maximum storage stability and minimum opsonization subsequent to intravenous 
administration. 
 
1.3.4.3 Crystallinity 
Crystallinity of a product is often assessed by X-ray diffraction (XRD), complemented by 
differential scanning calorimetry (DSC). When a compound is known to form hydrates or 
solvates, thermogravimetric analysis (TGA) is used as well to determine any weight loss 
at elevated temperature.  These analyses also play a key role in characterizing 
polymorphic forms of a crystalline formulation.  In one study to formulate  SN 30191, an 
anticancer drug (PI3K inhibitor), by high pressure homogenization, the pre-milled form II 
particles were converted to form I when the sample was subjected to a pressure between 
500 and 1500 bar [193]. Further increase in pressure to 1750 bar led the formation of a 
hydrate. Polymorphic transitions can considerably change the solubility and dissolution 
rate, which may alter a compound’s in vivo performance, such as its bioavailability. 
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1.3.4.4 Dissolution 
Dissolution behavior of nanocrystals can be determined by the USP dissolution apparatus 
2 (paddle) or similar methods.  A large volume of dissolution medium (e.g., more than 
500 mL) may be needed to minimize the influence of withdrawing samples during the 
measurement. Careful attention is needed when carrying out the solubility measurement 
of nanocrystals. It is reported that solubility results determined by centrifugation, 
ultracentrifugation, or filtration may be questionable because of poor separation of solid 
particles from the solution [194].  In the presence of high-concentrations of stabilizers or 
surfactants, solubility of a drug may be apparently increased, likely due to micellar 
solubilization of the drug  [194].  It must be noted that although the dissolution rate of a 
nanocrystal formulation can be enhanced considerably because of the increase in surface 
area, the solubility increase is minimal. For instance, the solubility of loviride 
nanosuspension was reportedly increased by 15% when the particle size was about 150 
nm [194].   
The complete dissolution of spherical micronized particles with diameter of less than 50 
μm under sink condition can be estimated based on the Hixson-Crowell cube root law in 
the following equation: 
? ? ???
?
????
                                                    (2) 
where τ is the estimated time for complete dissolution, ρ is the density, ro is the particle 
radius, D is diffusion coefficient, and Cs is the solubility of the solid material [195].  
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Table 1.1 and Figure 1.2 represents the plots and calculated values, respectively, of 
predicted time for complete dissolution of spherical particles (radius of 100 to 500 nm) 
composed of poorly water soluble materials, with solubility of 0.5 and 1 μg/ml. As the 
solubility decreased by half, the time for a complete dissolution is doubled. The reported 
diffusion coefficient of compounds may vary depending on the method of calculation or 
analysis. For illustration purposes, the diffusion coefficients of two poorly water soluble 
compounds, camptothecin and paclitaxel are utilized to calculate the time for complete 
dissolution in Table 1.1 and Figure 1.2. Camptothecin was reported to have diffusion 
coefficient ranged from 7×10-7 cm2/sec to 2×10-7 cm2/sec [196], while paclitaxel has 
approximate diffusion coefficient value of  2×10-7 cm2/sec [197].  
 
 
Table 1.1. The predicted time to achieve complete dissolution of spherical particles under 
sink condition based on the Hixson-Crowell cube root law equation.  
 
Time for Complete Dissolution of Spherical Particles under Sink Condition (min) 
Radius (nm) 
D = 7x10-7 cm2/s D = 2x10-7 cm2/s 
Cs = 1 μg/ml Cs = 0.5 μg/ml Cs = 1 μg/ml Cs = 0.5 μg/ml 
500 29.8 59.5 104.2 208.3 
400 19.0 38.1 66.7 133.3 
300 10.7 21.4 37.5 75.0 
200 4.8 9.5 16.7 33.3 
100 1.2 2.4 4.2 8.3 
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Figure 1.2. Predicted time for complete dissolution of spherical particles composed of 
poorly water soluble compounds in sink condition based on Hixson-Crowell cube root 
law equation.  
 
1.3.5 Nanocrystals for Cancer Therapy 
Combinatorial chemistry and high throughput screening have resulted a steady increase 
in the number of drug candidates over the years, but the majority have been poorly 
soluble [198-200].  Among various formulation strategies, reducing the size of solid 
particles of a drug compound has gained considerable attention as a delivery method 
[176].  Although the marketed nanocrystal-based products are mainly for oral delivery, 
formulated mostly by the top-down approach, nanocrystals have been exploited for other 
routes as well, including parenteral, dermal, mucosal, ocular, and pulmonary [122]. 
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Relative to the conventional delivery approaches, nanocrystal formulations are free of 
organic solvents or other solubilizing chemicals which may cause adverse effects.  The 
administration of escalated doses of nanocrystals, which can be up to three to ten-fold 
higher than the maximum tolerated dose of a conventional formulation may result in 
improved patient tolerability and enhanced therapeutic efficacy [201, 202].  Compared to 
other nano-sized drug delivery systems, nanocrystals contain nearly 100% drug loading 
(surfactant(s) may be used in some cases). This is a key property of nanocrystals since 
less than 5% of the total administered dose is delivered to the tumor site [29, 30]. Once 
delivered to the tumor site, the dissolution rate of drug molecule will mainly be 
determined by its solubility in the accumulation environment and concentration gradient. 
Inhibition of cancer cell growth in the delivery site begins when the drug concentration 
starts to exceed the IC50 value (i.e. half the maximum inhibitory concentration).  In 
addition, because the majority of the nanoconstruct consists of the drug, the additional 
toxicity and hazard that may be introduced by the delivery carrier [203] is avoided. 
Depending on the method of preparation, drug nanosuspension products can either be 
crystalline or amorphous. In order to achieve better physical stability, a final product in 
crystalline state is generally preferable. 
Another advantage of formulating chemotherapeutics as nanocrystals is the ease of 
manufacturing and scale-up. The top-down approach dominates the production of 
nanocrystals and has generated several marketed products [126]. Meanwhile, commercial 
scales of techniques that are based on bottom-up approach is continually being developed 
[125]. Although no such product is currently in the market, there is certainly a growing 
interest and need in this field.  To date, the number of studies reported to use nanocrystals 
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for cancer therapy is still limited (Table 1.1).  Because of their promising values, more 
studies are expected to emerge. Some recent studies that characterize the behavior and in 
vitro, in vivo, and clinical performance of nanocrystal formulations of antineoplastic 
agents are reviewed as follows. 
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Table 1.2 Nanocrystal Formulations of Anticancer Drugs 
Compound Methoda Stabilizer(s) Average Size (nm) Zeta Potential (mV) Ref 
Piposulfan MM Tween 80, Span80 210.2±38.9 N/A [201] 
Camptothecin MM Pluronic® F108 202.3±30.5 N/A [201] 
Etoposide MM Pluronic® F127 256.2±53.0 N/A [201] 
Paclitaxel MM Pluronic® F127 279.2±29.60 N/A [201] 
Asulacrine HPH Poloxamer 188  (Pluronic® F68) 702±0.02(d90) N/A [204] 
SN30191 HPH Poloxamer 407, Solutol HS15, Mannitol 1200-1300 (d90) N/A [193] 
Paclitaxel 3PNET Pluronic® F127 122±35 0.82 [202, 205] 
Oridonin HPH Pluronic
® F68, lecithin, 
HPMC, PVP 
(i) 322.7;  
(ii) 103.3±1.5 & 897.2±14.2;  
(iii) 912.5±17.6 
(i) -26.74±2.68; 
(ii) -20.3±0.4, -21.8±0.8; 
(iii) N/A 
(i) [174], 
(ii) [206], 
(iii) [207] 
Deacetymyco
epoxydiene HPH 
Lecithin, Pluronic® F68, 
HPMC, PVP 423±11 -23.1±3.5 [208] 
Quercetin HPH, EPAS Pluronic
® F68, Lecithin 213.6±29.3 (HPH); 282.6±0.02 (EPAS) 
-22.48±4.6(HPH); 
       -21.12±2.7(EPAS) [209] 
Paclitaxel SLbL, US Polyelectrolytes, BSA 
100±20 (SLbL); 
220±20 (US) -45±3 [210] 
Camptothecin Anti-solvent Without stabilizer 234.4±35.6 -41.8±1.3 [168] 
Paclitaxel Anti-solvent Without stabilizer 438.5±8.3 -15-22 [169] 
a HPH: high pressure homogenization; MM: media milling; EPAS: evaporative precipitation into aqueous solution; 3PNET: three-
phase nano-particle engineering technology; SLbL: sonication assisted layer-by-layer polyelectrolyte coating; US: ultrasonication. 
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1.3.5.1 In Vitro Evaluation of Nanocrystals 
Free drug molecules dissolved from nanocrystals enter cells through passive diffusion. 
Additionally, nanocrystals can be taken up by cells via endocytosis.  Particles having a 
size of 200 nm or less are preferentially internalized after binding to clathrin-coated pits, 
while particles between 200 and 500 nm are internalized by the caveolae-mediated 
pathway [211, 212]. The maximum size of particles that can be endocytosed is 500 nm 
[213]. In one of our studies, the addition of chlorpromazine (CPZ), which disrupts 
clathrin and hence clathrin-mediated endocytosis, reduced the cellular uptake of 
camptothecin (CPT) nanocrystals by about 20% compared with that of CPT nanocrystals 
without the inhibitor [168]. This finding suggested that clathrin-mediated endocytosis 
was, in some degree, responsible for the uptake of CPT nanocrystals in cancer cells. 
Moreover, nanocrystals were observed to exert greater cytotoxicity than a solution 
formulation, particularly when the incubation time was relatively short.  One study 
showed that, against prostate cancer cells PC-3, the IC50 value of 
deacetymycoepoxydiene (DM) nanocrystals was much lower than that of the drug 
solution after a 12-hour incubation; the IC50 value of the nanosuspension and solution 
converged when observed at 48 hours [208]. The cell internalization of nanocrystals, 
which were able to provide a higher intercellular concentration of drug, may have been 
responsible for the increased toxicity in the early incubation period. 
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1.3.5.2 In Vivo Evaluation of Nanocrystals 
One of the early in vivo studies of nanocrystals was conducted in a murine 
adenocarcinoma model by testing ball-milled nanocrystals of piposulfan, camptothecin, 
etoposide, and paclitaxel [201].  Solubility values of these drugs range from 200 to less 
than 4 μg/mL.  It was found that, when given intravenously using a multiple-dose 
regimen at the maximum tolerated dose (MTD), the nanocrystal formulations of the four 
chemotherapeutic drugs were able to suppress the tumor burden with no deaths reported, 
while control formulations using organic solvents and surfactants to solubilize the drugs 
caused 20% or more mortality.  A significant increase in the MTD of nanocrystals was 
also reported by a recent study in which paclitaxel nanocrystals were formulated by a 
three-phase nanoparticle engineering technique and tested in two murine tumor models 
[202]. The nanocrystals were given at a dose equivalent to the MTD of a Cremophor-EL 
solubilized dosage form (20 mg/kg), and both formulations showed similar treatment 
efficacy. The nanocrystals showed a much improved therapeutic outcome when 
administered at 60 mg/kg. The PTX nanosuspensions were also tested by oral 
administration but found to be less effective than the parenteral dosage form. 
Intravenously administered nanocrystals are expected to reach tumors via the EPR effect.  
We found that camptothecin nanocrystals, administered in a MCF-7 xenografted murine 
tumor model, yielded significantly better antitumor activity (p<0.01) than the drug salt 
solution [168].  Biodistribution results at 24 hour after the injection further revealed that 
CPT nanocrystals accumulated in the tumor at a much higher level than the salt solution. 
Note that a majority of nanocrystals (or any nanoparticle drug delivery systems) are still 
being taken up by the reticuloendothelial system (RES), mainly liver and spleen [214]. A 
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common practice to reduce the RES uptake and enhance biocompatibility is to modify the 
surface of a nanosystem, physically or chemically, with biocompatible polymers, such as 
polyethylene glycol (PEG), which is known to prolong the systemic circulation [215]. 
Because nanocrystals continue to dissolve after their administration, surface coating by 
polymeric surfactants onto the nanocrystals may not work. Thus, there is a critical need to 
investigate new ways to incorporate biocompatible molecules (and other functional 
molecules) into nanocrystals.  
The particle size of a nanoparticle delivery system has a fundamental influence on the 
pharmacokinetics (PK) and biodistribution of the nanoparticles. It has been suggested that 
particles between 50 and 300 nm can achieve prolonged blood circulation [214, 216], 
which helps their accumulation in solid tumors via the EPR effect [214, 217, 218]. With 
the same surface charge of -25 mV, polymeric nanoparticles with the size of 150 nm were 
reported to have significantly longer circulation time due to the low uptake by the RES 
than particles of 500 nm [189]. Compared with a solution formulation, optimally 
designed nanovehicles are expected to bear improved PK behaviors, including increased 
half-life (t½), reduced clearance (Cl), increased area under the curve (AUC), and 
increased mean residence time (MRT) [218]. The PK of intravenously injected 
nanocrystals of chemotherapeutics (e.g., paclitaxel, asulacrine, and oridonin) was 
reported to be quite distinctive, best described by a two-compartmental model, where the 
elimination was non-zero order [204, 206, 219]. In a rabbit model, the pharmacokinetic 
profile of 103-nm oridonin nanocrystals, which were shown to dissolve rapidly, was 
similar to that of the drug solution [174]. On the contrary, the 300-nm paclitaxel [219] 
and 700-nm asulacrine nanocrystals [204] were rapidly taken up by the RES organs, such 
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as liver, spleen, and lungs, resulting in shortened distribution half-lives (t½α) and 
decreased AUC. The decreased and yet prolonged AUC in plasma was found to be 
beneficial to minimize the toxic drug exposure. Interestingly, the 900-nm oridonin 
nanocrystals were found to achieve decreased Cl and t½α and increased AUC as 
compared with the dissolved drug [174].  Overall, prolonged elimination half-life (t½β) 
and MRT were observed for nanocrystals between 300 and 900 nm [204, 206, 219]. The 
sustained blood concentrations likely resulted from slow release of drug molecules from 
nanocrystals trapped by the RES organs [204, 206]. Size has also been found to affect 
particle accumulation and retention in the tumor. Small particles may accumulate faster 
in tumors, but larger ones can be retained longer [29]. Moreover, particle accumulation in 
the tumor relies on the leakiness of the tumor vasculature, which is further determined by 
the tumor type [220, 221], histological grade, and malignant severity [222].  The cutoff 
sizes of pores in the tumor vasculature range from 200 nm to as large as 1.2 ?m, with the 
majority between 380 and 780 nm [221].  Collectively, it has been suggested that in order 
to take advantage of the EPR effect and target tumors, nanoparticles should be smaller 
than 400 nm [29]. The particle size is nonetheless one of many factors that determine the 
pharmacokinetics and biodistribution of nanoparticles. Surface chemistry plays an 
important role as well. Because their surface is decorated with hydroxyl groups, 
amorphous silica particles with sizes of 50 and 250 nm exhibited significantly higher 
blood to liver ratios compared with 180-nm PEG-coated solid lipid nanoparticles in a 
Wistar rat model [216]. Despite their intrinsic hydrophilicity, which resulted in decreased 
RES clearance, detailed toxicological studies of amorphous silica particles are still 
limited [223].  
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1.3.5.3 Clinical Study of Nanocrystal Formulation 
A recent clinical study of Panzem®, a nanocrystal dispersion of 2-methoxyestradiol 
(2ME2), an endogenous estradiol-17β metabolite that bears antimitotic and 
antioangiogenic activities, demonstrated an improved pharmacokinetic performance and 
antitumor activity relative to its capsule formulation when given orally to 16 patients with 
advanced solid malignancies and 14 patients with taxane-refractory, metastatic castrate-
resistant prostate cancer [224, 225].  Despite the fact that the 2ME2 nanocrystal 
formulation was well-tolerated and showd evidence of biologic activity, the active 
ingredient did not appear to have sufficient clinical activity and the study was terminated 
at phase II. No other clinical studies to test parenteral nanocrystal formulations for cancer 
therapy have been reported 
 
1.4. Hybrid Nanocrystals for Theranostics 
In vivo imaging in animals has been extended tremendously due to the advancement in 
molecular and cellular techniques, increased numbers of animal models, and development 
of novel imaging probes. Non-invasive in vivo imaging is more advantageous relative to 
conventional, non-quantitative cytology/histology microscopy techniques [226]. The 
advancement in in vivo imaging has facilitated the ability to: optimize drug and gene 
therapy, visualize drug response at the molecular and cellular level, and assess disease 
progression [35]. Besides providing a visualization of the temporal and spatial 
biodistribution of the molecular probe and its relation to biological pathways, in vivo 
imaging also allow researchers to acquire longitudinal imaging of the same animal at 
multiple time points.  More specifically, in vivo imaging can significantly benefit the 
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development of novel cancer nanotechnologies, in terms of providing early assessment of 
therapeutic response. Additionally, imaging may also permit the evaluation of 
biodistribution as well as pharmacokinetics.  
Relative to other non-invasive imaging modalities, such as MRI and PET, optical 
imaging, which is being continuously developed, has several advantages, including high 
sensitivity, absence of radioactive irradiation, low running cost, and potential application 
in image-guided surgery [227]. In recent years, optical imaging has been used extensively 
to provide early assessment of therapeutic response of novel cancer nanotherapeutics. 
The evaluation of biodistribution and pharmacokinetics of fluorescent-labeled agents in 
vivo has been attempted as well, either by analyzing the excised tissues [228-233] or non-
invasively via tomographic imaging [234]. Assuming that the optical probe remains with 
to the delivery vehicle, optical imaging serves as a fast screening tool for assessing the 
temporal accumulation in the tumor and comparing percent distribution of different 
formulations in the same tissue type (e.g. tumor to tumor).  
With an objective to gain a better understanding of nanocrystal behavior in vivo, our 
laboratory has developed novel nanosized hybrid crystals containing a physically 
integrated material. The concept was inspired by a well-known phenomenon in solid-state 
chemistry wherein impurities are entrapped in the crystal lattice of a host particle.  The 
existence of foreign substances in a host is typically insignificant, having little effect on 
the structure and integrity of the host crystal structure but capable of casting drastic 
influence on the optical appearance and other physical properties of the host.  Examples 
are abundant.  Colored diamonds are one famous example; synthetic hybrid crystals 
include alloys and semiconductors. The most relevant examples are “dyeing crystals”, 
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where guest dye molecules are integrated in organic crystals [235]. As a proof of concept, 
our laboratory has tested whether or not fluorophores can be entrapped in individual drug 
crystals. Examples are the incorporation of rhodamine B and fluorescein into 
acetaminophen and aspirin, respectively, drug crystals (Figure 1.2). 
 
 
Figure 1.3. The illustration (left) and examples (right) of hybrid crystals. Rhodamine B 
(red) and fluorescein (green) were embedded in acetaminophen (top) and aspirin (bottom) 
crystals, respectively.  
 
Similar to pure drug nanocrystals, hybrid nanocrystals can be prepared using the anti-
solvent method, where a concentrated drug solution (in organic solvent) is added rapidly 
to the anti-solvent, water, under intense stirring and sonication. Fluorophore(s), which 
is/are pre-mixed with water, can be entrapped as the crystals grow. Because nanocrystals 
are being formed rapidly due to the sudden drop in solubility, they have a large quantity 
of defects, where imaging agents can be integrated. It is important to note that the 
fluorophore is physically integrated, requiring no chemical conjugation. The tiny amount 
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of integrated-fluorophore can be detected in animals by optical imaging. Based on some 
preliminary results, hybrid nanocrystals of paclitaxel containing a near infrared 
fluorophore were able to accumulate in the tumor and exert efficacy in a breast cancer 
MCF-7 xenograft [169]. 
 
1.5. Statement of Problems 
Chemotherapy remains as the cornerstone of cancer therapy, specifically in inhibiting the 
growth of residual or metastasized cancer cells after the debulking surgery. Nonetheless, 
in clinical settings, the delivery of chemotherapeutics has been impeded by their poor 
aqueous solubility. Take paclitaxel (PTX) as an example. Over the past two decades, it 
has played a significant role in the treatment of various malignancies, including ovarian, 
lung, breast, and head and neck carcinomas [236]. After its discovery in the early 1960s, 
problems related to its solubility remain challenging. Early investigations led to the 
conclusion that the solubilization of PTX in a 1:1 ratio of Cremophor EL®, a 
polyoxyethylated castor oil vehicle, and dehydrated ethanol was the most viable option 
for commercial formulation of PTX (Taxol®).  A high incidence of acute hypersensitivity 
reactions, nephrotoxicity, neurotoxicity, and neutropenia [3, 4] has been associated with 
the inherent toxicity of the delivery vehicle, Cremophor EL. Even with premedication of 
corticosteroids and a histamine antagonist, 40% of patients still developed minor 
reactions (e.g. flushing and rash) and nearly 3% of them experienced potentially life-
threatening reactions [4, 237]. Overall, conventional chemotherapy, which utilizes small 
molecule drugs, suffers from toxicity due to the lack of tumor selectivity and the use of 
harsh solvents for solubilization.  
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Efforts in minimizing systemic toxicity by targeted anti-tumor therapy are underway. 
Specifically, chemotherapeutics have been encapsulated into nano-sized vehicles, which 
can selectively accumulate and be retained in the tumor due to the EPR effect [5-7]. The 
leakiness of the tumor blood vessel and decreased efficiency of tumor lymphatic drainage 
allow the accumulation of nanovehicles at the target site.  
In the past two to three decades, numerous research efforts have been concentrated on 
creating nanoconstructs, including liposomes, micelles, solid lipid nanoparticles, 
polymeric nanoparticles, dendrimers, and core-shell structures, for the delivery of cancer 
therapy. Although some products are currently being investigated in clinical trials, only a 
few have been approved by the FDA [22, 23]. One of them is Abraxane® (nab paclitaxel; 
ABI-007), which is a novel formulation of PTX prepared by high-pressure 
homogenization in the presence of human serum albumin [238]. The resultant amorphous 
particles have a mean diameter of 130-150 nm, which can be injected intravenously 
without any further need of solubilization. Adverse side effects, albeit minimized, were 
still observed during the clinical trials [239]. However, the cost of Abraxane® is 
outrageously high, relative to the generic formulation, Taxol®. Depending on the dose 
needed, patient may need to spend between $10,000 to 22,000 over the period of 12 
weeks [240].  
In general, the current approaches for solubilizing and encapsulating antineoplastic 
agents into nano-sized vehicles are still limited by low drug loading, drug leakage [24, 
25], inherent toxicity of the encapsulating materials [27], and complex fabrication 
methods [28], which makes the manufacturing at large scale hard to achieve. Nano-sized 
drug crystals (nanocrystals) contain close to 100% drug, and it is feasible to produce 
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them at a large scale. Due to the absence of harsh solvents, nanocrystal formulations of 
anticancer drugs also were reported to have elevated maximum tolerated dose relative to 
conventionally delivered drug [201, 202]. Hence, nanocrystals possess appealing 
properties, which may be suitable for cancer therapy.  
Indeed several antineoplastic active ingredients, including PTX, have been formulated as 
nanocrystals for intravenous administration. Most PTX nanocrystals were generated by 
top-down approaches, either via milling [201, 241] or high-pressure homogenization 
[219]. One study developed PTX nanocrystals via a novel bottom-up approach [242]. 
Most studies only reported the extent of efficacy and toxicity of the formulation in 
murine xenograft models. When administered at the same dose, 20 mg/kg, PTX 
nanocrystals were reported to exert a similar efficacy as Taxol [242]. Increased efficacy, 
with minimal toxicity, was observed when the dose was elevated to 60 mg/kg [242] and 
100 mg/kg [129]. Pharmacokinetics and tissue distribution of PTX nanocrystals, prepared 
by high-pressure homogenization, were studied in the rats. Although PTX nanocrystals 
were rapidly cleared by the reticuloendothelial system (RES), it was postulated that the 
prolonged half-life of elimination was due to the slow release of PTX from macrophages. 
Yet, the degree of tumor accumulation has not been investigated thus far.  
Furthermore, the advancement of in vivo imaging modalities, specifically optical 
imaging, has significantly benefited the development of novel cancer nanotechnologies, 
in terms of providing an early assessment of therapeutic response. The in vivo imaging 
devices have enabled the visualization of the temporal and spatial biodistribution as well 
as longitudinal imaging of nanotheranostics in the same animal at multiple time points.  
Novel hybrid nanocrystals were developed by entrapping near infrared fluorophore(s) in 
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drug nanocrystals in a simple, one-pot synthesis. Even with continuous advancement in 
technology, optical imaging has inherent limitations in terms of fluorescent probe 
localization, depth of detection, and quantification. Although in vivo fluorescence 
imaging is widely utilized in pre-clinical settings, minimum efforts habe been expanded 
to investigate the correlation between drug concentration and fluorescence signal in ex 
vivo tissues. 
 
1.6. Objectives 
The overall goal of this dissertation is to formulate both pure and hybrid nanocrystals, 
evaluate their performance in vitro and in vivo, and investigate the extent of tissue 
distribution and tumor accumulation in a murine model. Specifically, paclitaxel (PTX) 
will be used as a model drug.   
Our central hypothesis is that solvent-free nanocrystals allow a safer delivery of poorly 
water soluble drugs and are able to accumulate in the tumor due of the EPR effect, 
releasing free drug molecules that exert comparable therapeutic effects to the 
conventional delivery method. As such, the following specific aims are pursued in order 
to test the hypothesis: 
1). Fabricate pure nanocrystals of paclitaxel, fully characterize their physical properties, 
and determine their physical and chemical stability in different media and storage 
conditions. 
PTX nanocrystals were produced by a combination approach. The nano-precipitates 
produced by the anti-solvent methods were further homogenized to obtain a narrow size 
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particle distribution. The particle size, size distribution, morphology, surface charge, 
crystallinity, and the crystal form of nanocrystals were determined. The alterations in 
particle size and morphology of paclitaxel nanocrystals in different media were evaluated 
by scanning electron microscopy and dynamic light scattering. The stability, in terms of 
maintaining particle size, morphology, surface charge, and chemical composition, of PTX 
nanocrystals in aqueous suspension stored at 4°C were compared to that in ambient 
temperature. The particle size and morphology of the freeze-dried product stored at 4°C, 
room temperature, and 40°C/75% relative humidity, were evaluated. 
2). Evaluate the cellular cytotoxicity of pure PTX nanocrystals and mechanism of cellular 
internalization of hybrid PTX/FPR-648 nanocrystals. 
PTX nanocrystal suspensions were tested for their inhibitory effect in vitro, particularly 
in human colon adenocarcinoma HT-29 cells. The IC50, the half maximum inhibitory 
concentration, of PTX nanocrystals were compared with Taxol at three different time 
points: 24, 48, and 72 hours, to elucidate any duration-dependent chemosensitivity. 
PTX/FPR-648 hybrid nanocrystals were produced by the combination approach, as 
previously mentioned. Particle size and morphology of the product were determined. The 
cellular internalization of PTX/FPR-648 nanocrystals in human breast cancer MCF-7 was 
investigated to elucidate higher cytotoxicity associated with PTX nanocrystals in human 
breast cancer MCF-7. Confocal microscopy was utilized to seek any evidence of 
nanocrystal internalization via non-phagocytic endocytosis pathways.   
3). Evaluate the efficacy and toxicity of pure and hybrid PTX nanocrystals in xenograft 
murine models as well as the performance of hybrid PTX nanocrystals in vivo. 
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a. The efficacy and toxicity of pure PTX nanocrystals were assessed from the Kaplan-
Meier plot and percent of body weight change generated through a survival study in 
colon cancer HT-29 xenograft. The PTX nanocrystals were compared against the 
negative control (saline) and positive control (Taxol) at the same dose, 20 mg/kg.  
b. Pure and hybrid PTX nanocrystals were produced using the anti-solvent method. The 
ability of PTX hybrid nanocrystals to perform as a theranostic system was tested in the 
murine human breast cancer MCF-7 orthotopic xenograft. Two fluorophores were 
incorporated: MMPSense 750, a bioactivatable fluorophore to monitor the disease state, 
and FPR-648, a regular near infrared fluorophore to trace the distribution and 
accumulation in the tumor site. The efficacy and toxicity of PTX/MMPSense/FPR-648 
were compared to untreated, Taxol, and pure PTX nanocrystals by evaluating the percent 
change in tumor volume and body weight, respectively, daily for a total of 7 days 
subsequent to a single injection of 20 mg/kg. 
c. Pure and hybrid nanocrystals were produced by the anti-solvent method. Nicardipine, a 
calcium channel blocker, which may enhance the EPR effect via local blood vessel 
dilation, was incorporated into the PTX nanocrystals. The efficacy and toxicity of 
PTX/nicardipine hybrid nanocrystals were compared to Taxol and PTX pure nanocrystals 
by evaluating the percent change of tumor volume and body weight, respectively, for 7 
days after a single dose of treatment at 20 mg/kg of PTX. 
4). Compare the tissue distribution and tumor accumulation of 3H-PTX/FPI-749 
nanocrystals and 3H-Taxol by radioactive analysis, and determine if the post-mortem 
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distribution of fluorescence signals from the optical imaging can be correlated to that of 
radiolabeled PTX.  
3H-PTX/FPI-749 nanocrystals were produced by using the combination approach. The 
morphology and particle size of hybrid nanocrystals without the radioactive payload were 
determined. The tumor accumulation and tissue distribution of 3H-PTX/FPI-749 
nanocrystals were compared head-to-head with the conventional formulation, 3H-Taxol. 
Furthermore, the ex vivo distribution of fluorescence signal detected under optical 
imaging and radiolabeled PTX were compared. 
 
In the following chapters, the results from each specific aim will be presented and further 
discussed. The purpose is to provide a thorough evaluation of the physicochemical 
characterization and behavior in vitro and in vivo of paclitaxel nanocrystals.  
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Chapter 2 - Preparation and Physicochemical Characterization of Paclitaxel 
Nanocrystals 
 
2.1 Introduction 
Paclitaxel (PTX) is isolated from the bark of North American pacific yew tree, Taxus 
brevifolia [243]. It exerts notable antineoplastic activity in clinical studies against various 
cancers, including ovarian, lung, breast, and head and neck carcinomas [236]. The 
efficacy of PTX in other human carcinomas is also actively being investigated. PTX 
prevents the ability of cells to perform normal mitosis (in G2 and M phases) by both 
promoting and stabilizing microtubule assembly [244].  It has a molecular weight of 
853.9 g/mol and is highly lipophilic (Figure 2.1). The clinical application of PTX has 
been limited due to its low solubility in water (< 1 μg/mL). Currently, Taxol and 
Abraxane are two commercially available formulations of PTX. In Taxol, PTX is 
dissolved in a mixture of Cremophor EL®, a polyoxyethylated castor oil vehicle, and 
dehydrated ethanol USP (1:1, v/v). Cremophor EL, however, is notably responsible for 
some adverse effects, including hypersensitivity reactions, nephrotoxicity, neurotoxicity, 
and neutropenia [3, 4]. To alleviate the reactions, corticosteroids and histamine antagonist 
are generally given prior to the infusion. Yet, 40% of the patients still develop minor 
reactions (e.g. flushing and rash) and nearly 3% of them experience potentially life-
threatening reaction [4, 237]. Abraxane (nab paclitaxel; ABI-007) is a novel formulation 
prepared by high-pressure homogenization of PTX in the presence of human serum 
albumin at a concentration of 3-4%, similar to that found in the blood [238]. With its 
mean particle diameter of 130-150 nm, close to one-hundredth the size of a single red 
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blood cell, the colloidal suspension eliminates the need for solubilization. This novel 
formulation does hold some promise in cancer therapy. The preclinical and clinical 
studies of Abraxane have been reviewed [239]. Other alternative attempts to create 
Cremophor-free formulations, such as cosolvents, emulsions, micelles, liposomes, 
microsphere nanoparticles, cyclodextrins, paste, and implants, have been made to 
improve the solubility of PTX and minimize side effects associated with the delivery 
vehicle [245].  
In recent years, PTX also has been formulated as nanocrystals (nanosuspension) [201, 
210, 219, 241, 242]. Compared to Taxol and Abraxane, nanocrystals exhibit a high ratio 
of drug to excipient (drug loading). Thus, upon infiltration to the target cells, nanocrystals 
can potentially unload elevated drug concentration to the cells, resulting in an increase in 
therapeutic efficacy. Nanocrystals are also simple to formulate and feasible for scale up. 
Additionally, relative to human serum albumin utilized in the production of Abraxane, 
the excipients used, if any, for nanocrystal formulation are readily available and cost-
effective [246]. Out of the five reported formulations of PTX nanocrystals 
(nanosuspension), three were produced solely by the size-reduction method, either by 
milling [201, 241] or high-pressure homogenization [219]. Patterkari and colleagues 
attempted to fabricate the nanocolloids by both top-down (ultrasonication) and bottom-up 
approaches (anti-solvent/evaporation) [210]. Meanwhile, Liu and others developed the 
PTX nanocrystals by a novel bottom-up approach known as three-phase nanoparticle 
engineering technology (3PNET), which requires at least a ratio of 1 to 5 of PTX and 
Pluronic F127® [242]. The nanocrystals generated by the aforementioned methods have 
particle sizes between 100 and 400 nm.  
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In this study, to obtain both narrow size distribution and approximate size of 200 nm, 
PTX nanocrystals were produced by combining the bottom-up (anti-solvent) and top-
down (homogenization) methods. Since the nanocrystals are intended for intravenous 
administration of cancer therapy, it is necessary that the fabricated nanocrystals are below 
400 nm, the suggested maximum value for particles to exploit the enhanced permeability 
and retention (EPR) effect [29].  The physical properties, crystallinity, and storage 
stability of the produced PTX nanocrystals were evaluated.                                                                          
 
 
Figure 2.1. Chemical structure of Paclitaxel (PTX) 
 
2.2 Materials and Methods 
2.2.1 Materials 
Paclitaxel (PTX, >99.5%, USP30) was purchased from 21CECPharm (United Kingdom). 
Ethanol (HPLC grade), acetonitrile (HPLC grade), phosphate buffered saline, and cell 
culture media were purchased from Fisher Scientific (Pittsburgh, PA). Sodium chloride 
was purchased from Sigma (St. Louis, MO). Saline (0.9% w/v sodium chloride) for 
injection was from Hospira (Lake Forrest, IL). PTX dihydate was obtained by drying 
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PTX anhydrous (from manufacturer) that had been placed and stirred in DI water 
overnight. Deionized (DI) water (by Milli-Q®, filtered through 0.2 ?m membrane) was 
used for all the experiments. 0.050 ?m (50 nm) Whatman® nuclepore polycarbonate 
track-etched membranes used for filtration were purchased from Fisher Scientific 
(Pittsburgh, PA).   
 
2.2.2 Preparation of Paclitaxel Nanocrystals 
Paclitaxel nanocrystals were produced by the combination approach as depicted in Figure 
2.2. Specifically, the nanocrystals produced by a bottom up approach, anti-solvent 
method, were then subjected to homogenization (i.e. a top-down approach).  In a typical 
experiment, 1 mL of 3 mg/mL of paclitaxel in ethanol was added rapidly to 20 mL 
deionized water in 3-neck round bottom flask (500 mL). The mixture was stirred at 1,100 
rpm with stirrer shaft and under intense sonication (in sonication bath F20D, output of 70 
W and 42±6 KHz, Fisher Scientific). Ice was added to the sonication bath to keep the 
temperature between 14-18°C. After 10 minutes of stirring time, the flask was removed 
from the stirring station and placed in a desiccator to remove bubbles generated due to 
rapid stirring. The mixture was then filtered through a 50 nm polycarbonate membrane. 
The retentate was re-suspended in 2 mL DI water placed in 20 mL scintillation vial and 
homogenized (Fisher Scientific® PowerGen® 125) for 6 minutes at 30,000 rpm. When 
needed, nanocrystal batches were combined to obtain the desired concentration. For 
solid-state characterization and storage stability studies, the concentrated suspension of 
PTX nanocrystals were freeze-dried (LabConco Freeze Dryer 4.5) overnight. 
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Figure 2.2. Schematic of nanocrystal preparation method by combination approach. 
 
2.2.3 Particle Size and Surface Charge Measurements of Paclitaxel Nanocrystals 
Scanning electron microscope (SEM) images were obtained using a Hitachi SEM 4300 at 
an accelerating voltage of 3 kV. All SEM samples were prepared similarly by the 
following method. A drop (10-20 μL) of nanocrystal suspension was placed on a 50 nm 
nuclepore filter membrane. After being vacuum-dried, the filter membrane was attached 
to the SEM sample holder by using PELCO Tabs™, Carbon Conductive Tabs, 9 mm OD 
(Ted Pella, Redding, CA). Prior to visualization, using a sputter coater, samples were 
coated with conductive layers of gold palladium (Au/Pd) for 1 minute with a current of 
20 mA, resulting in an approximately 10-15 nm thick coating. Analysis of particle size 
from the SEM images was performed using SigmaScan (Systat software Inc, San Jose, 
CA). The mean size (i.e. longest dimension) and standard deviation from approximately 
one hundred particles are presented. In addition to SEM analysis, the hydrodynamic 
diameter of PTX nanocrystals was measured in deionized water (viscosity of 0.8872 cP 
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and refraction index of 1.330) at a concentration of 0.1 mg/ml using dynamic light 
scattering (DLS), Malvern Nano-ZS instrument (Malvern Instruments, UK). The zeta 
potential was measured using the same instrument in 10 mM sodium chloride (NaCl) at a 
concentration of 0.1 mg/ml. Both particle size and zeta potential measurements were 
performed in triplicate. 
 
2.2.4 Solid-state Characterization of Paclitaxel Nanocrystals 
The crystallinity of freeze-dried PTX nanocrystals was assessed by using a Rigaku X-ray 
diffractometer (Rigaku Americas Corp.) with Cu Kα radiation (40 kV, 44 mA). Scans 
were obtained from 5 to 40o2?, with steps of 0.04o and scan rate of 0.5o2?/min. 
Modulated differential scanning calorimetry (MDSC) analysis was performed on a TA 
Instruments Q2000 (TA Instruments, New Castle, DE). DSC thermograms for both PTX 
nanocrystals and dihydrate were obtained using a 3°C/minute heating rate from 25 to 
300°C in pinhole pans. PTX nanocrystals and dihydrate were modulated at ± 1.5°C / 60 
seconds and ± 0.48°C / 60 seconds, respectively. Thermogravimetric analysis (TGA) 
analysis was performed on TA Instruments Q50 (TA Instruments, New Castle, DE) at a 
heating rate of 10°C/minute from 25 to 300°C. The corresponding TA Instruments 
Universal Analysis software was used to analyze the DSC and TGA data. 
 
2.2.5 HPLC Analysis 
Quantification of paclitaxel was conducted by high liquid chromatography (HPLC, 
Waters Breeze) with a Waters’ Symmetry C18 5 ?m column (4.6 x 150 mm); it was 
analyzed by a UV detector (Waters 2487 dual λ absorbance detector) at 227 nm with a 
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mobile phase of ethanol/acetonitrile (50:50) pumped at a rate of 2 mL/min (Waters 1525 
binary pump). The column was equilibrated to 35oC prior to sample injection (20 ?L).  
 
2.2.6 Solubility of Paclitaxel Nanocrystals in PBS 
Excess amount of PTX anhydrous (from manufacturer), PTX dihydrate, and PTX 
nanocrystals were placed in 20 mL of scintillation vials (n=3) containing PBS, which had 
been equilibrated to 37°C. The vials were sealed, placed in rotator, and kept in a 37°C 
incubator (VWR Shel Lab Model 1525, Sheldon Manufacturing, Inc., Cornelius, OR) for 
the entire period of the study. At various sampling intervals, 1 mL of solution was 
removed from each vial and passed through a Millex LCR 0.45μm PTFE filter, 25 mm. 
The filtrate was appropriately diluted with ethanol and assayed by HPLC. 
 
2.2.7 Particle Size Analysis of Paclitaxel Nanocrystals in Different Media 
Particle size of PTX nanocrystals was monitor after incubation in the following media (at 
0.1 mg/mL) was monitored: (a) saline, (b) cell culture media (Dubelco’s Modified Eagle 
Medium (DMEM) with no phenol red + 10% fetal bovine serum), and (c) nude mouse’ 
whole blood/buffered sodium citrate (9:1 v/v, 0.109 M, 3.2%, to prevent coagulation). 
Specifically, PTX nanocrystals were suspended in the media at a concentration of 0.1 
mg/ml and incubated at 37°C with a shaking speed of 100 rpm (Series 2.5 Incubator 
Shaker, New Brunswick Scientific Co., Inc, Edison, NJ).  Prior to SEM analysis, the 
mixture was briefly mixed using a vortex mixer, and 10-20 μL of sample was withdrawn 
for SEM analysis. All SEM images were analyzed with SigmaScan as described 
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previously. The hydrodynamic size of the PTX nanocrystals in saline and cell culture 
media were also evaluated at 37°C by using a DLS Malver Nano-ZS. 
 
2.2.8 Storage Stability of Paclitaxel Nanocrystals 
The storage stability of PTX nanocrystals was analyzed for both suspension and freeze-
dried forms. The suspension of PTX nanocrystals was stored at 3 mg/ml in a refrigerator 
at 4°C and at room temperature. The freeze-dried form was stored in a refrigerator at 4°C, 
at room temperature, and in a stability chamber at 40°C/75% relative humidity. At 
various sampling intervals, key parameters were analyzed. For the suspension, particle 
size (DLS and SEM), zeta potential, and % PTX remaining were determined. The freeze-
dried product was re-suspended in DI water and subjected to sonication prior to the SEM 
analysis.  
 
2.3 Results and Discussion 
2.3.1 Particle Size and Surface Charge Measurements of Paclitaxel Nanocrystals 
PTX nanocrystals with average size of 200 nm can be produced by the combination 
approach. Figure 2.3 illustrates the typical morphology and size of the PTX nanocrystals. 
Particularly for the specific batch imaged, the hydrodynamic diameter (ZD) was 176 ± 1 
nm. Compared to the DLS result, the particle size measured from the SEM images using 
the SigmaScan, 200 ± 60 nm, correlates fairly well. When measured in 10 mM NaCl at a 
concentration of 0.1 mg/mL, the surface charge was -6.3 ± 0.2 mV (pH: 6.3 ±0.4). Figure 
2.4 and 2.5 show the graphs obtained from the Nano-ZS for particle size and zeta 
potential measurements, respectively. The DLS generated a polydispersity index (PI) of 
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0.08 ± 0.02. The measured PI, which was less than 0.25, suggested the presence of 
narrow particle size distribution.  
 
 
Figure 2.3. SEM image showing typical morphology and size of PTX nanocrystals 
produced with the combination approach. 
 
Figure 2.4. Particle size measurements of PTX nanocrystals suspended in DI water at 0.1 
mg/mL by Nano-ZS. The three lines represent the triplicate measurements.  
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Figure 2.5. Zeta potential measurements of PTX nanocrystals suspended in 10 mM NaCl 
at 0.1 mg/mL by Nano ZS. The three lines represent the triplicate measurements.  
 
 
The PTX nanocrystals produced by the combination approach had a well-defined, short 
rod-like morphology. Because the nanocrystals had an aspect ratio (i.e. length/width of 
particle) of approximately 2 and narrow size distribution (i.e. as indicated from the PI), 
DLS was able to provide a fairly good correlation and serve as a non-invasive technique 
to measure the particle size. The intensity-weighted average hydrodynamic size (ZD) of 
particles correlates to the number-weighted distribution generated by analysis from the 
SigmaScan.  
Particle size is known to have an impact not only on biodistribution, but also clearance 
and tumor uptake [29]. The smaller particles (e.g. 50-300 nm) generally have a tendency 
to be slowly removed from the circulation [214, 216].  However, due to the tumor 
dynamic status and heterogeneity (e.g. vascular leakiness or cut-off [220, 221]) as well as 
specific characteristics (e.g. size, shape, charge) of the particle, it is difficult to predict the 
maximal value of particle size that can exploit EPR. Nonetheless, it has collectively been 
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suggested that particles up to 400 nm are able to take advantage of the EPR effect [29, 
247]. To that end, with the particle size of approximately 200 nm, nanocrystals should be 
able to extravasate into the tumor site.  
Acquired data on surface charge will provide some insight on stability and particle 
interactions with biological fluid in vivo. It is well-accepted that in order to obtain an 
electrostatically stabilized suspension, a surface charge of ±30 mV or larger (absolute 
value) is desired [191].  However, studies have indicated that highly charged 
nanoparticles had a much higher opsonization rate than neutral or slightly charged 
nanoparticles of the same size [191, 192]. The zeta potential of our PTX nanocrystal 
product was generally around -15 to -22 mV when measured in DI water [169].  The 
observed negative surface charge might possibly be due to the surface adsorption of PTX 
degradation (i.e. hydrolysis) products [248]. The large fluctuations, which often observed 
during zeta potential measurements in water, may be due to the lack of pH control and 
low ionic strength. Because pH of the medium, conductivity of the fluid, and 
concentration of additive heavily affect the surface charge, it is imperative to note the 
specific parameters during measurement. When measured in 10 mM NaCl at 25°C and a 
concentration of 0.1 mg/mL, the zeta potential of PTX nanocrystals ranged between -6 to 
-9 mV. The zeta potential of the batch presented in Figure 2.3 was -6.3 ± 0.2 mV (pH: 6.3 
±0.4). A decrease of electrostatic stability, which was due to the decrease of double layer 
thickness, was expected with the increased in ionic strength [249].  
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2.3.2 Solid-state Characterization of Paclitaxel Nanocrystals 
The PXRD diffractograms of PTX anhydrous, PTX dihydrate, and freeze-dried PTX 
nanocrystals are compiled in Figure 2.6. The PTX obtained from the manufacturer was in 
the anhydrous form. However, since PTX nanocrystals came in contact with water during 
the preparation process and storage prior to being freeze dried, they were found to be in 
the dihydrate form. The sharp diffraction peaks of PTX nanocrystals confirmed they were 
crystalline and therefore superior in chemical stability relative to the amorphous form. 
The PTX dihydrate was obtained by suspending and stirring the commercial PTX in 
water at ambient temperature for 24 hours [250]. Solid dihydrate product was then 
collected by filtration and vacuum drying. 
Both freeze-dried PTX nanocrystals and dihydrate were also analyzed by modulated DSC 
(Figure 2.7). The MDSC reversible heat flow may give information regarding the 
existence of a glass transition temperature Tg, which could hardly be detected. It further 
confirmed that the PTX nanocrystals did not contain a significant amount of amorphous 
material. The endothermic peaks between 50-100°C and 160-170°C suggested the 
removal of water and a solid-solid transition from the dihydrate to the dehydrate 
(anhydrous) form, respectively [250]. Degradation was then observed between 210-
230°C. TGA analysis was performed on PTX nanocrystals and presented in Figure 2.8. 
The weight loss of 4.4%, which corresponds to 2.01 mol of water/mol of PTX, further 
confirmed that PTX nanocrystals were indeed in the PTX•2H2O (dihydrate) form. 
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Figure 2.6. Powder X-ray diffractograms of PTX nanocrystals, dihydrate, and anhydrous. 
 
 
 
Figure 2.7. Modulated DSC thermograms of PTX nanocrystals and dihydrate. 
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Figure 2.8. TGA analysis of PTX nanocrystals. 
 
2.3.3 Solubility of Paclitaxel Nanocrystals in PBS 
The kinetic and thermodynamic solubility of PTX nanocrystals were evaluated in 
comparison with the two forms of PTX, anhydrous and dihydrate. Their solubility 
profiles in 37°C PBS were plotted against time (Figure 2.9). The kinetic solubility of 
PTX nanocrystals (2.00 ± 0.11 μg/ml) was significantly higher (p < 0.05) than that of 
PTX dihydrate (1.78 ± 0.11 μg/ml) in the first hour. In addition to an increase in 
dissolution rate, an increase in saturation solubility is often associated with nanocrystal 
formulation. The increase in saturation solubility can be related to the particle radius 
(curvature) [251] by the Ostwald-Freundlich equation as follows: 
???
????
???
?
????
???
 
with Cs,r and Cs,? the solubilities of particle with radius r and of a very large particle, 
respectively, ? the interfacial surface between the solid surface and surrounding medium, 
Vm the molar volume of the compound, R the gas constant, and T the absolute 
temperature. Nonetheless, nanocrystals were not able to maintain the high energy 
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supersaturation state. It transformed to a lower energy state as observed by the decrease 
in the solubility. PTX anhydrous behaved similarly. Typically, the anhydrous form had 
an elevated kinetic solubility (dissolution) in aqueous media. The solubility concentration 
decreased as the anhydrous form transformed to the dihydrate after 24 hours of 
equilibration time.  The solid PTX dihydrate, which was obtained from suspending 
commercial PTX (anhydrous) for 24 hours, may still contain a small percentage of PTX 
anhydrous as it had a similar solubility pattern as the anhydrous form during the first day 
of study. After equilibrating for 72 hours, the solubilities of the PTX anhydrous, 
dihydrate, and nanocrystals in PBS at 37°C were 1.38 ± 0.08, 1.15 ± 0.09, 1.20 ± 0.03 
μg/ml, respectively. No significant solubility change was observed after 96 hours of 
equilibration time. 
 
 
Figure 2.9. Solubility profiles of PTX anhydrous, dihydrate and nanocrystals in PBS at 
37°C. 
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2.3.4 Particle Size Analysis of Paclitaxel Nanocrystals in Different Media 
The stability of PTX nanocrystals in saline and cell culture media was evaluated. The 
SEM images and analysis were compiled in Table 2.1 and 2.2. The hydrodynamic 
diameters were plotted in Figure 2.10. The studies were carried out to further understand 
any change in size and/or morphology when PTX nanocrystals interacted with: (a) saline 
prior to the intravenous injection (Chapter 4), (b) cell culture media during cell 
cytotoxicity studies (Chapter 3). When incubated in 37oC saline, there seemed to be no 
significant alteration of the individual particle morphology (Table 2.1) or size (Table 
2.2). However, some degree of flocculation of PTX nanocrystals might have occurred in 
undisturbed saline as suggested by the increase in the hydrodynamic size (Figure 2.10). 
The reduced stability of PTX nanocrystals in higher ionic strength solution is discussed in 
Section 2.3.1. With this knowledge, PTX nanocrystals, which were suspended in saline, 
were subjected to vigorous sonication prior to their intravenous administration of 
treatment.   
The SEM images (Table 2.1) and particle size analysis (Table 2.2) of PTX nanocrystals 
incubated in 37°C complete cell culture media (+10% fetal bovine serum (FBS) + 1% 
penicillin streptomycin) suggested the following observations: (a) some PTX 
nanocrystals aggregated due to temperature elevation, and (b) some interaction between 
PTX nanocrystals and cell culture media occurred. Typically, FBS contains 
approximately 15 mg of bovine serum albumin (BSA). When 0.1 mL of 0.1 mg/mL 
(~11.7 μM) PTX nanocrystals was incubated in 0.1 mL of medium containing 10% FBS 
(~2.3 μM), there was a ratio of approximately 1 to 5 PTX to BSA. Strong interactions 
between PTX and albumin have been reported. One study reported that in the presence of 
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3 μM of HSA and 1% ethanol, PTX bound both non-specifically and specifically to 
albumin at more than six sites with different, yet non-independent, affinities [252]. 
Assuming a similar interaction between PTX and BSA, then at the concentration studied, 
albumin was not saturated with PTX. Albumin might have encouraged dissolution of 
PTX from PTX nanocrystals.  The plotted hydrodynamic diameters of PTX nanocrystals 
in cell culture media (Figure 2.10) showed that there was no observable change, which 
may suggest that the rate at which PTX nanocrystals aggregated may be similar to that of 
dissolution (i.e. due to interaction of free PTX with albumin). Inaccuracy in the 
instrument measurements due to these dynamic phenomena was also probable.  
Aggregation due to albumin molecules can be minimized by stabilizing the nanocrystals 
with poly(ethylene glycol) (PEG). A study reported that dipalmitoylphosphatidylcholine 
(DPPC) vesicles became physically unstable, aggregating within minutes upon mixing 
with BSA [253]. Yet, upon modifying the lipid vesicle with PEG, which was able to 
provide steric repulsion, the vesicles showed no tendency to aggregate with albumin 
molecules for days.  
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Table 2.1. SEM images of PTX nanocrystals incubated in 37°C saline and cell culture 
media (DMEM + 10% fetal bovine serum (FBS)) at concentration of 0.1 mg/ml. Two 
images were presented for each time point. Scale bars represent 500 nm.  
Time Saline DMEM + 10% FBS 
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Table 2.1 (continued). SEM images of PTX nanocrystals incubated in 37°C saline and 
cell culture media (DMEM + 10% fetal bovine serum (FBS)) at concentration of 0.1 
mg/ml. Two images were captured and presented for each time point. Scale bars 
represent 500 nm. 
Time Saline DMEM + 10% FBS 
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Table 2.2. Particle size analysis of SEM images presented in Table 2.1 by SigmaScan. 
Data represents mean ± S.D. 
Media 
PTX nanocrystal particle size (nm) after the following incubation times: 
20 minutes 40 minutes 1 hour 2 hours 3 hours 
Saline 210 ± 70 240 ± 90  280 ± 90 240 ± 80 240 ± 90 
Cell 
culture 
350 ± 130 90 ± 30 280 ± 130 170 ± 80 150 ± 70 
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Figure 2.10. Particle size analysis of PTX nanocrystals incubated in different media at 
37°C by DLS. 
 
To study the interaction between PTX nanocrystals and blood subsequent to intravenous 
administration, PTX nanocrystals were incubated in 37°C whole nude mouse 
blood/buffered sodium citrate (9:1 v/v, 0.109 M, 3.2%, to prevent coagulation) at 
concentration of 0.1 mg/mL. The visualization of the particle morphology was attempted 
by imaging a small portion of the mixture under SEM. However, obtaining SEM images 
representing the PTX nanocrystals in blood sample was rather difficult, especially at 
longer incubation times (Table 2.3). In most samples, PTX nanocrystals were rather 
embedded in a thick layer of blood as observed at the 2 hour incubation time (Table 2.3 
right panel). Some captured images that may resemble PTX nanocrystals were presented 
in the table. After 45 minutes of incubation, some particles that bore a resemblance to 
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PTX nanocrystals were imaged. Analyzed by SigmaScan, the longest dimension of the 
particles was determined to be 50 ± 15 nm. Although the morphology of particles 
observed at that time point shared a rod-like morphology with PTX nanocrystals, it is 
difficult to accurately confirm. If the assumption was correct, then images from 45 
minutes (Table 2.3) suggested that roughly 75% of the particles had dissolved.  
Based on Hixson-Crowell cubic root law, assuming that particles are spherical and under 
sink condition, equation (2) (Section 1.3.4.4) can be used to calculate the time to reach a 
complete dissolution. With PTX having approximate diffusion coefficient and solubility 
of 2x10-7 cm2/s and 1 μg/ml, respectively, the calculation presented in Table 1.1 suggests 
that complete dissolution for particles with 100 nm radius could be reached within 4.2 
minutes. Here, the concentration of PTX nanocrystals in blood was 0.1 mg/mL, which is 
approximately half of the initial concentration in the mouse body subsequent to a typical 
intravenous injection at a PTX dose of 20 mg/kg. At concentration of 0.1 mg/mL, which 
is 100 times higher than aqueous solubility (c.a. 1 μg/ml [250]), the sample may not have 
been under sink condition. In addition, aggregation of nanocrystals may decrease the 
surface area exposed to the blood, hence delaying the time to reach complete dissolution. 
Thus, although some nanocrystals may have dissolved, a good portion may still remain 
even after 45 minutes of immersion in blood, as observed in the SEM images (Table 2.3).  
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Table 2.3. SEM images of PTX nanocrystals incubated in nude mouse whole blood/ 
buffered sodium citrate (9:1 v/v, 0.109 M, 3.2%, to prevent coagulation) at a 
concentration of 0.1 mg/ml. At each pre-determined incubation time, two SEM images 
were presented. Scale bars represent 1 μm. 
Time SEM Images of PTX Nanocrystals in Nude Mouse Whole Blood 
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Table 2.3 (continued). SEM images of PTX nanocrystals incubated in nude mouse whole 
blood/ buffered sodium citrate (9:1 v/v, 0.109 M, 3.2%, to prevent coagulation) at a 
concentration of 0.1 mg/ml. At each pre-determined incubation time, two SEM images 
were presented. Scale bars represent 1 μm. 
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2.3.5 Storage Stability of Aqueous Suspensions of Paclitaxel Nanocrystals 
The stability of PTX nanocrystal suspensions in DI water was evaluated over a period of 
3 months at either 4°C or room (ambient) temperature. The concentration of the stock 
solution was 3 mg/mL, and prior to parameter measurements, they were diluted to 0.1 
mg/mL. The SEM images to show the morphology of the particles are presented in Table 
2.4. The change in nanocrystals’ properties (size, polydispersity index, percent drug 
remaining, zeta potential, and pH) were summarized in Table 2.5 (4°C) and 2.6 (room 
temperature). When stored at 4°C, there was no significant change in the particle size, 
measured either from SEM images (SigmaScan) or analyzed by DLS. When stored at 
room temperature, the particle size and polydispersity index (PI) drifted as the time 
elapsed. The increase in PI value may suggest that PTX nanocrystals might experience 
some flocculation that may shift the particle size distribution.  
The percent drug remaining suggested that the shelf life (i.e. when concentration 
decreased by 10%) was less than 1 month. In both storage conditions, approximately 5% 
of drug degraded after 2 weeks of storage. Since the suspension stock was kept at high 
concentration, 3 mg/mL, the amount of dissolved (free) molecules that were prevalent for 
aqueous degradation was minimal. The kinetics and products of PTX degradation have 
been thoroughly studied by Tian and Stella [248, 254, 255], with maximal stability 
obtained near pH 4-5. Dordunoo and Burt [256] also observed a U-shaped pH-profile 
suggesting that the hydrolytic reaction would involve neutral species of PTX catalyzed by 
H+, H2O, or OH-. If PTX was in the dissolved state, the degradation would have occurred 
rapidly. However, since the stock suspension was supersaturated (i.e. 3 mg/mL), the rate 
of degradation was limited by the dissolution rates governed by the solubility. Since the 
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solubility is higher at room temperature, it was not surprising to find that the percent of 
drug remaining, when stored at room temperature, was less.  
The zeta potential data for PTX nanocrystals stored in 4°C could be logically correlated 
to the change in pH. During storage, dissolved PTX may undergo hydrolysis [248], which 
caused the decline in pH. In more acidic condition, the numbers of OH- ions decreased, 
causing the zeta potential to become more positive and vice versa.  Meanwhile, there was 
lack of correlation between zeta potential and pH measurements of suspensions stored in 
room temperature. Errors in measurements and uncleanliness of zeta potential cells 
(folded capillary cells) could contribute to the discrepancies observed.   
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Table 2.4. SEM images of PTX nanocrystals suspension in water (at concentration of 1 
mg/ml) stored at 4°C and room temperature. Two images were presented for each time 
point. Scale bars represent 1 μm. 
Storage 
Duration 
SEM images of PTX nanocrystals during storage 
4°C Room temperature 
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Table 2.4 (continued). SEM images of PTX nanocrystals suspension in water (at 
concentration of 1 mg/ml) stored at 4°C and room temperature. Two images were 
presented for each time point. Scale bars represent 1 μm. 
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Table 2.5. Summary of the key parameters of PTX nanocrystals during storage at 4°C. 
Data represents mean ± S.D. 
Time 
(mo.) 
Size (nm) 
(SigmaScan) 
Size (nm) 
(DLS) 
PI 
(DLS) 
% Drug 
Remaining 
Zeta 
Potential 
(mV) 
pH 
0 200 ± 60 176 ± 1 
0.08 ± 
0.02 
100.0 -9.0 ± 0.3 6.7 ± 0.1 
0.5 200 ± 60 167 ± 3 
0.10 ± 
0.05 
96.2 ± 2.2 -7.3 ± 0.1 5.5 ± 0.1 
1 210 ± 70 158 ± 1 
0.07 ± 
0.01 
88.9 ± 0.8 -6.8 ± 0.4 5.3 ± 0.1 
2 200 ± 70 169 ± 2 
0.06 ± 
0.04 
91.4 ± 2.2 -7.0 ± 0.9 5.7 ± 0.1 
3 200 ± 70 179 ± 6 
0.03 ± 
0.01 
85.4 ± 4.9 -7.8 ± 0.9 7.0 ± 0.1 
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Table 2.6. Summary of the key parameters of PTX nanocrystals during storage at room 
temperature. Data represents mean ± S.D. 
Time 
(mo.) 
Size (nm) 
(SigmaScan) 
Size (nm) 
(DLS) 
PI 
(DLS) 
% Drug 
Remaining 
Zeta 
Potential 
(mV) 
pH 
0 200 ± 60 176 ± 1 
0.08 ± 
0.02 
100.0 -9.0 ± 0.3 6.7 ± 0.1 
0.5 200 ± 70 181 ± 2 
0.10 ± 
0.01 
96.6 ± 3.9 -11.6 ± 0.7 6.4 ± 0.1 
1 210 ± 70 207 ± 5 
0.15 ± 
0.01 
88.0 ± 0.7 -7.3 ± 1.0 6.2 ± 0.1 
2 200 ± 70 233± 4 
0.22 ± 
0.02 
88.2 ± 5.7 -9.4 ± 1.0 5.8 ± 0.1 
3 290 ± 70 235 ± 20 
0.24 ± 
0.17 
84.8 ± 2.5 -6.9 ± 1.0 5.8 ± 0.1 
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2.3.6 Storage Stability of Freeze Dried Paclitaxel Nanocrystals 
The stability of freeze-dried PTX nanocrystals was monitored to assess the possibility of 
storing nanocrystals for the long term. Figure 2.11 represents the fresh freeze-dried of 
PTX nanocrystals. The SEM images and subsequent analysis of reconstituted freeze-
dried product in DI water are shown in Table 2.7 and 2.8. It is worth noting that it was 
difficult to image the dry form of the freeze dried product by SEM due to the significant 
charging effect (i.e. caused by poor electrical conductivity of the specimen). SEM images 
(Table 2.7) and particle size analysis (Table 2.8) suggested that 200 nm-PTX 
nanocrystals maintained their physical integrity well when stored at 4°C but might be 
prone to degradation when stored at room temperature. However, after 2 months of 
storage in an accelerated stability chamberat 40°C/75%RH, particle size decreased 
significantly (up to 50%), which suggested the likelihood of  product degradation upon 
long-term storage. Particle size measurements by DLS were not carried out because some 
portion of PTX nanocrystals were still aggregated even though they were sonicated upon 
reconstitution in DI water. Ease in reconstitution could be achieved by stabilizing 
nanocrystals with surfactant(s) or polymer(s). 
 
Figure 2.11. SEM image of fresh freeze-dried PTX nanocrystals re-suspended in DI 
water. Scale bar represents 1 μm.   
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Table 2.7. SEM images of freeze-dried PTX nanocrystals re-suspended in DI water at 
various time points. Scale bars: 1 μm. 
4°C Room Temperature 40°C / 75%RH 
- 0.5 month - 
 
 
 
 
 
 
- 1 month - 
 
 
 
 
 
 
- 2 month - 
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Table 2.8. Particle size analysis of SEM images presented in Table 2.7 by SigmaScan. 
Data represents mean ± S.D. 
Time 
Particle Size (nm) Measurements 
4°C Room Temperature 40°C / 75% RH 
0 day 190 ± 60 
0.5 month 220 ± 80 230 ± 70 210 ± 60 
1 month 210 ± 70 190 ± 60 180 ± 80 
2 months 210 ± 90 180 ± 70 120 ± 50 
 
2.4 Conclusion 
PTX nanocrystals were successfully produced by an anti-solvent method and further 
homogenized to achieve an average particle size of approximately 200 nm. The freeze-
dried product was confirmed to be the crystalline dihydrate form. The slight negative 
charge in DI water, about -15 mV, suggested that small portion of dissolved PTX has 
been hydrolyzed and adsorbed to the surface.  The suspension, however, became less 
stable (i.e. increased in zeta potential) at lower ionic strength. PTX nanocrystals were 
stable when incubated in DI water, but interactions with components of cell culture media 
and blood were observed. At size of 200 nm, the physical integrity of PTX nanocrystals 
in stability chamber was compromised after 2 months of storage. When kept at 4°C, 
aqueous suspensions should be stable enough to be used for up to 1 month of storage. 
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Chapter 3 - Cellular Toxicity and Uptake of Paclitaxel Nanocrystals 
 
3.1 Introduction 
In order to reach the tumor tissues, intravenously an administered drug nanoparticle has 
to be able to cross various biological membranes (e.g. walls of blood cells, tissue matrix 
surrounding the target cells), and eventually penetrate through the cell membrane barrier, 
either by passive diffusion or active transport, to access the biological target. Efficient 
internalization of the nanovehicles, via non-phagocytic endocytosis pathways, is often 
better than simple free diffusion, which may admit a low concentration of therapeutics. 
Thus, it is necessary to evaluate the performance of PTX nanocrystals at the cellular 
level, prior to conducting any in vivo study. Two in vitro studies were conducted:  
(1)  PTX nanocrystal suspensions were tested for their inhibitory effect on cell growth in 
vitro, particularly in human colon adenocarcinoma HT-29 cells. The IC50, the half 
maximum inhibitory concentration, of PTX nanocrystals was compared with Taxol at 
three different time points: 24, 48, and 72 hours, to elucidate any duration-dependent 
differences. 
(2) The cellular internalization of PTX nanocrystals in human breast cancer MCF-7 was 
investigated to rationalize the higher potency associated with PTX nanocrystals in human 
breast cancer MCF-7. Confocal microscopy was utilized to seek any evidence of 
nanocrystal internalization via non-phagocytic endocytosis pathways.   
Unlike phagocytosis, which is mostly restricted to specialized cells (professional 
phagocytes: macrophages, monocytes, neutrophils, dendritic cells [257]; nonprofessional 
phagocytes: fibroblasts, epithelial and endothelial cells [258]), endocytosis pathways 
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occur in all cells. Overall, endocytosis is classified into four main mechanisms, which 
have been extensively reviewed [259-261]: clathrin-dependent, caveolae-dependent, 
other clathrin- and caveolae-independent, and macropinocytosis.  
(i) Clathrin-mediated endocytosis (CME) generally serves as the main mechanism of 
internalization of macromolecules. Via this pathway, endocytosed material accumulates 
in degradative lysosomes, where drug content can be released intracellularly as a result of 
lysosomal biodegradation.  
(ii) Depending on the properties, particles can be alternatively endocytosed via caveolae-
mediated endocytosis (CvME). Unlike CME, caveolae from the membrane generates a 
distinctive cytosolic caveolar vesicle (caveosome), which does not contain any 
degradation enzyme. When enzyme-sensitive therapeutics (e.g. peptides, proteins, nucleic 
acids) are encapsulated in the nanocarrier, it is best to tailor the properties of the vehicle 
to by-pass the lysosomal degradation via the caveolae-mediated endocytosis.  
(iii) Macropinocytosis occurs in many cells, including macrophages. It refers to the 
formation of large endocytic vesicles of random shape and size created by actin-driven 
invagination of the plasma membrane [262].  Unlike phagocytosis, however, the 
protrusions do not zipper up (to form U shape) along the ligand-coated particles. Instead, 
they collapse onto and fuse with plasma membranes [263], forming a macropinosomes. 
Intracellularly, macropinosomes either: (a) acidify and shrink, or (b) fuse with lysosomal 
compartments.  
 (iv) Nanoparticles can alternatively be taken up by clathrin- and caveolae- independent 
pathways [264], but the understanding of their interactions is still at a preliminary stage. 
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The pathway by which a particle can be endocytosed depends heavily on both particle 
properties (e.g. size, geometric shape, surface charge and characteristics) and cell type 
[261].  A study on size-dependent endocytosis showed that when 50-1000 nm fluorescent 
polystyrene beads were tested in non-phagocytic murine melanoma B16 cells, particles 
with diameters of less than 200 nm were found to be taken up via the  CME, while those 
with approximate size of 500 nm were internalized via the CvME pathway [211]. 
Although each study could be particle- and cell-dependent, it is generally accepted that 
smaller sized particles gain faster cellular entry, but large particles with sizes up to 5 μm 
could still be engulfed through pinocytosis [260]. Since cell plasma membranes are 
negatively charged, nanoconstructs possessing a positively charged surface typically have 
stronger association and thus more rapid internalization. As for shape, no general trend 
has been identified yet due to other predominant factors, including size, nature, and the 
surface charge of the particles. Some indicated that spherical nanoparticles had a higher 
efficiency and faster rate of endocytosis compared to rod- or disc- [265, 266] shape 
particles, while others suggested the preferential uptake of cylindrical [267] or rod-shape 
[268] particles. In this study, we attempted to unveil the cellular uptake of PTX 
nanocrystals, particularly in the human breast adenocarcinoma MCF-7 cells. A weakly 
basic amine probe, Lysotracker Red®, was used to identify the cell’s endo-lysosomal 
compartment, the accumulation point of either the CME or macropinocytosis pathway. 
Since PTX does not fluoresce, hybrid PTX nanocrystals were synthesized by entrapping 
the near-infrared fluorophore FPR-648 (dye number 7l, synthesized by Park et al. [269]). 
Cell internalization of the fixed cells was visualized by confocal microscopy, which 
arguably generates the least artifacts [260]. 
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The idea of preparing hybrid nanocrystals was inspired by a common phenomenon in 
nature, colored diamonds and gems. Crystals are hardly perfect – most if not all, have 
defects. When a minute amount of impurities or guest molecules get entrapped in the 
defect sites of the host crystal lattice, the structural integrity of the hosting crystal is 
barely altered but the optical properties changes dramatically. Kahr and coworkers have 
demonstrated numerous organic crystals that are ‘dyed’ by guests [235].  
Hybrid nanocrystals can be prepared using the same precipitation method, except that a 
fluorophore was mixed in water prior to the addition of the drug solution. Because 
nanocrystals are being formed rapidly due to the sudden drop of solubility, they have a 
large quantity of defects, where imaging agents can be integrated. It is important to note 
that the fluorophore is physically integrated, requiring no chemical conjugation. The tiny 
amountintegrated-fluorophore can be detected by optical imaging (e.g. confocal 
microscope and in vivo imaging system). 
 
3.2 Materials and Methods 
3.2.1 Materials 
Paclitaxel (>99.5%, USP30) was purchased from 21CECPharm (United Kingdom); FPR-
648 fluorophore (maximum excitation wavelength, ?ex=648 nm; maximum emission, 
?em=671 nm) was obtained from Polyscitech (West Lafayette, IN).  Ethanol (HPLC 
grade), acetonitrile (HPLC grade), DMSO (dimethyl sulfoxide, ACS grade), Dulbecco’s 
Modified Eagle’s Medium (DMEM), penicillin streptomycin, and 0.25% trypsin-EDTA 
were purchased from Fisher Scientific (Pittsburgh, PA).  McCoy’s 5A medium, HT-29 
human colon adenocarcinoma and MCF-7 human breast adenocarcinoma cells were 
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purchased from American Type Culture Collection (ATCC) (Manassas, VA). Prolong® 
Gold Antifade Reagent with DAPI was obtained from Invitrogen (Grand Island, NY). All 
chemicals and solvents were utilized without further purification.  Deionized water (by 
Milli-Q®, filtered through 0.2 μm membrane) was used for all the experiments. 0.050 μm 
(50 nm) Whatman® nuclepore polycarbonate track-etched membranes used for filtration 
were purchased from Fisher Scientific (Pittsburgh, PA).   
 
3.2.2 Preparation of Pure and Hybrid Paclitaxel Nanocrystals 
Paclitaxel nanocrystals were produced by the combination approach as previously 
described in Section 2.2.2. For the pure PTX nanocrystals, 1 mL of 3 mg/mL paclitaxel in 
ethanol was added rapidly to 20 mL deionized water in a 3-neck round bottom flask (500 
mL). The mixture was stirred at 1,100 rpm with a stirrer shaft and under intense 
sonication (in sonication bath F20D, output of 70 W and 42±6 KHz, Fisher Scientific). 
Ice was added to the sonication bath to keep the temperature between 14-18°C. After 10 
minutes of stirring time, the flask was removed from the stirring station and placed in 
desiccator to remove bubbles generated due to rapid stirring. The mixture was then 
filtered through a 50 nm polycarbonate membrane. The retentate was re-suspended in 2 
mL DI water, placed in a 20 mL scintillation vial, and homogenized (Fisher Scientific® 
PowerGen® 125) for 6 minutes at 30,000 rpm. PTX/FPR-648 hybrid nanocrystals were 
produced in a similar manner, except that 0.25 mL of 1 mg/mL FPR-648 was added to DI 
water prior to the addition of 5 mg/mL PTX/ethanol solution. 
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3.2.3 Cytotoxicity Study of Paclitaxel Nanocrystals in HT-29 Cells 
The cellular cytotoxicity of PTX nanocrystals and dissolved PTX in DMSO 
(PTX/DMSO) in colon cancer HT-29 cells were compared using the sulforhodamine B 
(SRB) assay. The SRB assay relies on the ability of the SRB dye to bind to the cell’s 
protein basic amino acid residue subsequent to cell fixation with trichloroacetic acid 
(TCA). The assay of SRB fluorescence was found to be linearly proportional to the 
number of cells and cellular proteins when measured at cellular density of 1 to 200% 
confluence [270].  Specifically, cells were cultured in McCoy’s 5A medium 
supplemented with 10% fetal bovine serum and 1% penicillin streptomycin in a 37°C 
humidified incubator containing 5% CO2. After reaching 80% confluence, cells were 
trypsinized and seeded in 96-well plates at a density of 1x104 cells/well for the 24- and 
48-hour incubation times or 0.8x104 cells/well for the 72-hour incubation time. Samples 
were prepared in duplicates, and cells were allowed to attach to the bottom of the wells 
by incubating them overnight. For the treatment with dissolved PTX/DMSO, 200 μg/mL 
stock of PTX in DMSO was diluted to a total of 9 stock solutions with targeted 
concentrations between 50 ng/mL to 2000 ng/mL. Prior to adding the treatment to the 
cells, the PTX/DMSO solution was further diluted 200 times (0.5% v/v) with complete 
cell culture media, to obtain targeted concentrations between 0.25 and 100 ng/mL. PTX 
nanocrystals were diluted in a similar manner, except that they were suspended in DI 
water. The actual concentration of each stock solution was determined by HPLC.  
The HT-29 cells were incubated with either PTX/DMSO solutions or aqueous suspension 
of PTX nanocrystals for 24, 48, or 72 hours. The schematic of the cytotoxicity study is 
depicted in Table 3.1. Wells in column 1 only contained complete culture media without 
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any cells seeded. In column 2, the seeded cells were incubated with complete culture 
media that had been added with either 1% of DMSO or DI water for control. Either 
PTX/DMSO or PTX nanocrystals were added in column 3 to 11. Column 12 was 
intentionally left as blank. Plates were briefly shaken subsequent to the addition of media 
and treatments. 
 
Table 3.1. The 96-well setup for the cellular toxicity study of PTX nanocrystals and 
dissolved PTX in HT-29 cells. 
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After cells had been incubated for the appointed time (24, 48, or 72 hours), the media 
were aspirated from the wells. Cells were subsequently fixed with 100 μL/well of cold 
10% trichloroacetic acid (TCA) and stored at 4?C for one hour. The 96-well plates were 
washed 5 times with deionized water and sharply flicked to remove excess water. Plates 
were left to air-dry overnight.  
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100 μL of 0.4% Sulforhodamine B (SRB) dissolved in 1% acetic acid, was added to 
every column except #12 in the 96 well plate. Plates were incubated for 30 minutes at 
room temperature and covered with aluminum foil to minimize light exposure. To 
remove excess SRB, plates were washed with a multichannel pipetter by layering 200 μl 
of 1% acetic acid over the fixed cells and flipped to remove the wash. This process was 
repeated five times. Plates were air dried in the biological safety hood overnight, covered 
with foil.  
The bound-protein dye was solubilized by adding 100 μL of 10 mM Tris Base (pH 10.0). 
Plates were wrapped in aluminum foil and gently shaken on a gyrator for 30 minutes. The 
optical density was determined by an automatic plate reader, SpectraMax M5 (Molecular 
Devices) at a wavelength of 560 nm.  
The optical density was recorded and correlated to the percent of protein for each 
respective well. The average of absorbance in each column was taken. The average 
values of column 2 to 11 were first subtracted from that of column 1, the background. 
The cell numbers (i.e. linear to the SRB absorbance) in treated wells (e.g. column 3 (C3) 
to 11 (C11)) were then compared to that of column 2 (C2), the positive control. The % 
cell viable was calculated with the following equation: 
????????????? ? ???? ? ?
???????????????????????????????????????
???????????????????????????????????
? ??????? 
The concentration of drug was graphed versus the percent cell viable on a log scale, and 
the IC50, the half maximal inhibitory concentration, was determined.  
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3.2.4 Characterization of Paclitaxel Hybrid Nanocrystals 
The morphology and size of the PTX hybrid nanocrystals were observed by SEM as 
previously described in Section 2.2.3. Analysis of particle size from the SEM images was 
performed using SigmaScan (Systat software Inc, San Jose, CA). The mean size (i.e. 
longest dimension) and standard deviation from approximately one hundred particles are 
presented.  
 
3.2.5 Analysis of  the Fluorophore Entrapment 
Quantification of paclitaxel was conducted by high liquid chromatography (HPLC, 
Waters Breeze) with a Waters Symmetry C18 5 ?m column (4.6 x 150 mm); it was 
analyzed by a UV detector (Waters 2487 dual λ absorbance detector) at 227 nm with a 
mobile phase of ethanol/acetonitrile (50:50) pumped at a rate of 2 mL/min (Waters 1525 
binary pump). The column was equilibrated to 35oC prior to sample injection (20 μL).  
The measurement of FPR-648 entrapment was done using a fluorescence (96-well) plate 
reader.  Standard solutions of FPR-648 fluorophore with concentrations ranging from 0.1 
μg/ml to 2 μg/ml were prepared in DMSO and measured at excitation and emission 
wavelengths of 650 and 670 nm, respectively, by SpectraMax M5 (Molecular devices).  
Similar to the standard solution, PTX/FPR-648 hybrid nanocrystals were dissolved in 
DMSO prior to the florescence analysis. Standards and samples were prepared in 
triplicate. Wells were filled with 150 μL solution.  
 
 
 
96 
 
3.2.6 Cellular Uptake Study of Paclitaxel Hybrid Nanocrystals in MCF-7 Cells 
Breast cancer MCF-7 cells were cultured in Dulbecco’s Modified Eagle Medium 
(DMEM) medium supplemented with 10% fetal bovine serum (FBS) in a humidified 
atmosphere containing 5% CO2 at 37 °C. For the cellular uptake study, cells were seeded 
on 22x22 mm2 glass cover slips in a 6-well plate at a density of 200,000 cells/well. To 
allow attachment to the cover slips, cells were incubated overnight prior to treatment. 
PTX/FPR-648 hybrid nanocrystals suspension was mixed with complete culture media 
(10% v/v) to a final concentration of 80 ?g/mL. The mixture was added to the cells, and 
they were incubated for 0.5, 1, and 2 hours. At the end of the incubation time, the media 
were aspirated, and Lysotracker Red (Invitrogen, Grand Island, NY), which was 
dissolved in PBS, was added at a concentration of 100 nM. The cells continued to be 
incubated at 37°C for 30 minutes. After staining the lysosomal compartment with 
Lysotracker, wells were washed gently three times with cold PBS. Subsequently, cells 
were fixed by adding 1 mL of 4% paraformaldehyde (Boston Bioproducts, Ashland, 
MA). The plates were placed in a 4°C refrigerator for 10 minutes during fixation. Cells 
were then washed carefully with PBS for three additional times. To prevent the 
fluorescence to fade (photobleach), approximately 20 μL Prolong Gold with DAPI was 
mounted to the microscope glass slide. The individual glass cover slip was then flipped 
onto microscope glass slide and sealed with nail polish on the edge. Slides were stored at 
4°C prior to viewing to preserve the integrity of the fluorescence.   
Slides were viewed under a Leica AOBS TCS SP5 inverted laser scanning confocal 
microscope equipped with Leica Application Suite Advanced Fluorescence 2.3.1 build 
5196 software. The DAPI, used to stain the cell nucleus, was excited with Argon 405 
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laser and observed at emission window of 415-485 nm. The Lysotracker Red, which 
stained the lysosomal compartment, was excited with HeNe 543 laser and viewed in the 
emission window of 555-583 nm. Meanwhile, the FPR-648, which was incorporated into 
the hybrid nanocrystals, was excited with a HeNe 633 laser and observed using an 
emission window of 695-740 nm.  
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3.3 Results and Discussion 
3.3.1 Cytotoxicity Study of Paclitaxel Nanocrystals in HT-29 Cells 
The results of the cellular cytotoxicity study of PTX nanocrystals versus dissolved PTX 
by the SRB assay in HT-29 human colon adenocarcinoma cells are shown in Figure 3.1. 
The calculated IC50 values for different incubation times are presented in Table 3.2. Both 
PTX nanocrystals and dissolved PTX exerted similar toxicity at all the three time points 
(i.e. 24, 48, and 72 hours), indicating that there was no duration-dependent 
chemosensitivity during those particular periods. We also learned that relative to the PTX 
nanocrystals, dissolved PTX in DMSO was approximately two to three times more 
potent, which is most likely due to the following reasons: (a) dissolved PTX 
(PTX/DMSO) was able to rapidly and freely diffuse through the cell membrane due to its 
concentration gradient; or (b) some PTX nanocrystals may aggregate during the 
incubation period, which might cause a heterogeneous PTX size distribution that led to 
reduced exposure to some cells. It is worth noting that cells were 100% viable when 
incubated with 0.5% v/v DMSO/cell culture media (in the control column, C2, described 
in section 3.2.3); thus, the cytotoxicity observed was due to the PTX and not due to the 
addition of DMSO. 
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Figure 3.1. The cytotoxicity curve of PTX nanocrystals and dissolved PTX in human 
colon cancer HT-29 by SRB assay. 
 
 
Table 3.2. The IC50 values of PTX nanocrystals and dissolved PTX in HT-29 cells at 
different incubation times. 
Incubation time 
IC50 (nM) in HT-29 Cells 
PTX nanocrystals Dissolved PTX (PTX/DMSO) 
24 hours 22.3 ± 1.7 9.6 ± 0.4 
48 hours 18.1 ± 0.3 9.2 ± 0.3 
72 hours 24.1 ± 2.7 7.1 ± 0.4 
 
 
 
100 
 
3.3.2 Particle Size Measurement 
The PTX/FPR-648 hybrid nanocrystals were imaged under a scanning electron 
microscope (SEM), and the individual particle sizes (Figure 3.2) were analyzed by Sigma 
Scan. The average longest dimension of the hybrid PTX nanocrystals was 190 ? 70 nm, 
which was similar to that of pure PTX nanocrystals, as discussed in section 2.3.1. The 
maximum size of nanoparticles that can be internalized by cells was reported to be about 
500 nm [213]. Thus, the produced nanocrystals, unless aggregated, should be able to 
infiltrate the cell membrane.  
 
 
Figure 3.2. SEM image of PTX/FPR-648 hybrid nanocrystals for cellular uptake in 
breast cancer MCF-7. Scale bar represents 1 μm. 
 
3.3.3 Analysis of the FPR-648 Fluorophore Entrapment 
There was a linear correlation between the concentration of FPR-648 and absorbance unit 
when measured between 0.1 and 2 μg/mL (Figure 3.3). The concentration of the 
entrapped FPR-648 in PTX hybrid nanocrystals can be determined by dissolving the 
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hybrid nanocrystals in DMSO. The dilution factor was 1:5 (v/v). Using the standard 
curve, it was determined that the FPR-648 concentration was 5.6 μg/mL, which 
corresponds to 0.13% (w/w) entrapment. Due to the dye sensitivity, PTX hybrid 
nanocrystals could still be visualized in confocal microscopy even at very low 
concentration. These PTX/FPR-648 hybrid nanocrystals were particularly used to study 
the cellular uptake of PTX nanocrystals in human breast cancer MCF-7, which will be 
discussed in the following section. 
 
 
Figure 3.3. The standard curve of FPR-648 in DMSO measured at ?ex:  650 nm and ?em: 
670 nm. 
 
3.3.4 Cellular Uptake Study of Paclitaxel Nanocrystals in MCF-7 Cells 
The cellular toxicities of PTX nanocrystals versus dissolved PTX in DMSO were also 
compared in breast cancer cells MCF-7 by previous laboratory members (unpublished 
data). For the dissolved PTX, with IC50 value of 37.4 ± 1.3 nM, MCF-7 cells were found 
to be less sensitive relative to the HT-29 cells. Even though tested by using different 
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cytotoxicity assays, XTT (2,3-bis (2-methoxy-4-nitro-5-sulfophenyl)-5-carboxanilide)-
2H terazodium), Chou and colleagues observed a similar trend [271]. Interestingly, the 
cytotoxicity of PTX nanocrystals after 72 hours post-incubation in both cells, MCF-7 
(IC50: 21.7 ± 0.3 nM) and HT-29 (IC50: 24.1 ± 2.7 nM), were not significantly different. 
Yet, PTX nanocrystals and dissolved PTX induced cytotoxicites with an opposite trend in 
the two cells.  Relative to dissolved PTX, the nanocrystals were more toxic to the MCF-7 
(had lower IC50) than HT-29 cells. Differences in particle size, size distribution, cell 
properties, cell-specific particulate uptake, and operator could affect the observed 
outcome. However, it is also possible that MCF-7 cells were able to internalize PTX 
nanocrystals via the endocytosis pathway, which could result in a higher payload 
delivered to the cytosol subsequent to lysosomal biodegradation. Meng et al. reported 
that rod-shaped mesoporous silica nanoparticles (MSNP) loaded with taxol and 
camptothecin were able to induce more toxicity relative to the spherical drug loaded-
MSNP and dissolved drug [272]. The rod-shape MSNPs had different longest dimension 
of approximately 120, 175, and 280 nm with corresponding aspect ratios of about 1.6, 
2.3, and 4.3. When tested in HeLa cells, all the rod-shape particles were internalized by 
macropinocytosis, which then transferred to acidifying endosomal compartment that 
specializes in particle degradation. The ones with a dimension of approximately 175 nm 
and aspect ratio (AR) of 2.1 to 2.5 were taken up the most.  
The following cellular uptake studies were carried out to investigate the intracellular 
pathways of PTX nanocrystals in MCF-7. Figure 3.4 shows a set of confocal images of 
breast cancer MCF-7 cells that had been incubated with PTX/FPR-648 hybrid 
nanocrystals for 0.5, 1, and 2 hours. Each image set was taken at the same z-level, 
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approximately in the middle of the cells (i.e. signals were not generated from the surface 
of the cells). The cell nucleus and endo-lysosomal compartment were stained with DAPI 
(blue) and Lysotracker Red, respectively. Hybrid PTX/FPR-648 nanocrystals (cyan) were 
utilized for this purpose. FPR-648 has a longer emission wavelength, where its 
fluorescence signal can be separated from other probes (e.g. DAPI and Lysotracker Red) 
in the visible range.  
 
 
Figure 3.4. Compilation of confocal microscopy images of MCF-7 cells incubated with 
PTX/FPR-648 hybrid nanocrystals (cyan) for 0.5, 1, and 2 hours. The cell nucleus and 
lysosome were stained with DAPI (blue) and Lysotracker Red, respectively. Scale bars in 
the top panel indicate 2 μm while those in middle and bottom panels indicate 5 μm. The 
purple, yellow, and white arrows might suggest the formation of membrane ruffles, 
macropinocytosis, and clathrin-mediated endocytosis, respectively. 
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The top panel (30 minutes) of Figure 3.4 shows that PTX/FPR-648 (cyan) nanocrystals 
started to accumulate on the surface of the membrane. MCF-7 might internalize some of 
the particles via macropinocytosis as formations of membrane ruffles (purple arrows) 
were observed. Macropinocytosis formation heavily relies on the movement of actin 
cytoskeleton and actin-driven membrane, which results in the membrane ruffling and the 
formation of filopodia for the closure of macropinocytotic vesicles [262]. The images 
may suggest that the actin-driven membrane ruffles protruded to engulf the nanocrystals 
in the extracellular matrix, melt with the cell membrane, formed intracellular vacuole 
(macropinosome), and fused with lysosome (red signal) [262, 273]. The macropinosomes 
generally have size between 0.5-10 μm [260].  
At 1 hour post-incubation time (Figure 3.4), it was observed that the cyan and red signals 
were co-localized in the middle of group of cells. This may suggest that some of the PTX 
hybrid nanocrystals (c.a. 200 nm) that were stable and did not aggregate were taken up 
by the CME. Similar to macropinocytosis, endocytosed nanocrystals ended up to 
accumulate in lysosome (red), where drug cargo could be released intracellularly 
subsequent to lysosomal biodegradation. Fluorescently-labeled polystyrene beads with 
size of 200 nm were taken up intracellularly by CME in non-phagocytic murine 
melanoma B16 cells  [211].  
After 2 hours of incubation, PTX hybrid nanocrystals started to aggregate to greater 
extent. Due to their large size, internalization via macropinocytosis was more preferable 
than the CME. Clusters of hybrid nanocrystals were found to merge with the Lysotracker 
Red signals on the cell peripheral. Though the significance is still uncertain, unlike the 
lysosomes that were responsible for degrading the endocytosed nanocrystals by CME (1 
105 
 
hour incubation), those that merged with nanocrystal-loaded macropinocytosis changed 
their localization from random to clustered arrangement in the cell [272].  Overall, the 
confocal images suggested that MCF-7 cells were able to internalize the PTX hybrid 
nanocrystals via macropinocytosis and/or CME. The rate and efficiency of these 
internalizations had not been studied. Beyond 2 hours of incubation, most of the PTX 
hybrid nanocrystals aggregated, which was likely due to their decreased stability in 
elevated temperature and interaction with albumin as described in Section 2.3.4.  
It is worth noting that there were only a portion of cells that were left during the fixation 
process (i.e. with 4% paraformaldehyde) and thus for viewing under the microscope. The 
nanocrystal suspemsion concentration at which cells were incubated was 80 μg/mL (93.6 
nM), approximately four times higher than its IC50 value. Sufficient addition of hybrid 
nanocrystals to the cells was necessary in order to have large numbers of nanocrystals for 
microscope visualization. Yet, since the IC50 of PTX in the cell is well below the 
solubility, the dissolved drug was able to promote rapid cell death, thus minimizing the 
number of cells left on the cover slip.  
To ensure that the cyan signal observed was coming from the dissolved dye, MCF-7 cells 
were also incubated with free FPR-648 at concentration of 0.1 ?g/ml (Figure 3.5). This 
concentration was equivalent to the amount of entrapped dye, 0.13% (w/w), in 80 ?g/mL 
of PTX/FPR-648 hybrid nanocrystals used for the cellular uptake studies (Figure 3.4). 
Although cells were incubated with same concentration of dye, hardly any cyan signal 
was observed in those exposed with the free dye (Figure 3.5). This observation suggested 
that the cyan signals in Figure 3.4 were from the PTX/FPR-648 hybrid nanocrystals. In 
the case where dye might leach out prematurely from the hybrid nanocrystals, it would be 
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rapidly dissolved to the cell culture media due to its high aqueous solubility (i.e. more 
than 1 mg/mL).  
 
 
Figure 3.5. The confocal images of MCF-7 cells incubated with free FPR-648 dye at 
concentration of 0.1 ?g/ml for 2 hours.  
 
Unlike in MCF-7 cells, PTX nanocrystals induced less toxicity in HT-29. Two working 
hypotheses are proposed: (a) PTX nanocrystals may not preferably be internalized in HT-
29 cells (e.g. due to particle size), (b) the amount of available dissolved PTX, which can 
passively diffuse to cell membrane, was reduced due to the decreased exposed surface 
area of aggregated PTX nanocrystals. The internalization of PTX nanocrystals may be 
cell-specific. Similar to the case of polystyrene nanoparticles (size from 20 -1000nm), 
due to their size, they were not preferably endocytosed by HUVEC endothelial, the EVC 
304 bladder carcinoma, and the HNX 14C squamous carcinoma cell lines. Meanwhile, 
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the 20-100 nm particles were internalized by Hepa 1-6 hepatoma and the HepG2 human 
hepatocyte cell lines, and the 20-600 nm particles by the KLN 205 squamous carcinoma 
cells [274]. HT-29 has been reported to internalize some nanoconstructs by endocytosis 
pathways. Third-generation (G3) polyamidoamine (PAMAM) dendrimers having a size 
of approximately between 5 and 12 nm were shown to colocalize with the lysosome 
compartment of HT-29 [275]. Folic acid-targeted chitosan-modified gold nanorods, with 
a size of 85 nm, were observed to be internalized via receptor-mediated endocytosis 
[276]. To rationalize for the discrepancy, the evaluation of cell internalization of PTX 
nanocrystals in HT-29 cells needs to be conducted in the future. 
 
3.4 Conclusion 
In HT-29 cells, PTX nanocrystals were found to be less toxic compared to the dissolved 
PTX. However, there was no duration-dependent chemosensitivity observed during the 
period of 24, 48, and 72 hours. Although further studies are needed to investigate the 
difference in the cytotoxicity, PTX nanocrystals may have aggregated during the 
incubation, decreasing the rate of dissolution and thus diffusion to the cell membrane. In 
contrast, PTX nanocrystals exerted more antitumor activity in MCF-7 cells. The ability of 
MCF-7 cells to internalize PTX nanocrystals either via macropinocytosis or chlatrin-
mediated endocytosis may result in the delivery of higher drug concentration into the cell 
cytosol subsequent to the lysosomal biodegradation.  
 
 
Copyright© Christin Pramudiati Hollis 2012  
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Chapter 4 - In Vivo Studies of Paclitaxel Pure and Hybrid Nanocrystals 
 
4.1 Survival Study in HT-29 Xenograft Model  
4.1.1 Introduction 
The work presented in this section was aimed at evaluating the efficacy and toxicity of 
PTX nanocrystals produced by the combination approach, as described in Chapter 2. The 
treatment was evaluated in a human colorectal adenocarcinoma HT-29 xenograft model 
in immunodeficient mice. The survival of these mice was compared against the negative 
(saline) and positive (Taxol) control groups to evaluate the antitumor activity of the PTX 
nanocrystals. In parallel, the toxicity was assessed by comparing the percent body weight 
change of the treatment groups. Due to the absence of Cremophor EL/ethanol, PTX 
nanocrystals were expected to induce less toxicity relative to Taxol. 
Since PTX nanocrystals are intended for intravenous administration, a small particle size 
is desired to avoid embolization. The optimum size of targeting tumor’s leaky vasculature 
is still debatable because other particle properties, including the shape, nature, and 
surface charge, also dictate the pharmacokinetics and distribution of the particles in vivo. 
However, collectively it has been proposed that in order to exploit the EPR effect, the 
particle size should be below 400 nm [29]. While high absolute surface charge (±30 mV) 
is needed to obtain stability, it has also been shown that highly charged nanoparticles had 
a much higher opsonization rate than neutral or slightly charged nanoparticles of the 
same size [191, 192]. Generally, due to the strong electrostatic interaction between the 
particles and anionic erythrocyte membrane, cationic particles caused higher hemolytic 
activity while anionic particles are not hemolytic [191]. Many have reported that 
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conjugation of poly-ethylene glycol (PEG) onto the surface of nanovehicles could 
produce stealth properties and decrease the phagocytic clearance by the 
reticuloendothelial system. Yet, PEGylated particles had also been reported to have 
slower uptake into tumor cells compared to bare ones – creating the PEG dilemma [277, 
278]. For the evaluation of efficacy and toxicity, a neutral and non-stabilized PTX 
nanocrystal suspension with a particle size of approximately 200 nm was produced and 
administered weekly for a total of four intravenous injections. 
 
4.1.2 Materials and Methods 
4.1.2.1 Materials 
Paclitaxel (>99.5%, USP30) was purchased from 21CECPharm (United Kingdom). 
Ethanol (HPLC grade), acetonitrile (HPLC grade), DMSO (dimethyl sulfoxide, ACS 
grade), penicillin streptomycin, and 0.25% trypsin-EDTA were purchased from Fisher 
Scientific (Pittsburgh, PA).  Saline (0.9% w/v sodium chloride) for injection was 
obtained from Hospira (Lake Forrest, IL). HT-29 human colon adenocarcinoma cells and 
McCoy’s 5A medium were purchased from ATCC (Manassas, VA). All chemicals and 
solvents were utilized without further purification.  Deionized water (by Milli-Q®, 
filtered through 0.2 ?m membrane) was used for all the experiments. 0.050 ?m (50 nm) 
Whatman® nuclepore polycarbonate track-etched membranes used for filtration were 
purchased from Fisher Scientific (Pittsburgh, PA).   
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4.1.2.2 Preparation of Pure PTX Nanocrystals and Taxol 
Paclitaxel pure nanocrystals were produced by the combination approach as previously 
described in Section 2.2.2. PTX nanocrystals were kept as a concentrated suspension in 
DI water and stored at 4°C. Prior to each intravenous injection, the PTX nanosuspension 
was diluted with saline to achieve a concentration of 3 mg/mL. The dilution factor was 
between 1:3 and 1:4 (v/v). Mixture was sonicated before intravenous administration to 
minimize any flocculation. Taxol was prepared by dissolving PTX into a 50:50 mixture 
of ethanol and Cremophor EL® at a concentration of 30 mg/mL. For the intravenous 
injection, 10% v/v of the concentrated stock was diluted with saline to obtain a 
concentration of 3 mg/mL. 
 
4.1.2.3 Characterization and Analysis of PTX Nanocrystals 
The particle size and surface charge of PTX nanocrystals were measured using the same 
methods as described in Section 2.2.3. Chemical quantification of PTX was conducted by 
high liquid chromatography (HPLC, Waters Breeze) with a Waters Symmetry C18 5 ?m 
column (4.6 x 150 mm) at 227 nm. Acetonitrile and water (50:50) were pumped at a total 
flow rate of 2 mL/min (Waters 1525 binary pump).  The column was equilibrated to 35oC 
prior to sample injection (20 μL).  
 
4.1.2.4 HT-29 Cell Cultures 
HT-29 human colon adenocarcinoma cells were cultured in McCoy’s 5A medium 
supplemented with 10% fetal bovine serum and 1% penicillin streptomycin in a 37°C 
humidified incubator containing 5% CO2. To establish HT-29 xenografts in nude mice, 
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HT-29 cells were harvested (by using 0.25% trypsin-EDTA) when they were 70-90% 
confluent. After being counted, cells were suspended in a 50:50 mixture of sterile 
phosphate buffered saline (PBS) and Matrigel (BD Biosciences, San Jose, CA) at 
concentration of 3x107 cells/mL. Cell suspensions were kept in ice prior to their 
inoculation. 
 
4.1.2.5 Animal Study 
The animal study was conducted under a protocol approved for using nude mice by the 
University’s Institutional Animal Care and Use Committee (IACUC).  Female nude 
outbred mice (Tac:Cr: (NCr)-Foxn1 Nu) were obtained from Taconic at 4 weeks of age 
(14.5-20 g).  Mice were acclimated for one week after arrival. Subsequently, mice were 
anesthetized by isoflurane inhalation for placing an ear identification tag and cell 
inoculation. HT-29 xenografts were established by injecting 100 ?L HT-29 cells (3×106) 
subcutaneously to each flank. Animals were monitored three times weekly for their 
weight and tumor volume. The tumor dimension was measured by digital calipers, and 
the volume was calculated by using the following equation:  
???????????? ? ?
?
?
?? ?????????????????? ? ????????????????????? 
Tumors became palpable (100-300 mm3) after nine days of inoculation. A total of 36 
mice were randomized into 3 groups to receive one out of the following injections: saline 
(control), Taxol, or PTX nanocrystals. Intravenous injection of Taxol and PTX 
nanocrystals were administered via tail vein weekly on day 10, 17, 24, and 31 after 
inoculation at concentration of 20 mg/kg. 150 uL of saline was administered to the 
control group. Body weight and tumor volume were measured three times weekly. 
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During the survival study, animals had to be euthanized as soon as the following criteria 
occured: (i) they became moribund, (ii) their tumor reached 1500 mm3 in size, became 
ulcerated, or impeded their ability to attain food or water, (iii) they lost 20% of their body 
weight, or (iv) they developed a severe medical condition or adverse effects. Those 
conditions are the typical humane endpoints recommended by the Institutional Animal 
Care and Use Committee (IACUC). The study was ended on day 32 after cell inoculation 
as all the mice in the control group had been euthanized.  
The percent body weight change (BWC) was calculated based on the following equation: 
????? ? ?
???????????? ? ??????????????????????????????
?????????????????????????????
?? ???? 
 
 
4.1.2.6 Statistical Analysis 
The statistical analysis was performed by Dr. Heidi Weiss’ group in the Biostatistics 
Shared Resource Facility (Markey Cancer Center, University of Kentucky). Descriptive 
statistics were calculated and graphical display of percent of change in body weight from 
the baseline levels were generated for each group.  Pairwise comparison at each time 
point of follow-up was performed using the non-parametric Wilcoxon rank-sum test to 
account for non-normality of data.  Kaplan-Meier curves for overall survival were 
estimated for each treatment group and comparison of overall survival across treatment 
groups were performed based on the log-rank test.  Median times as well as proportion 
surviving at specific time points were estimated from the Kaplan-Meier curve.   Tumor 
volume was summarized descriptively and the percent change of tumor volume from 
baseline was plotted.  The percent change in tumor volume at specific time points was 
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compared between groups using an analysis of variance model with pairwise 
comparisons between groups generated from the model.    
 
4.1.3 Results and Discussion 
4.1.3.1 Characterization of PTX Nanocrystals 
PTX nanocrystals used for this particular animal study were produced by using the 
combination approaches as described in Section 2.2.2. With this approach, nanocrystals 
with approximate size of 200 nm can be produced. The SEM images of intravenously 
administered PTX nanocrystals are presented in Table 4.1. The mean and standard 
deviation of the particle size were analyzed by using the SigmaScan (Systat Software, 
San Jose, CA) and summarized in Table 4.2. Additionally, the hydrodynamic diameters, 
polydispersity index, and zeta potential of the four PTX nanocrystal batches administered 
during the survival study were determined (Table 4.2).   
Except for PTX nanocrystals used for the first injection, the particle size measurements 
analyzed by SigmaScan (from the SEM images) and DLS were comparable. Due to more 
heterogeneous size distribution, as indicated by the PI value (c.a. 0.25), the particle size 
measurement by DLS was higher. Other injections had narrower size distribution as their 
PI values were less than 0.25. As discussed in Section 2.3.1, the zeta potential of PTX 
nanocrystals measured in DI water was approximately between -15 and -22 mV, but it 
was increased (i.e. more positive) as it was dispersed in 10 mM NaCl. The understanding 
of this destabilization is important because the PTX nanocrystal stock suspension was 
diluted with saline in order to achieve isotonic intravenous injection. Any flocculation 
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that might occur due to the increase in the ionic strength could be minimized by mixing 
the stock just a few minutes before injection and subjecting the mixture to sonication.  
 
Table 4.1. SEM images of PTX nanocrystals utilized for four weekly treatments during 
the survival study. Scale bars represent 1 μm. 
Injection 1 Injection 2 
 
 
 
 
 
 
Injection 3 Injection 4 
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Table 4.2. The physical characterizations (mean ± S.D.) of PTX nanocrystals used during 
the survival study. 
Properties 
Paclitaxel Nanocrystals 
Injection 1 Injection 2 Injection 3 Injection 4 
Particle size 
(SigmaScan) 
149 ± 44 198 ± 63 193 ± 63 195 ± 62 
Hydrodynamic 
diameter (DLS) 
179 ± 1 200 ± 4 197 ± 3 198 ± 2 
Polydispersity 
Index 
0.25 ± 0.01 0.16 ± 0.02 0.15 ± 0.04 0.17 ± 0.04 
Surface charge 
(in 10 mM NaCl) 
Not measured Not measured Not measured -9.85 ± 0.52 
 
 
4.1.3.2 Animal Study 
The colon cancer HT-29 tumor xenografts were palpable nine days subsequent to the 
subcutaneous implantation of the cells. A total of 36 mice were randomized into three 
groups (n=12): saline, 20 mg/kg Taxol, and 20 mg/kg PTX nanocrystals. They were 
scheduled to receive four weekly injections (i.e. day 10, 17, 24, and 31 after inoculation). 
The mean and standard deviation (error bar) of the tumor volume from each group are 
summarized in Figure 4.1. After body weight and tumor volume measurements at day 23, 
some mice in the control and Taxol groups had to be euthanized due to the large tumor 
volume or rapid body weight decrease (see explanation in the following paragraph). 
Since the number of mice in the control and Taxol groups decreased, the percent change 
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of the tumor volume was no longer graphed starting on day 23 after inoculation. Due to 
the absence of PTX treatment, the tumors of mice in the saline group grew rapidly. 
Conversely, compared to the control group, there was a trend of tumor suppression (p < 
0.001) in both Taxol and PTX nanocrystal groups starting on day 16 after inoculation, 
although the difference between the treatments was marginally significant (p = 0.1). 
There was no significant difference (p = 0.49) between the change in the tumor volume of 
mice in the Taxol and PTX nanocrystal groups at day 23. 
On day 23 after inoculation, 2 mice in the control (saline) group and Taxol were 
euthanized because the sum of their tumor volume had exceeded 1500 mm3. Large tumor 
size generally impedes the ability of mouse to walk and obtain enough food to support its 
normal body function and tumors. On the same day, another mouse in the Taxol group 
was sacrificed due to significant weight loss (i.e. more than 20%).  For this particular 
mouse, the decrease in body weight was most likely due to the toxicities that are 
associated with the utilization of Cremophore EL and ethanol as 3-5% of the body loss 
was observed subsequent to each intravenous injection. By day 32 after inoculation, all 
the mice in the control group had to be sacrificed due to their large tumor size. Thus, 
following the established animal protocol, which was based on the recommended humane 
endpoint, the survival study was ended. The survival of treatments groups was plotted 
with Kaplan-Meier curves as presented in Figure 4.2.  Out of the 12 mice in the Taxol 
group, 2 mice had to be euthanized due to significant body weight loss, while 2 others 
had uncontrollable tumor growth. All the 4 mice in the PTX nanocrystal group were 
sacrificed due to large tumor volume (i.e. larger than 1500 mm3). The survival 
probabilities at day 30 after inoculation for control, Taxol, and PTX nanocrystal group 
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were 16.7%, 66.7%, and 83.3%, respectively. The mice in the control group reached the 
median survival time by day 25 after inoculation, while the median survival time was not 
reached for the Taxol and PTX nanocrystal group.  Overall, the log-rank analysis 
revealed that there were significant differences between the control and Taxol (p = 
0.0032) as well as the control and PTX nanocrystals (p = 0.001), indicating the 
treatments’ efficacy. However, there was no significant difference between the two 
treatments (p>0.5). Liu et al. also reported that when administered with the same dose, 20 
mg/kg, PTX in Cremophore-EL and their PTX nanocrystal formulation exhibited similar 
tumor inhibition activity (i.e. there was no significant difference between the two 
treatments) [242]. The low toxicity of the nanocrystals prompted them to increase the 
dose of administration. Significant tumor inhibition (p<0.001) was achieved when the 
PTX nanocrystal dose was increased to 60 mg/kg. 
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Figure 4.1. The tumor volume chart from the three different groups: control (saline), 20 
mg/kg Taxol, 20 mg/kg PTX nanocrystals up to day 23 after inoculation (prior to 
euthanization, n=12 for all the groups).  
 
Figure 4.2. The percent of animal survival versus time. Animals were administered either 
with saline, 20 mg/kg Taxol or PTX nanocrystals at day 10, 16, 24, and 31 after 
inoculation (n=12 on day 0).  
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PTX nanocrystals were formulated with an objective to offer a safer delivery of PTX. 
The chart signifying the mean and standard deviation (i.e. the error bars) of the percent 
body weight change during the course of the survival study is depicted in Figure 4.3. 
Upon statistical analysis, the differences in the percent body weight change of the Taxol 
and PTX nanocrystals groups on day 16 and 23 after inoculation (i.e. 6th day after weekly 
injections) were significant (p<0.05). In the Taxol group, out of the 8 mice that survived 
on day 32 after inoculation, half of them had more than 5% loss of their body weight. In 
contrast, only 1 of the 8 mice left in the PTX nanocrystal group had body weight loss of 
more than 5%.  
It is important to note that similar to previous animal studies conducted in our lab, mice 
in the Taxol group had a tendency to lose their body weight during the course of the 
study. A decrease in body weight could be associated with cancer cachexia, loss of body 
weight that hardly can be reversed nutritionally, and/or treatment. Yet, the repetitious 
observed trends suggested that it was likely due to the solvent-associated toxicity. 
Therefore, in spite of the similarity in the efficacy effect when administered at 20 mg/kg, 
PTX nanocrystals potentially could offer safer delivery of PTX relative to Taxol.  
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Figure 4.3. Percent body weight change of animals in three treatment groups up to day 
23 after inoculation (prior to euthanization, n=12 for all the groups). 
 
4.1.4 Conclusion 
PTX nanocrystals for intravenous injection were produced by the combination approach. 
The efficacy and toxicity of PTX nanocrystals were compared to control (saline) and 
Taxol in a human colorectal adenocarcinoma HT-29 xenograft model in immunodeficient 
mice. Subsequent to four weekly treatments, the result of the survival study revealed that 
there was no significant difference in the efficacy of Taxol and PTX nanocrystals at 20 
mg/kg dose. However, relative to Taxol, the solvent-free PTX nanocrystal suspension 
was able to offer less toxic, thus safer delivery of PTX. 
 
 
Copyright © Christin Pramudiati Hollis 2012  
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4.2 Evaluation of PTX/MMPSense/FPR-648 Nanocrystals in MCF-7 Xenograft 
4.2.1 Introduction 
“Theranostics” is defined as a material that is designed to have combination of 
therapeutic and diagnostic modalities. In (pre)clinical settings, theranostic nanomedicines 
can be utilized to validate and optimize the properties of drug delivery systems and 
enable personalized medicine, as opposed to adopting a “one size fits all” approach. The 
inclusion of the diagnostic probe(s) in theranostics allows one to longitudinally monitor 
the therapeutic efficacy and possibly predict a potential treatment response. For the 
therapy and diagnosis of cancer, theranostic nanomedicines are aimed to have the ability 
to accumulate in the tumor efficiently, exert treatment efficacy with minimal toxicity, and 
simultaneously provide real-time, non-invasive information about the distribution and the 
diseased tissue. In the past few years, vast numbers of theranostic nanomedicines have 
been reported and reviewed [31, 32, 68, 72, 279]. Most theranostic systems are 
constructed from lipid bilayer vesicles, polymers, and inorganic materials, which may 
generate additional toxicity. By utilizing hybrid nanocrystals, which are composed mostly 
of the drug molecules, the extraneous hazards could be minimized. Additionally, high 
drug-loaded hybrid nanocrystals can be produced using a “one-pot” synthesis, permitting 
simple formulation. 
The ability of PTX hybrid nanocrystal system to perform as a theranostic system was 
tested in the murine human breast cancer MCF-7 orthotopic xenograft (inoculated in the 
mammary fat pads). The tumor growth and metastatic potential rely heavily on the site of 
inoculation [280-283]. Orthotopic implantation, where cells are re-inoculated into the site 
of the original tumor, produce metastatic lesions more frequently than those inoculated 
122 
 
elsewhere [281]. Two imaging moieties, bioactivatable MMPSense 750 FAST and near-
infrared fluorophore FPR-648, were concurrently incorporated into the nanocrystals. 
MMPSense 750 was expected to give a feedback of the disease state (e.g. metastasis), 
while the entrapped FPR-648 could assist in non-invasively tracing the distribution of the 
nanocrystal system. Because their emission wavelengths are separated by 100 nm 
(MMPSense λem: 775 nm, FPR-648 λem: 672 nm), the fluorescent signals can be observed 
in two separate excitation/emission windows by the in vivo imaging system IVIS®.  
MMPSense 750 FAST is a bioactivatable dye, which is optically silent in its native 
(quenched) state but becomes highly fluorescent as the peptide bond portions are cleaved 
by matrix metalloproteinases (MMPs). Matrix-metalloproteinases (MMPs), a large family 
of zinc –dependent proteolytic enzyme, particularly MMP-2 (gelatinase-A) and MMP-9 
(gelatinase-B) are involved in the progression of breast cancer [284]. While MMP-2 is 
expressed in very early stage breast cancer and believed to play role in the first events 
leading to the tumor formation [285], MMP-9 appears to be associated with lymph-node 
metastasis [286]. MCF-7 human breast adenocarcinoma expressed both MMP-2 and 
MMP-9 only when co-cultured with tumor-derived fibroblasts [284]. Clapper et al. have 
reported the successful use of bioactivatable molecular imaging probes, MMPSense, to 
correlate the positive fluorescence signal and the presence of pathologically confirmed 
colonic adenocarcinoma [287]. The ability of entrapped MMPSense (i.e. in hybrid 
nanocrystals) to monitor the disease state (e.g. metastasis) was non-invasively evaluated 
by using the IVIS Spectrum system (λex: 745 nm and λem: 800 nm). The signals detected 
from hybrid nanocrystals suggested that subsequent to tumor and tissue accumulation, the 
quenched MMPSense was able to be released from the crystal lattice and undergo 
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cleavage by MMPs in the site where their activity is elevated. The co-entrapment of 
bioactivatable probe and therapeutic agents can be beneficial, in that response to therapy 
can be monitored longitudinally subsequent to each treatment, which may take a few 
weeks. Since the bioactivatable probe is highly sensitive, it should be able to detect a 
very small number of precancerous or cancerous cells with elevated protease activity 
[287].  
 
4.2.2 Materials and Methods 
4.2.2.1 Materials 
Paclitaxel (>99.5%, USP30) was purchased from 21CECPharm (United Kingdom); FPR-
648 fluorophore (?ex=648 nm; ?em=672 nm) was obtained from Akina (West Lafayette, 
IN); MMPSense 750 Fluorescent Activatable Sensor Technology (FAST) (?ex=745 nm; 
?em=800 nm) was purchased from Perkin Elmer (Waltham, MA).  Ethanol (HPLC grade), 
acetonitrile (HPLC grade), and DMSO (dimethyl sulfoxide, ACS grade) were purchased 
from Fisher Scientific (Pittsburgh, PA).  All chemicals and solvents were utilized without 
further purification.  Deionized water (by Milli-Q®, filtered through 0.2 ?m membrane) 
was used for all the experiments. 0.050 ?m (50 nm) Whatman® nuclepore polycarbonate 
track-etched membranes used for filtration were purchased from Fisher Scientific 
(Pittsburgh, PA).  MCF-7 human breast adenocarcinoma cells were obtained from ATCC 
(Manassas, VA). 
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4.2.2.2 Preparation of Pure and PTX/MMPSense/FPR-648 Hybrid Nanocrystals 
Pure and hybrid paclitaxel nanocrystals were produced by using an anti-solvent method.  
For the pure nanocrystal, 1 mL of 5 mg/mL of paclitaxel in ethanol was added to 20 mL 
deionized water in round-bottom flask.  The mixture was subjected to stirring at 800 rpm 
and sonication (sonication bath, F20D, Fisher Scientific) for 10 minutes.  To make hybrid 
PTX/MMPSense/FPR-648 nanocrystals, 6.48 nmol (in 0.27 ml) of MMPSense 750 FAST 
and 0.635 mg (in 0.127 ml) of FPR-648 were added to deionized water prior to the 
addition of PTX solution. After stirring at 800 rpm for 10 minutes, the speed was 
adjusted to 300 rpm (for 15 minutes) and 150 rpm (for another 15 minutes) in order to 
minimize bubbles formed and encourage entrapment of the imaging agents.  After 
crystallization, the solution was filtered through a 50-nm polycarbonate membrane, and 
the retentate was re-suspended in water for additional filtration-re-suspension cycles to 
remove imaging agents that may potentially adhere to the surface of the crystals.   
 
4.2.2.3 Physical Characterization and Chemical Analysis of Nanocrystal Systems 
SEM images were obtained using the Hitachi SEM 4300 at accelerating voltage of 3 kV.  
Using a sputter coater, samples were coated with conductive layers of gold palladium 
(Au/Pd) for 1 minute with a current of 20 mA.  Particle size and zeta potential were 
measured in deionized water using Malvern Zetasizer (Nano-ZS).  
PTX concentrations were analyzed by a high-performance liquid chromatography 
(HPLC) system (Waters Breeze with a dual wavelength absorbance detector, Waters 
2487) at an absorbance wavelength of 227 nm.  A reverse-phase C-18 column (5 μm, 150 
mm × 4.6 mm, Waters) was used. The mobile phase composed of 50% acetonitrile and 
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50% deionized water was pumped at a total flow rate of 2 mL/min.  The column was 
equilibrated to 35°C prior to sample injection (20 μl). 
IVIS® Spectrum was utilized to measure the percent entrapment of fluorophores 
(MMPSense 750 and FPR-648) in the hybrid nanocrystals. When tested with near-
infrared dye Cy5.5, small animal optical imaging system, such as IVIS®, was capable of 
producing high linear correlation between fluorescence intensity and concentration for 
more than 3 log orders of magnitude (i.e. 1 to 1000 nM) with R2 of 0.996 [288]. Standard 
solutions of MMPSense 750 and FPR-648 were prepared in DMSO. MMPSense 750 
standards were prepared at concentrations of 0.2, 0.5, 1, and 2 nmol/mL, while those of 
FPR-648 were at concentrations of 0.25, 0.5, 0.75, and 1 μg/mL. MMPSense 750 was 
analyzed at excitation and emission wavelengths of 745 and 800 nm, respectively, while, 
FPR-648 was analyzed at lower wavelengths (?excitation: 640 nm, ?emission: 700 nm).  
 
4.2.2.4 Cell Culture of MCF-7 
The MCF-7 human breast adenocarcinoma cells were cultured with DMEM (Dulbecco's 
Modified Eagle Medium, Hyclone) with 10% fetal bovine serum (Hyclone) and 1% 
penicillin/streptomycin (Hyclone).  Trypsin-EDTA (ethylenediaminetetraacetic acid, 
Mediatech) was used to dissociate cells from the dish.  All the cell culture reagents were 
purchased from Fisher Scientific (Pittsburgh, PA).  Cells were cultured at 37 °C in a 
humidified atmosphere with 5% CO2. To establish the MCF-7 xenograft in nude mice, 
cells were harvested (by using 0.25% trypsin-EDTA) when they were 70-90% confluent. 
After being counted, cells were suspended in serum-free DMEM at a concentration of 
5x107 cells/ml. Cell suspensions were kept in ice bucket prior to their inoculation. 
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4.2.2.5 Animal Study 
Female nude outbred mice (Tac:Cr: (NCr)-Foxn1 Nu) were obtained from Taconic at 4 
weeks of age (14.5-20 g). All of the animal experiments complied with the principles of 
care and use of laboratory animals and were approved by the University of Kentucky 
Institutional Animal Care and Use Committee (IACUC). Seven days after arrival, one 
17β-estradiol pellet (1.7 mg, 60-day release; Innovative Research of America, Inc.) was 
implanted under the skin between the ears of each mouse. Two days later, 5×106 MCF-7 
cells (100 ?L) were inoculated subcutaneously into each side of the mammary fat pad. 
All experimental procedures were performed under general anesthesia by isoflurane 
inhalation. Subsequent to the treatment injections, animals were monitored daily for their 
body weight and tumor volume using a digital caliper. The tumor volume was calculated 
by using the following equation:  
???????????? ? ?
?
?
?? ?????????????????? ? ????????????????????? 
Approximately 8 weeks after tumor inoculation, a total of 24 mice were randomized into 
4 groups (n=6): untreated (control), Taxol, PTX nanocrystals, and PTX/MMPSense/FPR-
648 hybrid nanocrystals. Taxol formulation (3 mg/ml) was prepared by diluting 300 μl of 
30 mg/ml of paclitaxel in Cremophore EL/ethanol (50:50) solution with 2.7 mL of saline 
(0.9% sodium chloride). The intravenous injections that were administered to the mice 
via tail veins were summarized in Table 4.3. Concurrently, 0.1 nmol of the bioactivatable 
dye, MMPSense 750, diluted in PBS was also injected into all mice, except those in the 
PTX/MMPSense/FPR-648 hybrid nanocrystal group. The in vivo performance of free and 
entrapped (i.e. in hybrid nanocrystals) MMPSense 750 were monitored by IVIS® 
Spectrum (?ex: 745 nm, ?em: 800 nm).  The fluorescence signal of entrapped FPR-648 in 
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PTX/MMPSense/FPR-648 hybrid nanocrystals was also longitudinally monitored by 
IVIS® at ?ex: 640 nm, ?em: 700 nm. All mice were euthanized at day 7.  
Table 4.3. The details of injections for evaluating MMPSense performance in vivo. 
Groups Number of mice Paclitaxel MMPSense 
No xenograft 5 - 0.1 nmol 
Untreated 6 - 0.1 nmol 
Taxol 6 20 mg/kg 0.1 nmol 
PTX nanocrystals 6 20 mg/kg 0.1 nmol 
PTX/MMPS/FPR-648 
nanocrystals 6 20 mg/kg 
0.2 nmol 
(1.83 % w/w entrapment) 
 
 
4.2.2.6 IVIS® Imaging 
Prior to and during the IVIS® imaging, mice were anesthetized by isoflurane inhalation.  
To monitor the MMPSense 750 fluorescence signals, mice were imaged at excitation and 
emission wavelengths of 745 nm and 800 nm, respectively. Images were all taken with 
the same parameters as follows: (a) exposure time: 4 seconds, (b) F/Stop: 2, (c) binning: 
8 (medium), (d) field of view (FOV): 13. To monitor the FPR-648 fluorescence signals, 
excitation wavelength of 640 nm and emission wavelength of 700 nm were utilized. 
Images were taken with 0.25 second exposure time, but the remaining parameters were 
kept constant.  
 
 
128 
 
4.2.2.7 Statistical Analysis 
The statistical analysis was performed by Dr. Heidi Weiss’ group in Biostatistics Shared 
Resource Facility (Markey Cancer Center, University of Kentucky). Graphical display of 
percent of change in body weight from the baseline levels were generated for each group.  
Pairwise comparisons at each time point of follow-up were performed using the non-
parametric Wilcoxon rank-sum test to account for non-normality of data.  The percent 
change in tumor volume at specific time points was compared between groups using an 
analysis of variance model with pairwise comparisons between groups generated from 
the model.    
 
4.2.3 Results and Discussion 
4.2.3.1 Characterization and Analysis of PTX Pure and PTX/MMPSense/FPR-648 
Hybrid Nanocrystals 
The PTX nanocrystals, both pure and hybrid, used for this particular animal study were 
produced by the anti-solvent method. The harvested nanocrystals were not subjected to 
any homogenization, as aforementioned in Section 2.2.2. The SEM images, size analysis 
(by SigmaScan), polydispersity index, and zeta potential of both products are presented in 
Table 4.4 and Table 4.5, respectively. For PTX pure nanocrystals, the hydrodynamic 
diameter determined from DLS was similar to the particle size analyzed from the SEM 
image (by SigmaScan). In contrast, the particle size of the PTX/MMPSense/FPR-648 
nanocrystals determined by DLS was underestimated possibly because of their elongated 
shape and particle size heterogeneity. The polydispersity indices suggest that the size 
distribution of the pure PTX nanocrystals was narrower than that of the PTX hybrid 
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nanocrystals. In addition, the more negative value of zeta potential of the hybrid 
nanocrystals is suspected due to the adsorption of MMPSense molecules, which are 
negatively charged in the aqueous environment [289]. Although the exact molecular 
structure of MMPSense is undisclosed, the technology was based on the bioactivatable 
probes previously reported [290]. The polymer backbone, which supports the cleavable 
site (proline-leucine-glycine-valine-arginine peptide) and unquenched fluorophores 
[291], could promote higher adsorption of MMPSense to the surface of the nanocrystals, 
in addition to being integrated in the crystal lattice.  
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Table 4.4. SEM images of PTX and PTX/MMPSense/FPR-648 nanocrystals. Scale bars 
represent 1 μm. 
PTX Pure Nanocrystals PTX/MMPSense/FPR-648 Nanocrystals 
 
 
 
 
 
Table 4.5. Physical properties of PTX pure and hybrid nanocrystals (mean ± S.D.). 
Properties PTX Nanocrystals 
PTX/MMPSense/FPR-648 
Nanocrystals 
Particle size (SigmaScan) 300 ± 140 nm 380 ± 140  nm   
Hydrodynamic diameter (DLS) 270 ± 5 nm 280 ± 20 nm   
Polydispersity Index 0.10 ± 0.03 0.19 ± 0.05 
Surface charge (in DI water) -14.9 ± 0.1 mV   -20.6 ± 0.6 mV   
 
The amount of fluorophores entrapped was analyzed by using the IVIS® Spectrum. The 
standard solutions and samples were placed in a 96-well plate, and the fluorescence 
intensity from the wells was analyzed by Living Image® software (Caliper Life Science, 
Hopkinton, MA) specifically written for the analysis of IVIS® images. The IVIS® image 
of a portion of the 96-well plate that was filled with the standard solutions of MMPSense 
750 and FPR-648 is shown in Figure 4.4. The MMPSense 750 and FPR-648 standard 
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solutions were placed in the top and bottom portion, respectively. When imaged at ?ex: 
640 nm and ?em: 700 nm, only the FPR-648 standard solutions fluoresced. Meanwhile, 
MMPSense solutions were detected when excitation and emission wavelengths of 745 
nm and 800 nm, respectively, were utilized. This image shows the specificity of the 
instrument, which is equipped with narrow bandwidth (30 nm) excitation filters and 
narrow bandwidth (20 nm) emission filters.  Additionally, the IVIS® spectral un-mixing 
algorithm allows researchers to separate signals from multiple fluorescent reporters 
within the same animal or source. 
 
 
Figure 4.4. IVIS® images of wells that were filled with standard solutions prepared in 
DMSO and imaged either with ?ex: 640 nm and ?em: 700 nm or ?ex: 745 nm and ?em: 800. 
Only the bottom part, FPR-648 solutions, fluoresced at the former excitation/emission 
window, while the top part, MMPSense 750 solutions, fluoresced at the latter. 
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The standard curves generated from triplicate standard solutions of MMPSense 750 and 
FPR-648 are presented in Figure 4.5 and 4.6, respectively. IVIS® was capable of 
producing high linear correlation between fluorescence intensity and concentration for 
more than 3 log orders of magnitude (i.e. 1 to 1000 nM) with R2 of 0.996 when tested 
with near infrared dye Cy5.5 [288]. From the standard curves, it was determined that 
there was 1.6 nmol/mL of MMPSense 750 (MW: ~43,000 g/mol) in 3.76 mg/mL of PTX 
nanocrystals, giving a percent entrapment of 1.83% (w/w). Meanwhile, there was 0.5 
μg/mL (0.01% w/w) of FPR-648 entrapped. Due to its high sensitivity, the IVIS® optical 
imaging modality, is able to detect fluorophore(s) even at nanomolar concentrations.   
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Figure 4.5. The standard curve of MMPSense 750 obtained from the IVIS® Spectrum 
 
 
Figure 4.6. The standard curve of FPR-648 obtained from the IVIS® Spectrum 
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4.2.3.2 Animal Study 
The MMPSense molecules are optically silent (quenched) in their native state, but they 
become highly fluorescent as the peptide bond portion gets cleaved by matrix 
metalloproteinases (MMPs), which facilitate tumor cell invasion and metastasis [292]. 
Specifically, MMP-2 and MMP-9 are overexpressed in MCF-7 cell lines [284]. To test 
the robustness of MMPSense 750 performance in an animal model, first, 0.1 nmol of the 
MMPSense 750 dissolved in phosphate buffered saline (PBS) was first injected into 
athymic mice without any tumor burden, and the animals were imaged by IVIS® (Figure 
4.7).  Because tumor was not initiated in the animals and MMPs were minimally 
expressed, little fluorescent signal should be observed. Nonetheless, fluorescent signals 
were detected up to day 2 after injection. Later, it was confirmed with the supplier 
(Perkin Elemer) that the dye was not 100% quenched (or conjugated), i.e. mixed with a 
small percentage of unquenched fluorophores due to the synthesis process. At day 2, 
most of the unquenched dye was renally cleared from the body. 
 
Figure 4.7. IVIS® images of non-xenograft mice (n=5) injected with 0.1 nmol 
MMPSense 750.  
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From the fluorescence analysis, it was determined that there was 1.83% w/w entrapment 
of MMPSense 750 in the PTX hybrid nanocrystal.  In a single intravenous injection of 
PTX hybrid nanocrystals at 20 mg/kg, the total amount of entrapped MMPSense was 
approximately equivalent to 0.2 nmol per animal. To validate and compare the ability of 
the entrapped versus free MMPSense to monitor the cancer state, 0.1 nmol (half 
concentration of the entrapped dye) of the free MMPSense/PBS was injected 
simultaneously with Taxol, pure PTX nanocrystals, or by itself in the case of the 
untreated group. The IVIS® images from the four groups were compared at day 2, when 
the majority of the pre-existing unquenched MMPSense had been cleared (Figure 4.8).  
 
 
Figure 4.8. IVIS images of mice from different treatment groups at day 2 after injection.  
MMPSense solution (0.1 nmol) was given to the first three groups with or without the 
treatment, while approximately 0.2 nmol of MMPSense were entrapped in the injected 
hybrid nanocrystals given to the last group.  The color intensity scale was doubled (4x10-
6 to 2x10-5) of the last group in order to match the half amount of the dyes used in the first 
three groups (2x10-6 to 1x10-5). 
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The apparent fluorescent signals at day 2, hence, should signify the intensities that were 
due to MMPSense activation. The cleaved fluorophores, which are hydrophilic, were then 
cleared renally. Due to the difference in the chemical makeup, the clearance of the 
paclitaxel may differ from the fluorophores. The images also showed that entrapped 
MMPSense in the PTX nanocrystals was capable of exerting the same functionality to 
respond to the elevation of MMPs as that by the unbound MMPSense. This suggests that 
the entrapped MMPSense dye were released out of the nanocrystals and cleaved by 
MMPs in the main tumor and metastasis sites.  
The IVIS images of mice from all the treatment groups from day 0 to 5 are summarized 
in Figure 4.9.A. The mean and standard deviation of fluorescent signal intensities are 
shown in Figure 4.9.B. Based on Figure 4.9.A (day 0 to 3 images), the stronger 
fluorescent signals observed in some mice of the pure and hybrid nanocrystals groups 
may rise from the variation in the amount of MMPSense in the intravenous injection. The 
mice showing stronger signals in later time points had higher initial intensities on day 0. 
Furthermore, although some degrees of variation were observed, the mean values of the 
photonic efficiency from all of the xenografted mice were almost doubled at 19 hours 
after the injection (Figure 4.9.B). Compared with the signal attenuation over time 
observed in the mice with no xenograft, the signal amplification in the xenografted mice 
signified that the MMPSense probe was activated by the MMPs. It is also worth noting 
tha the MMPSense incorporated in the hybrid nanocrystals were able to perform similarly 
to the free MMPSense, which was injected by itself (for the untreated group) or along 
with other treatments (Taxol and pure paclitaxel nanocrystals). The large standard 
deviation in the hybrid nanocrystal group was caused by the variability on the amount of 
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Figure 4.9. (A) IVIS images of mice from untreated, Taxol, PTX pure, and PTX hybrid 
nanocrystal groups from day 0 to day 5.  Day 0 images were taken 2 hours post-injection. 
The color scale from the PTX hybrid nanocrystal group (left) was doubled compared to 
the other groups (as in Figure 3). (B) The average IVIS efficiency (i.e., IVIS efficiency 
(cm2) divided by the area of each mouse (cm2)) was plotted against the time.  The data 
points indicate mean ± S.D.  n=6 for the xenografted mice (Figure 4.8) and n=5 for no-
xenograft group (Figure 4.7). 
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MMPSense, both integrated and on the surface of the nanocrystals, in each injection. 
Figure 4.9.A further suggests that there were more unquenched dyes integrated with the 
nanocrystals, likely resulting from the integrity of MMPsense being compromised due to 
the exposure to ethanol, rapid stirring, and intense sonication during the process of 
nanocrystal production. The unquenched dyes were mostly cleared before day 2 through 
the kidney and urinary bladder, and most of the fluorescence imaging observed on day 2 
should have arisen from the quenched dyes that were relased from the nanocrystals and 
cleaved by the MMPs. In all groups, the fluorescence signals died down significantly 
after day 3. The similarity in the fluorescence imaging of the pure and hybrid nanocrystal 
groups did imply the possibility that MMPSense molecules were mostly adsorbed to the 
surface of the hybrid nanocrystals, detached quickly upon the injection of the 
nanocrystals. Moreover, given the relatively large entrapment ratio (1.83% w/w), a 
majority of the dyes were more likely not integrated throughout the nanocrystals, 
differing from FPR-648 discussed below.  
In order to non-invasively trace the distribution of the hybrid nanocrystal in vivo, it was 
intended to incorporate the NIR dye FPR-648 in the crystal lattice of the nanocrystals. 
IVIS® images of mice treated by the PTX/MMPSense/FPR nanocrystals were obtained at 
the lower emission wavelength (Figure 4.10). The weak fluorescent spots observed in the 
images prior to the injection were due to the autofluorescence. Post-injection IVIS® 
images indicate that the majority of the hybrid nanocrystals were accumulated in the 
liver. Because of their size range, 250-600 nm, the hybrid nanocrystals were prone to be 
sequestered by the Kupffer cells in the mononuclear phagocyte system (MPS). It is 
important to note that the observed fluorescence arose from the combination of both 
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entrapped and dissolved dye molecules.  In a previous animal study, the solution of FPR-
749 dye, which has similar chemical structure to FPR-648, were cleared approximately 
72 hours subsequent to the injection [169]. Thus, given the fact that the fluorescent 
remains up to day 7, it is highly plausible that the nanocrystals were not completely 
dissolved, continuously releasing the dye moecules.  Figure 4.10 may suggest that the 
hybrid nanocrystals, which accumulated in the liver, may slowly be released to the blood 
circulation and passively to the tumor site. Small amounts of fluorescence were observed 
in the excised tumor and liver (bottom of Figure 4.10). The imaging results differ from 
our earlier data, where tumor showed the strongest intensity [169]. Note that only one 
NIR dye was integrated in the PTX nanocrystals in the earlier study [169]; the integration 
and possibly surface adsorption of the large, negatively charged molecules, MMPSense, 
altered the surface properties (e.g., surface charge and wettability) and possibly the 
biodistribution of the hybrid nanocrystals, compared with the PTX/FPR-749 nanocrystals 
[169]. From the theranostic point of view, the bioimaging results do support a great 
potential of the hybrid nanocrystals whose distribution can be traced in the real-time. 
Still, it is worth pointing out that the live fluorescence imaging that is contrinuted by both 
integrated and unbound dye molecules. More importantly, the biodistribution of free dyes 
may be significantly different from that of drug molecules and/or nanocrystals. 
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Figure 4.10. IVIS® images of mice in the hybrid nanocrystal group viewed at ?ex: 640 
nm and ?em: 700 nm signifying the fluorescence signal detected from the near-infrared 
dye, FPR-648, incorporated in the hybrid nanocrystals. The excised tumors and major 
organs (liver, spleen, kidneys, lung, and heart) were imaged on day 7 with the same 
imaging parameters. 
The amount of drug accumulated in the tumor was sufficient to induce some degree of 
tumor volume suppression, as seen in Figure 4.11. Compared to the control group, the 
treatments (Taxol, PTX nanocrystals, and PTX hybrid nanocrystals) induced tumor 
suppression (p<0.05) starting on day 3 after injection and continuing to day 7.  On day 7, 
the treatments significantly suppressed the tumor growth compared to the control group 
(p-values <0.01 for all treatments). There was no significant difference in the percent of 
tumor volume change between the treatments (p>0.1) throughout the study.  Clearly, 
without any solubilization means, the nanocrystals were capable of inducing similar 
degree of tumor growth suppression as the solubilized formulation (e.g. Taxol). 
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Figure 4.11. Percent change in tumor volume measured daily after single injection of 
treatments on day 0. Each point indicates the mean ± S.D. (n=6). *P<0.01 compared to 
the untreated group on day 7. All treatements induced tumor suppression (P<0.05) on 
days 3, 4, 5, and 6.  
 
Furthermore, the treatment toxicity was evaluated by the percent body weight change 
during the course of the study (Figure 4.12). Note that all of the mice, including ones 
with no tumor (MCF-7 xenograft), experienced some extent of body weight loss due to 
the induced stress from daily transportation and exposure of anesthesia during the 
(IVIS®) imaging process. Compared to the control (untreated), the percent of body weight 
of the Taxol group was significantly different (p < 0.05) on days 2, 3, 4, and 6, and 
tretnds towards significance were observed on day 5 (p = 0.07) and 7 (p = 0.16). The 
mice in the Taxol group were likely able to recoup their body weight back by day 7 
because most of the treatments might have been cleared. Conversely, the body weights of 
mice in the pure and hybrid nanocrystals group were not significantly different (p>0.1) 
from the control (untreated). This result suggested that nanocrystals were able to offer 
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safer and less toxic delivery than the solubilized formulation. As such, it is possible to 
increase the dose of nanocrystals to achieve more efficient treatment.  
 
Figure 4.12. Percent change in body weight measured daily. Each point indicates the 
mean ± S.D. (n= 6). # P < 0.05 compared to the untreated group on days 2, 3, 4, and 6. 
 
4.2.4 Conclusion 
In this study, the potential of paclitaxel hybrid nanocrystals as a cancer theranostic 
system was evaluated.  Two imaging probes, MMPSense 750 and FPR-648, were 
intended to be physically incorporated in the drug nanocrystals that were formulated by 
crystallization.  Both dyes were imaged at different excitation and emission wavelengths.  
While MMPSense reported the degree of metastasis, the integrated FPR-648 served as a 
tracer for the biodistribution of the nanocrystals in the animals.  At a dose level of 20 
mg/kg, PTX pure and hybrid nanocrystals were as efficacious as Taxol in suppressing the 
growth of MCF-7 xenograft.  Yet, the nanocrystals induced less toxicity than the 
conventional solubilized formulation. The bioimaging capability of the hybrid 
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nanocrystals was limited by the size and impurities of MMPSense.  Despite the likeliness 
that MMPSense molecules may mostly adsorbed to the crystal surface, the study 
demonstrates that hybrid nanocrystals have a great potential to be utilized as a simple, 
versatile, and enabling platform for cancer theranostics.  Studies are under way to explore 
other types of bioimaging modalities, using smaller and purer dyes, which are compatible 
with crystal integration.  Furthermore, to have a better understanding of the optical 
imaging and the release of the optical dyes from nanocrystals, the biodistribution of 
nanocrystals, free drug, and dye molecules will be further investigated. 
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4.3 Evaluation of PTX/Nicardipine Nanocrystals in MCF-7 Xenograft 
4.3.1 Introduction 
Solid tumors generally possess distinctive anatomical and pathophysiological 
characteristics, including extensive angiogenesis, hypervasculature, defective vascular 
architecture, ineffective lymphatic drainage, and increased production of vasculature 
permeability mediators [5, 7, 293]. This phenomenon is known as the enhanced 
permeability and retention (EPR) effect, which has become the basis of modern 
anticancer drug design and strategies. Despite its popularity, limitations associated with 
the EPR strategy still exist: (a) absence of EPR effect in the central area of metastatic 
cancers [294, 295], (b) necrotic tissues or large hypovascular areas in larger tumors (e.g. 
1-2 cm in diameter) [5], and (c) low vascular densities (hypovasculature) in certain 
tumors (e.g. metastatic liver and prostate cancers) [296]. Efforts to intensify the EPR 
effect and achieve more homogenous drug delivery to tumors have been pursued. One is 
through angiotensin II (ATII)-induced hypersensitivity (hydrodynamic enhancement) and 
another is by applying a nitric oxide (NO)-releasing agent.  
(i) By hydrodynamic enhancement of drug delivery. Suzuki [297] and Hori [298, 299] 
demonstrated the irregularity of tumor blood flow. Unlike normal blood flow, that of 
tumor was only seen once within 15 to 20 minutes time frame. It often stopped 
temporarily or flowed in the opposite direction. Maeda et al. employed this knowledge to 
increase the tumor uptake of macromolecular drugs, SMANCS (styrene-
maleic/anhydride-neocarzinostatin), [294, 300] by using ATII infusion.  Upon slow 
intravenous administration of ATII, normal blood vessels experienced systemic 
hypertension as a result of vasoconstriction. In addition, the endothelial cell-cell junctions 
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became tighter, which results in less extravasation of drug into normal tissue. In solid 
tumor, due to defective smooth muscle cells and ATII receptors and large endothelial cell 
gaps, the opposite effect was observed. As a result of increased systemic blood pressure, 
tumor blood vessels dilated and blood flow increased. Overall, the induced systemic 
hypertension resulted in a markedly increased tumor blood flow while that of normal 
tissue remained constant [297]. The positive increment in blood flow was frequently 
accompanied by extravasation of macromolecules. SMANCS, when given with slow 
infusion of ATII, tended to leak out more easily from vessels to tumor tissue, 
demonstrating the enhanced EPR effect [30, 294]. 
 (ii) By applying nitric oxide (NO)-releasing agent. Nitroglycerin (NG) has been used to 
treat angina pectoris (i.e. painful heart condition due to an imbalance of blood and 
oxygen supply). In cardiology, NG liberates nitrite (NO2-), which is then reduced to NO* 
under hypoxic conditions [301]. Similar to hypoxia in cardiac infarct tissue, the tissue 
oxygen tension (pO2) of hypovascular tumor tissues is low, resulting in a decrease in pH 
(more acidic) [302]. Since NO is one of the mediators of vascular permeability, the 
enhancement of the EPR effect could be obtained by applying NG, a NO-releasing agent. 
When NG (≥ 1.0 μg/mouse, up to 1.0 mg/mouse) was applied topically over the tumor or 
skin opposite or distal to the tumor site, a dose-dependent increase in the EPR effect was 
produced [303].  
In this study, we aimed to enhance the EPR effect by entrapping a vasodilation agent, 
which potentially can be released locally near the tumor site, in PTX nanocrystals. We 
shied away from incorporating ATII into the nanocrystals due to its potential to affect the 
entire systemic circulation subsequent to intravenous injection. Additionally, due to the 
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low solubility and stability of nitrates, a calcium channel blocker was chosen to locally 
induce vasodilation instead. Among the class of calcium channel blockers (e.g. 
nifedipine, felodipine, amlodipine), nicardipine has the highest solubility in aqueous 
solution (i.e. adjusted with acetic acid). The molecular structure of nicardipine is 
presented in Figure 4.13. The efficacy and toxicity of PTX/nicardipine hybrid 
nanocrystals were compared to Taxol and PTX pure nanocrystals by evaluating the 
percent change of tumor volume and body weight, respectively, for 7 days after a single 
dose of treatment at 20 mg/kg of PTX. 
 
 
Figure 4.13. The chemical structure of nicardipine. 
 
4.3.2 Materials and Methods 
4.3.2.1 Materials 
Paclitaxel (>99.5%, USP30) was purchased from 21CECPharm (United Kingdom). 
Ethanol (HPLC grade), acetonitrile (HPLC grade), DMSO (dimethyl sulfoxide, ACS 
grade), penicillin streptomycin, and 0.25% trypsin-EDTA were purchased from Fisher 
Scientific (Pittsburgh, PA).  Nicardipine was purchased from Sigma (St. Louis, MO). All 
chemicals and solvents were utilized without further purification.  Deionized water (by 
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Milli-Q®, filtered through 0.2 ?m membrane) was used for all the experiments. 0.050 ?m 
(50 nm) Whatman® Nuclepore polycarbonate track-etched membranes used for filtration 
were purchased from Fisher Scientific (Pittsburgh, PA).  MCF-7 human breast 
adenocarcinoma cells were obtained from American Type Culture Collection (Manassas, 
VA). 
 
4.3.2.2 Preparation of Pure and PTX/Nicardipine Hybrid Nanocrystals 
Pure and hybrid paclitaxel nanocrystals were produced by using an anti-solvent method.  
For the pure nanocrystal, 1 mL of 5 mg/mL of paclitaxel in ethanol was added to 20 mL 
deionized water in a round-bottom flask (500 mL).  The mixture was subjected to stirring 
at 1000 rpm and sonication (sonication bath, F20D, Fisher Scientific) for 10 minutes. The 
stirring rate was changed to 300 rpm for 30 minutes and subsequently to 150 rpm for 30 
minutes. To make hybrid PTX/Nicardipine nanocrystals, 1 mL of 5 mg/mL of 
PTX/ethanol solution were added to 20 mL of 10% aqueous acetic acid containing 5 
mg/mL of nicardipine. After stirring at 1000 rpm for 10 minutes, the speed was adjusted 
to 300 rpm (for 30 minutes) and 150 rpm (for another 30 minutes) in order to minimize 
bubbles formed and encourage entrapment of nicardipine.  After crystallization, the 
solution was filtered through 50-nm polycarbonate membrane, and the retentate was re-
suspended in water for additional filtration-re-suspension cycles to remove nicardipine 
that may potentially adhere to the surface of the crystals.   
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4.3.2.3 Characterization of Nanocrystal Systems 
SEM images were obtained using a Hitachi SEM 4300 at an accelerating voltage of 3 kV.  
Using a sputter coater, samples were coated with conductive layers of gold palladium 
(Au/Pd) for 1 minute with a current of 20 mA.   
 
4.3.2.4 Chemical Analysis 
PTX concentrations were analyzed by high-performance liquid chromatographic (HPLC) 
system (Waters Breeze with a dual wavelength absorbance detector, Waters 2487, and 
multi λ fluorescence detector, Waters 2475) at an absorbance wavelength of 227 nm.  A 
reverse-phase C-18 column (5μm, 150mm×4.6mm, Waters) was used. The mobile phase 
composed of 50% acetonitrile and 50% deionized water was pumped at a total flow rate 
of 1 mL/min.  The column was equilibrated to 35oC prior to sample injection (10 ?L). 
Nicardipine was separated by using a 30:70 mixture of acetonitrile and 0.015M KH2PO4 
aqueous buffer (pH 3.95) at a flow rate of 1 mL/min. The column temperature was 
equilibrated to 40°C. The percent of entrapped nicardipine was determined by dissolving 
the hybrid nanocrystals in ethanol. Standard solutions were prepared by solubilizing 
nicardipine in ethanol. 
 
4.3.2.5 Cell Culture 
The MCF-7 human breast adenocarcinoma cells were cultured with DMEM (Dulbecco's 
Modified Eagle Medium, Hyclone) with 10% fetal bovine serum (Hyclone) and 1% 
penicillin/streptomycin (Hyclone).  Trypsin-EDTA (ethylenediaminetetraacetic acid, 
Mediatech) was used to dissociate cells from the dish.  All the cell culture reagents were 
149 
 
purchased from Fisher Scientific (Pittsburgh, PA).  Cells were cultured at 37 °C in a 
humidified atmosphere with 5% CO2. To establish the MCF-7 xenograft in nude mice, 
cells were harvested (by using 0.25% trypsin-EDTA) when they were 70-90% confluent. 
After being counted, cells were suspended in serum-free DMEM at a concentration 
of5x107 cells/mL. Cell suspensions were kept in ice until their inoculation. 
 
4.3.2.6 Animal Study 
Female nude outbred mice (Tac:Cr: (NCr)-Foxn1 Nu) were obtained from Taconic at 4 
weeks of age (14.5-20 g). All of the animal experiments comply with the principles of 
care and use of laboratory animals and were approved by the University of Kentucky 
Institutional Animal Care and Use Committee (IACUC). Seven days after arrival, one 
17β-estradiol pellet (1.7 mg, 60-day release; Innovative Research of America, Inc.) was 
implanted under the skin between the ears of each mouse. Two days later, 5×106 MCF-7 
cells (100 ?L) were inoculated subcutaneously to each side of the flank. All experimental 
procedures were performed under general anesthesia by isoflurane inhalation. Animals 
were monitored daily for their body weight and tumor volume using a digital caliper. The 
tumor volume was calculated by using the following equation:  
???????????? ? ?
?
?
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A total of 18 mice were randomized into 3 groups (n=6): Taxol, PTX nanocrystals, and 
PTX/nicardipine hybrid nanocrystals. Taxol formulation (3 mg/ml) was prepared by 
diluting 300 ?L of 30 mg/ml of paclitaxel in Cremophore EL/ethanol (50:50) solution 
with 2700 ?L of saline (0.9% sodium chloride). Treatments were administered at day 0 
with a single PTX dose of 20 mg/kg. All animals were euthanized at day 7.  
150 
 
4.3.2.7 Statistical Analysis 
The statistical analysis was performed by Dr. Heidi Weiss’ group in Biostatistics Shared 
Resource Facility (Markey Cancer Center, University of Kentucky). Graphical display of 
percent of change in body weight from the baseline levels were generated for each group.  
Pairwise comparisons at each time point of follow-up were performed using the non-
parametric Wilcoxon rank-sum test to account for non-normality of data. The percent 
change in tumor volume at specific time points was compared between groups using an 
analysis of variance. 
 
4.3.3 Result and Discussion 
4.3.3.1 Characterization and Analysis of Nanocrystals 
The mean particle size of the pure PTX and hybrid PTX/nicardipine nanocrystals (Table 
4.6) analyzed by SigmaScan were 360 ± 120 nm and 370 ± 130 nm, respectively. The 
incorporation of nicardipine did not seem to alter the morphology of the crystal 
significantly. Based on the HPLC analysis, there was 1.18% (w/w) of nicardipine 
entrapped in the hybrid nanocrystals.  
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Table 4.6. SEM images of PTX and PTX/Nicardipine nanocrystals. Scale bars represent 
1 μm. 
PTX Pure Nanocrystals PTX/Nicardipine Nanocrystals 
 
 
 
 
 
4.3.3.2 Animal Studies 
The percent change of tumor volume (Figure 4.14) of PTX pure and PTX/nicardipine 
hybrid nanocrystals were compared to the positive control, Taxol, at the same dose of 20 
mg/kg. Statistically, there was no significant difference (p > 0.05) in the percent tumor 
volume change between the groups. In a 20 mg/kg paclitaxel dose, the 1.18% (w/w) 
entrapment of nicardipine would be equivalent to 0.24 mg/kg, which is approximately 20 
times lower than the typical intravenous dose, 4 mg/kg, administered in murine model 
[304]. The amount of nicardipine entrapped in the hybrid nanocrystals might have been 
too minute, in that it did not alter any therapeutic significance. Additionally, the 
nicardipine that was able to be released from the hybrid nanocrystals may have been 
extensively metabolized hepatically since it is known as a substrate for CYP3A4 and P-
gp [304]. Across the treatment groups, the tumor volume suppression was minimally 
observed, which may be due the fact that the treatments were administered when the 
tumors were rather large (i.e. with an average size of larger than 900 mm3 / flank). A 
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single dose of injection administered during this study may not be sufficient to suppress 
the exponentially-growing tumor xenograft.  
Figure 4.15 depicts the percent change in body weight of the mice in the three groups, 
Taxol, pure PTX nanocrystals, and PTX/nicardipine nanocrystals, monitored 7 days 
subsequent to a bolus treatment on day 0. Although the average body weight change of 
the Taxol group was shifted downwards (i.e. weight loss), there was no significant 
difference (p > 0.05) in the body weight change between the groups. The largest body 
weight difference between the PTX nanocrystals and Taxol groups was at day 6 (p = 
0.17). The toxicity associated with Taxol was most likely due to the exposure of solvents 
(e.g. ethanol and Cremophor EL), which were utilized for solubilization prior to the 
intravenous injection. The percentages of body weight change of PTX nanocrystals and 
PTX/nicardipine nanocrystals were similar. This observation suggested that the minute 
amount of nicardipine incorporated in the nanocrystals did not induce additional toxicity.  
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Figure 4.14. The percent of tumor volume change of animals administered with Taxol, 
PTX nanocrystals, and PTX/Nicardipine nanocrystals (n=6). 
 
 
Figure 4.15. The percent of body weight change of animals administered with Taxol, 
PTX nanocrystals, and PTX/Nicardipine nanocrystals (n=6). 
154 
 
4.3.4 Conclusion 
This study was aimed to incorporate a calcium channel blocker, nicardipine, which can 
serve as a vasodilation agent, in the crystal lattice of PTX nanocrystals. Both PTX pure 
and PTX/nicardipine nanocrystals were produced with anti-solvent method, having a 
rectangular prism-shaped morphology, with an average longest dimension of about 350 
nm. The incorporated amount of nicardipine was equivalent to 1.18% w/w with respect to 
the PTX. Mice bearing MCF-7 xenograft were divided into three groups, receiving a 
single intravenous 20 mg/kg dose of Taxol, PTX nanocrystals, or PTX/nicardipine 
nanocrystals on day 0. Statistical results suggested that there were no significant 
differences (p > 0.5) in the percent change of tumor volume and body weight.  The 
amount of nicardipine that was entrapped in the nanocrystals was most likely too minute 
to exert enhanced macromolecules permeability surrounding tumor and ultimately the 
therapeutic significance. In order to understand the influence of vasodilation agent to the 
EPR effect, it may need to be pre-administered intratumorally prior to the treatment 
injections.  
 
 
 
 
 
 
 
Copyright © Christin Pramudiati Hollis 2012  
155 
 
Chapter 5 - Tumor Accumulation and Tissue Distribution of 3H-Taxol versus 3H-
Paclitaxel/FPI-749 Hybrid Nanocrystals 
 
5.1 Introduction 
In cancer therapy, nanomedicines have been designed to increase the tumor targeting 
efficiency, facilitate controlled drug release, and minimize toxicity, which stems from the 
delivery vehicle(s) and/or lack of target selectivity. In order to reach the target (i.e. 
tumor), the nanomedicines must circumvent a vast number of biological barriers [305], 
which protect the body from the entry of “foreign” materials.  Thus, in order to 
understand the behavior and performance of a nanoconstruct in the biological system, an 
assessment of the pharmacokinetics and biodistributon is essential.   
Nanoconstructs, virtually irrespective of the particle composition [261], may be rapidly 
cleared from the bloodstream by macrophages of the MPS shortly after intravenous 
injection. Macrophages, which are known as professional phagocytes, generate pathways 
of entry of particles into cells by: (a) recognition of opsonization in the bloodstream, (b) 
adhesion to the opsonized particles, and (c) ingestion of the material. During the 
opsonization, foreign materials are tagged by proteins (opsonins) and become visible to 
macrophages. The opsonized particles are then attached to the surface of macrophage via 
distinctive receptor-ligand interaction. At the cellular level, phagosomes are being 
formed, and the cargo is being unloaded throughout the cytoplasm. Eventually, 
phagosomes will emerge with lysosomes to form phagolysosomes, the rate of which 
relies heavily on the combination of particle properties (e.g. size, geometric shape, 
rigidity, and surface properties) [261]. The minimization of opsonization via PEGylation 
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has been mentioned previously in Chapter 4. Particles, which are able to escape from the 
macrophages, are circulated in the blood and ultimately can reach the tumor via the EPR 
effect. 
In order to effectively exert the anticancer therapy, nanovehicles have to release the 
active ingredient into the tumor at an optimum rate (e.g. 3-10% per day [5]). If the release 
rate is too slow then insufficient concentrations of the drug can reach the tumor site. 
Similarly, a fast release rate would lead to a high free drug in the circulation, which could 
generate systemic toxicity, but minimum tumor accumulation [5].  
Relative to normal tissue, tumors are known to lack effective lymphatic drainage [30, 
306-308]. Under normal conditions, the lymphatic system can effectively recover 
macromolecules (e.g. proteins, nanosize drug delivery vehicle) from the interstitial space 
back into the blood circulation. The impaired lymphatic system in tumors, hence, leads to 
lower clearance of macromolecules from the tumor interstitium and longer retention. 
Lipiodol (iodinated poppyseed oil)-solubilized SMANCS (drug) selectively accumulated 
and remained in tumor tissue [306, 307]. Similarly, intravenously administered Evans 
blue/albumin extravasated to the tumor but did not disappear for 1 to 2 weeks [30]. 
Unfortunately, the ineffective lymphatic drainage also leads to an increased interstitial 
fluid pressure (IFP), which limits the convective extravasation of the nanovehicle despite 
the presence of a leaky vasculature. To that end, the tumor’s impaired lymphatic drainage 
could either amplify the ‘retention’ effect or hinder therapy due to the IFP. 
Preclinical pharmacokinetics and biodistribution studies are generally conducted in order 
to understand the behavior and assess the ability of investigational agents to target the site 
of action in vivo. Routinely, the data are obtained from the chemical and/or radioactivity 
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analysis of excised organs and tissues. As an alternative, the use of near infrared 
fluorescence imaging to carry out the aforementioned studies has gained popularity in 
recent years. Optical imaging can provide a convenient, easy, and rapid means of 
assessing the agent’s biodistribution in the excised organs [229, 231, 233, 309]. 
Furthermore, a quantitative, non-invasive whole body biodistribution of fluorescent-
labeled agents has recently been attempted by employing fluorescence molecular 
tomography (FMT) [234].  
Optical imaging in small animals can be generally categorized into two approaches [310-
314]:  
(a) Planar imaging also called fluorescence reflectance imaging (FRI), is based on a 
simple two-dimensional photographic method. Here, the light source is being excited, and 
the reflectance is being detected from the same side of the imaged animals. A laser (e.g. 
light emitting diode or white light source with appropriate low-pass filter), which offers 
high power yet narrow excitation bandwidth, is generally employed as the light source to 
illuminate a large part of the animal or the whole animal. The fluorescent light from the 
tissues is then detected by a highly sensitive charged-couple device (CCD) camera using 
an appropriate emission filter. The detection depth is restricted to a few millimeters due 
to: (i) the constant background noise caused by unattenuated autofluorescence from the 
superficial layer, and (ii) the photon attenuation in the deep tissue due to scattering and 
absorption, specifically by protein, blood (oxy- (HbO2) and deoxyhemoglobin (Hb)), and 
water. For topographical registration, the fluorescence image is typically superimposed 
with the animal photographic image acquired with white light illumination.   
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Reflectance imaging is widely used and can offer a high-throughput imaging and 
screening of surface fluorescence events in vivo or in excised tissue. Besides the fast 
acquisition time, the instrument is safe (no ionizing radiation) and simple to operate, 
relatively inexpensive, and space efficient [313]. However, planar imaging suffers from 
inherent limitations in terms of fluorescent probe localization, accurate quantitation, and 
depth of detection. The fluorescent probe depth and concentration cannot be decoupled, 
in that a strong signal from a deep lesion may appear similar to a weak one generated 
from the surface.  
(b) Tomography imaging offers deeper detection, better quantification and sensitivity, 
and accurate localization. Currently, there are three approaches for generating images in 
optical tomography: continuous wave (CW), time domain (TD), and frequency domain 
(FD) [310, 311]. In CW, the subject’s surface is illuminated by the light source at 
multiple points. The transmitted light measurements collected from various projections 
are then combined with an inverse mathematical model to reconstruct the fluorophore 
volumetric distribution [315, 316]. In TD, a spot on the object of interest is illuminated 
with a sub-nanosecond duration of a laser pulse, and the arrival distribution of photons is 
measured by a fast detector as a function of time at different locations. Besides providing 
spatial intensity distribution, TD system can offer temporal information on the 
fluorescence lifetime [317, 318].  In FD, the subject is illuminated by a radio frequency 
modulated light source. The tomography is reconstructed based on the measurement of 
amplitude attenuation and phase delay of emitted fluorescence light as it propagates to 
tissue [319]. Overall, CW and FD systems are relatively inexpensive, easy to develop, 
and acquire data in a shorter time. The TD, albeit slower, is highly sensitive.   
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The hyper-sensitivity due to modeling errors and statistical noise is one of the current 
limitations of fluorescent tomography [312]. Spatial resolution can also be improved by 
combining with other modalities, such as CT, MRI, or ultrasound, but it shifts the cost 
markedly. Most fluorescence tomography systems can only image one animal at a time, 
which may not permit a high throughput screening for accelerated research. 
The in vivo optical imaging has enabled the visualization of the temporal and spatial 
biodistribution as well as longitudinal imaging of the same animal at multiple time points 
for nanotheranostics.  Although in vivo fluorescence imaging is widely utilized in the pre-
clinical setting, minimum effort has been made to investigate the correlation between 
drug concentration and detected fluorescence signals in ex vivo tissues. 
In this chapter, the tumor accumulation and tissue distribution of tritium-labeled 
PTX/FPI-749 hybrid nanocrystals were compared head-to-head with the conventional 
formulation, (tritium-labeled) Taxol. Detailed studies on Taxol’s pharmacokinetics [320, 
321], biodistribution, metabolism and excretion [322, 323] in murine models have been 
reported in the past. One study also had recently reported the pharmacokinetics and tissue 
distribution of Taxol and a paclitaxel nanosuspension (c.a. 200 nm), produced by high-
pressure homogenization, at a dose level of 10 mg/kg in male Sprague Dawley (SD) rats 
[219]. However, the extent of tumor accumulation of nanocrystals composed of 
chemotherapeutics has not been reported yet. Furthermore, the ex vivo distribution of the 
fluorescence signal detected under optical imaging and radiolabeled PTX were compared.  
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5.2 Materials and Methods 
5.2.1 Materials 
Paclitaxel (>99.5%, USP30) was purchased from 21CECPharm (United Kingdom). 3H- 
Paclitaxel in ethanol (≥ 97% chemical purity, 4 mCi/mmol, 0.145 mCi/mL) was 
purchased from Moravek Biochemicals and Radiochemicals (Brea, CA). FPI-749 
fluorophore (maximum excitation wavelength, ?ex=750 nm; maximum emission, ?em=782 
nm) was obtained from Polyscitech (West Lafayette, IN).  Ethanol (HPLC grade) and 
acetonitrile (HPLC grade) were purchased from Fisher Scientific (Pittsburgh, PA).  All 
chemicals and solvents were utilized without further purification.  Deionized water (by 
Milli-Q®, filtered through 0.2 ?m membrane) was used for all the experiments. 0.050 ?m 
(50 nm) Whatman® Nuclepore polycarbonate track-etched membranes used for filtration 
were purchased from Fisher Scientific (Pittsburgh, PA).  HT-29 human colon 
adenocarcinoma cells were purchased from American Type Culture Collection (ATCC) 
(Manassas, VA). 
 
5.2.2 Preparation and Analysis of 3H-Taxol and 3H-PTX/FPI-749 Nanocrystals 
The majority of the tritium in the 3H-PTX was distributed in the p- and m- positions of 
the aromatic rings. 3H-Taxol was prepared by spiking the Taxol injection concentrate 
containing PTX at 30 mg/mL in a 50:50 (v/v) mixture of Cremophor EL and ethanol, 
with 3H-PTX to achieve a specific activity of 2.058 mCi/mmol. Prior to intravenous 
injection, the stock was diluted with saline (1:9 v/v) to obtain an equivalent concentration 
of 3 mg/mL. 3H-PTX/FPI-749 hybrid nanocrystals were produced by the combination 
approach as previously described in Section 2.2.2. Specifically, 0.7 mL of 1 mg/mL FPI-
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749 was added to 20 mL deionized water in 3-neck round bottom flask (500 mL).  Then, 
1 mL of 5 mg/mL (2.058 mCi/mol) of 3H-paclitaxel in ethanol was added rapidly to the 
flask. The mixture was stirred at 1,100 rpm with a stirrer shaft and under intense 
sonication (in sonication bath F20D, output of 70 W and 42±6 KHz, Fisher Scientific). 
Ice was added to the sonication bath to keep the temperature between 14-18°C. After 10 
minutes of stirring time, the stirring speed was reduced to 600 rpm (10 minutes) and 300 
rpm (10 minutes) to encourage further crystal growth and fluorophore entrapment. The 
sonication bath was turned on for the entire period of the stirring. The flask was removed 
from the stirring station and placed in a vacuum desiccator to remove bubbles generated 
due to rapid stirring. The mixture was then filtered through 50 nm polycarbonate 
membrane. The retentate was re-suspended in water for additional filtration-re-
suspension cycles to remove imaging agents that may potentially adhere to the surface of 
the crystals. The combination of washed retentate (from 16 batches) was re-suspended in 
2.8 mL of DI water and homogenized (Fisher Scientific® PowerGen® 125) for 6 minutes 
at 30,000 rpm. A trial batch of PTX hybrid nanocrystals without any radioactivity was 
produced using a similar method. The sample was analyzed under scanning electron 
microscope (SEM) for size measurement (by SigmaScan). The preparation of the SEM 
sample was similar to that described in Section 2.2.3. 
To quantitate the radioactivity in the dosing preparations, three 10 μL aliquots of 
injection solutions was added into liquid scintillation cocktail and analyzed by a liquid 
scintillation counter, Tri-Carb 2910TR (Perkin Elmer). 
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5.2.3 Cell Culture 
HT-29 human colon adenocarcinoma cells were cultured in McCoy’s 5A medium 
supplemented with 10% fetal bovine serum and 1% penicillin streptomycin in 37°C 
humidified incubator containing 5% CO2. To establish the HT-29 xenograft in nude mice, 
HT-29 cells were harvested (by using 0.25% trypsin-EDTA) when they were 70-90% 
confluent. After being counted, cells were suspended in 50:50 mixture of sterile 
phosphate buffered saline (PBS) and Matrigel (BD Biosciences, San Jose, CA) at a 
concentration of 3x107 cells/mL. Cell suspensions were kept in ice until their inoculation. 
 
5.2.4 Animal Study 
The animal study was conducted under a protocol approved for using nude mice by the 
University’s Institutional Animal Care and Use Committee (IACUC).  Female nude 
outbred mice (Tac:Cr: (NCr)-Foxn1 Nu) were obtained from Taconic at 4 weeks of age 
(14.5-20 g).  Mice were acclimated for one week after arrival. Subsequently, mice were 
anesthetized by isoflurane inhalation for placing ear identification tag and cell 
inoculation. HT-29 xenograft was established by injecting 100 ?L HT-29 cells (3×106) 
subcutaneously to each flank. When tumors became palpable, a total of 111 athymic mice 
were randomized into different groups. Three mice were allocated to receive no treatment 
(control). For the Taxol group, 48 mice were divided into 12 time points (n=4): 5, 15, 30 
minutes, 1, 2, 4, 6, 8, 24 hours, 2, 3, and 4 days. For the PTX hybrid nanocrystals, 60 
mice were divided into group of 4 for 15 time points: 11, 15, 30 minutes, 1, 2, 4, 6, 8, 24 
hours, 2, 3, 4, 5, 6, and 7 days. 3H-Taxol and 3H-PTX nanocrystals were administered 
intravenously once at a concentration of 20 mg/kg via the tail vein. 3H-Taxol and 3H-
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PTX/FPI-749 nanocrystal formulatioins were diluted in saline prior to injection. Each 
mouse received approximately 1 ?Ci of tritium dose per injection. Mice in the PTX 
hybrid nanocrystal group were imaged under IVIS® prior to euthanization. Due to 
transportation and imaging time, the first time point at which animals could be euthanized 
was 11 minutes. Mice were euthanized at pre-determined time points by CO2 
asphyxiation. After performing cervical dislocation, blood, tumor, and major organs (e.g. 
liver, spleen, heart, lungs, and kidneys) were collected and weighed in pre-weighed 
scintillation vials.  
 
5.2.5 Tritium Analysis in Blood and Tissue 
Blood and tissue were prepared according to the protocol established by Perkin Elmer for 
“liquid scintillation counter sample preparation by solubilization”. Blood (0.1-0.4 mL) 
was digested with 1 mL of a mixture of tissue solubilizer Soluene® 350 (Perkin Elmer, 
Waltham, MA) and ethanol (1:1 ratio) and placed in a 50-60°C oven (Fisher Scientific 
Isotemp) for at least 2 hours. After cooling to room temperature, sample was decolorized 
by adding 500 μL (in 100-200 μL aliquots) of 30% hydrogen peroxide solution.  Once the 
reaction subsided, samples were placed back in the oven for another 30 minutes. 15 mL 
of liquid scintillation cocktail (Perkin Elmer) was added to the blood samples, and the 
mixture was vortexed. Samples were allowed to quench for 1 hour in the dark before 
measurement was carried out with a Tri-Carb 2910TR liquid scintillation counter (Perkin 
Elmer). The counting efficiency for blood samples was low, and therefore was subject to 
greater measurement error. 
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Prior to tissue homogenization, 3 mL of deionized water was added to the tumor and liver 
samples while 1 mL water was added to the spleen, heart, lungs, and kidneys. To obtain 
complete tissue digestion, only 50-200 mg of tissue sample was utilized. Thus, 
homogenate (0.5 mL for tumor and lungs, 0.2 mL for liver and kidneys, 1 mL for spleen 
and heart) was digested with Soluene® 350 and placed in 50-60°C oven for at least 4 
hours.  After cooling the digested homogenates, 200 μL of 30% hydrogen peroxide was 
added to decolorize them. Once the reaction subsided, vials were placed back in the 50-
60°C oven for another 30 minutes. Prior to analysis, 10 mL of Hionic-Fluor was added to 
the sample. Samples were allowed to quench for 1 hour in the dark before measurement 
was carried out with a Tri-Carb 2910TR liquid scintillation counter. 
  
5.2.6 IVIS® Imaging 
Prior to euthanization, mice were subjected to IVIS® imaging to potentially visualize the 
extent of PTX/FPI-749 hybrid nanocrystal biodistribution at pre-determined time points. 
Mice were imaged both from the dorsal and ventral side. The following were the 
parameters used for the imaging:  ?excitation: 745 nm, ?emission: 800 nm, exposure 
time: 4 seconds, F stop: 2, binning: medium (8), and field of view (FOV): 13. After being 
euthanized, tumor and major organs were imaged by using the same set of parameters.  
 
5.2.7 Statistical Analysis 
Tumor accumulation measured at specific time points between groups was analyzed 
using analysis of variance, which includes treatment group, time and interaction between 
these two factors in the model.   
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5.3 Results and Discussion 
5.3.1 Characterization of Hybrid PTX /FPI-749 Nanocrystals 
The SEM image of the PTX hybrid nanocrystals is presented in Figure 5.1. Measured by 
SigmaScan (Systat software, San Jose, CA), the averaged longest dimension of the 
crystals was 200 nm. The size of the hybrid nanocrystals was comparable to that of the 
pure PTX nanocrystals, described in Section 2.3.1.  Although particle accumulation in the 
tumor depends on various parameters, including size, shape, surface charge, and 
leakiness of the tumor vasculature , collectively it has been suggested that nanoparticles 
less than 400 nm should be able to take advantage of the enhanced permeability and 
retention (EPR) effect [29]. To that end, these hybrid PTX nanocrystals having a size of 
approximately 200 nm were expected to able to extravasate into the tumor site. 
 
 
Figure 5.1. SEM image of PTX hybrid nanocrystals without any radioactive payload. 
Scale bar represents 1 μm. 
 
  
166 
 
5.3.2 Tissue Distribution by Tritium Analysis 
The normalized tissue distribution of 3H-Taxol (3H-Tax) and 3H-PTX/FPI-749 
nanocrystals (3H-PTX NCs) are presented in Figure 5.2 and 5.3, respectively. Similar to 
previous studies [322, 323], 3H-Tax was distributed extensively to the all the major 
organs and exhibited a non-linear, two compartmental, pharmacokinetic profile. The 
extensive tissue distribution of PTX and solubilizing agents can potentially induce 
profound toxic effects, as suggested by the body weight change (Chapter 4). Compared to 
3H-Tax, 3H-PTX NCs were cleared rapidly from the blood circulation. By 15 minutes 
post-injection, only 0.42±0.12% of injected dose/gram of blood was detected in the 3H-
PTX NCs group as opposed to 2.89±0.24% in 3H-Tax. The significant decrease in blood 
level and high drug concentration in the liver, spleen, and lungs suggested that PTX 
nanocrystals were sequestered by the macrophages of the reticuloendothelial system 
(RES)  most likely within seconds of intravenous administration [324].  Despite the fact 
that close to 40% of the injected dose accumulated in the liver, it has been demonstrated 
repeatedly that the engulfment of nanoparticles by Kupffer cells (specialized 
macrophages) does not adversely affect the safety profile of the drug [129]. Histological 
analysis of rat spleen revealed that intravenously administered itraconazole nanocrystals 
were engulfed by macrophages and resided within the cytoplasm; the number of resident 
macrophages was increased with dose elevation to accommodate the particle burden 
[325]. Specifically for PTX nanocrystals, the MPS deposition also did not seem to expose 
any significant toxicity to the animals. As observed in Figure 4.3 (Section 4.1.3.2), the 
animals treated with PTX nanocrystals experienced the least body weight loss relative to 
Taxol and even control during the survival study in HT-29 xenograft. Similar trends were 
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also noted in Section 4.2.3.2 and 4.3.3.2 (performance evaluation in MCF-7 xenograft). 
 
Figure 5.2. The distribution (% injected dose/gram of blood or tissue) of 20 mg/kg 3H-
Taxol. The term “asap” refers to 5 minutes post-injection time.
 
Figure 5.3. The distribution (% injected dose/gram of blood or tissue) of 20 mg/kg 3H-
PTX/FPI-749 nanocrystals. The term “asap” refers to 11 minutes post-injection time. 
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Administration of higher dose may be possible, and liver may temporarily act as a depot 
site to release the drug back into the circulation.  
Compared with the 3H-Taxol distribution (Figure 5.4.A), 3H-PTX/FPI-749 nanocrystals 
were distributed rapidly to the major organs within the first 11 minutes (Figure 5.4.B).  
Nonetheless, Figure 5.4.B suggested the free 3H-PTX was redistributed from the clearing 
organ (i.e., liver) back to the systemic circulation, especially at the 1- and 6-hour time 
points.  The decreased mean concentration of 3H-PTX in the liver was accompanied with 
an increased mean concentration in the blood.  This observation suggests that there was 
higher concentration of 3H-PTX that was redistributed than being cleared.  Conversely, 
subsequent to the intravenous injection of 3H-Taxol, 3H-PTX concentration in the blood 
circulation continually decreased. The difference in the blood concentrations observed in 
the 3H-Tax and 3H-PTX NCs was also generated due to the micellar entrapment of PTX 
by Cremophor EL in plasma [239]. In Taxol, the free paclitaxel is able to partition 
reversibly into circulating Cremophor EL, which serves as a circulating PK compartment 
in the blood and alters the blood PK. This reversible partitioning also reduces the fraction 
of unbound drug, the form that penetrates into tumor [320].  
The relative amounts of the drug out of every injection in the major organs and tumor 
were also analyzed for both 3H-Taxol and 3H-PTX nanocrystals (Figure 5.5.A and B).  
Within the first 10-15 minutes, the total percentage of PTX in the major organs and tumor 
was only summed up to approximately 50%.  The remainder of the injected dose was 
largely distributed in other tissues, likely due to the lipophilic nature of the drug.  A 
previous study indicated that within 0.5 hour post-injection of Taxol, PTX was found 
mostly in the liver, kidney, lung, spleen, heart, gall bladder (bile), and small intestine 
169 
 
[323]. A good portion was also found in the stomach, dorsal fat, colon, cecum, breast, 
and lymph nodes. It is striking to see that less than 1% of the drug accumulated in the 
tumor.  The comparison of tumor accumulation between the two formulations will be 
further discussed later. 
 
 
 
Figure 5.4. The distribution (mean ± S.D.) of 3H-PTX in female nude mice after a bolus 
intravenous injection of (A) 3H-Taxol and (B) 3H-PTX/FPI-749 nanocrystals at 20 mg/kg. 
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Figure 5.5. The distribution (% absolute amount in blood or tissue/amount injected, 
mean ± S.D.) of 20 mg/kg (A) 3H-Taxol and (B) 3H-PTX/FPI-749 nanocrystals. The term 
“asap” refers to 5 and 11 minutes post-injection time of 3H-Taxol and 3H-PTX/FPI-749 
nanocrystals, respectively. 
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Generally, the macrophages are unable to necessarily identify the nanocrystals, but rather 
recognize specific opsonin proteins bound to the surface of the particles. Opsonins are 
broadly defined as any component of blood serum that assists the process of phagocytic 
recognition [326]. To temporarily circumvent the recognition by the RES, nanovehicles 
are often camouflaged by “PEGylation” (i.e. coating the surface with poly-ethylene 
glycol (PEG) [327].  Though the mechanisms are still controversial, it is believed that the 
ability of PEG to decrease surface charge and/or hydrophobicity, wet the particle surface,  
squeeze out water molecules, and create a repulsive force to inhibit opsonin protein 
binding, play a significant role in prolonging circulation time [326, 328]. 
The nanocrystals used in the study were bare, without any functionalization or adsorption 
by surfactants or polymers.  PEGylation is a common practice to circumvent or delay the 
recognition by the MPS, possibly due to the hydrophilic polymer shell that prevents 
opsonins from attaching to the surface and subsequent phagocytosis [329, 330].  Because 
nanocrystals undergo consistent dissolution no matter how low the solubility is, surface 
decoration by PEGs may not be as effective as other nanosystems (e.g., covalently 
conjugated by the polymers).  There are a few studies where drug nanocrystals were 
stabilized by PEG or PEG block polymers but they were still sequestrated in MPS 
significantly [331-333].  Clearly, it is a challenging task to secure surfactants to the 
surface of nanocrystals, especially during the administration and blood circulation stages. 
. 
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5.3.3 Tumor Accumulation 
Figure 5.6 depicts the comparison between the normalized tumor accumulation 
subsequent to intravenous injection of 3H-Tax or 3H-PTX NCs to athymic mice. The 
maximum tumor accumulation in both treatments was observed during 1 to 6 hours post-
injection. Statistically analyzed by analysis of variance at all time points, the tumor 
accumulation of 3H-Tax was significantly different from 3H-PTX NCs across all time 
points (p<0.0001). Furthermore, the analysis from group*time interaction was not 
significant (p = 0.182), which indicated that there was a consistent difference between the 
treatments across all time points. A major reason for the low tumor accumulation by the 
nanocrystals obviously lies in the short duration in the blood circulation and the quick 
sequestration by MPS.  Elevated tumor intersitial pressure and unique vasculatures of 
HT-29 xenograft may also be responsible.  HT-29 tumors were reported be less vascular, 
for example, than the human colon adenocarcinoma LS174T [334].  The result could be 
attributed to the following factors:  
(1) Elevated tumor intersitial fluid pressure, which is often associated with solid tumors, 
could deter the therapy.  
(2) Less severity and abnormalities in the tumor vessels of HT-29. The pore cut-off size 
of the tumor vasculature has been reported to be dependent on the tumor type and 
histological grade [220-222]. As evidenced by a functional pore size of 1200 to 2000 nm, 
blood vessels of MCa-IV mouse mammary carcinoma are on the high end of the range of 
leakiness for tumors [221]. Three pathways, including openings between the vessel lining 
cells, holes through the lining cells, and endothelial fenestrae, were reported to be 
responsible for the unsual leakiness of MCa-IV tumor vessels [220]. HT-29, in contrast, 
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has been reported to be less vascular than LS174T [335], which has pore size of 400-600 
nm [221].   
 (3) Short distribution half-life (t1/2α) [219] only allowed low concentrations of PTX 
nanocrystals available in the blood circulation and reduced the probability of nanocrystal 
infiltration into the tumor.  
(4) The high intratumoral accumulation of 3H-Tax could be ascribed to the fact that 
Cremophor EL encapsulates PTX as micelles [239]. Thus, the Taxol formulation is not 
necessarily the same as a drug solution (in organic solvent). Our laboratory recently 
compared the tumor accumulation of camptothecin nanocrystals, produced by the anti-
solvent method, with a camptothecin salt solution. The result revealed that camptothecin 
nanocrystals, even with a particle size between 200 and 700 nm (needle-like), were able 
to accumulate significantly in the tumor relative to the salt solution [168].  
Nonetheless, as observed in Figure 5.6, the tumor accumulation of 3H-Tax continued to 
decrease after 6 hours, which corresponded well to the blood concentration. 3H-Tax was 
rapidly cleared from the tumor due to the reversible partitioning of PTX into the 
circulating Cremophor EL, which reduces the free drug amount [320]. Interestingly, the 
tumor accumulation of 3H-PTX nanocrystals after 6 hours was steadily maintained.  It is 
likely that, once the nanocrystals successfully accumulated in the tumor site, they would 
not be cleared easily due to relatively large particle size and ineffective lympathic 
drainage surrounding the tumor.  Also as pointed out earlier, the sequestered nanocrystals 
in MPS continued to dissolve releasing PTX molecules back to the blood stream and 
maintaining the drug concentration in the tumor.  The finding of initial sequestration of 
nanoparticules by phagocytosis followed by slow release is commonly observed [336].  
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Relative to solubilized formulation, nanocrystals are shown to have prolonged half-lives 
of elimination in murine models [331-333, 337, 338].  Thus, it is highly possible that, 
upon multiple injections, drug accumulation in the tumor will become significant, as 
demonstrated by the treatment regimen in the survial study discussed above. 
Needless to say, the EPR effect as observed in this study was minimal.  If the Taxol 
formulation may be regarded as a nanoparticle delivery system because of the possible 
micellar encapsulation of PTX, both nanosystems extravasated to the tumor less than 1% 
of the total injected dose. 
 
 
Figure 5.6. The tumor accumulation (% injected dose/gram of tumor) comparison 
between 3H-Taxol and 3H-PTX/FPI-749 nanocrystals. The “asap” refers to 5 minutes for 
3H-Taxol and 11 minutes for 3H-PTX/FPI-749 nanocrystals. 
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5.3.4 IVIS® Imaging for Non-Invasive Tissue Distribution 
The performance of optical imaging (e.g. IVIS®) as a tool to non-invasively trace the 
tumor accumulation and tissue distribution of hybrid PTX nanocrystals (3H-PTX/FPI-749 
nanocrystals) was evaluated. Prior to euthanization at pre-determined time points, mice 
injected with 3H-PTX/FPI-749 nanocrystals were imaged with the IVIS® Spectrum both 
from the dorsal and ventral sides. The IVIS images obtained from the dorsal and ventral 
sides were compiled in Figure 5.7 and 5.8, respectively. Three mice were allocated as 
controls (no treatment). The near infrared fluorophore FPI-749 (?ex=750 nm, ?em=782) 
was chosen as the optical probe because the contamination with autofluorescence 
decreases for longer wavelengths (i.e. between 650-900 nm) and is significantly lower 
once excitation is longer than 750 nm [312].  
As shown in Figure 5.7, strong peripheral fluorescence signals were detected within the 
first few hours after injection.  There was also an increase in the fluorescence ratio 
between the tumor and peripheral areas starting after 1 hour (Figure 5.8).  This seems to 
be supported by the tumor accumulation data of the tritium-labeled drug that was 
maximized at 1 hour (Figure 5.5.B).  The signal in the tumor site was significant after 1 
day and decreased after 5 days.  From the ventral side, the strongest intensity came from 
the liver area within a few minutes of intravenous injection and remained as the site with 
the strongest fluorescent signal throughout the observation period (Figure 5.8).  After 30 
minutes, the intensity in the bladder area was increased steadily for about 4 hours, 
indicating urinary clearance of the dye.  The signals in the flank areas were also 
noticeable particularly after 8 hours, but significantly weakened after 5 days. 
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Nonetheless, discrepancies existed between the biodistribution results determined by 
tritium labeling and what the whole-body fluorescence imaging indicated.  This is 
particularly pertinent for the tumor sites. While only less than 1% of the injected dose 
was extravasated to the tumor, the IVIS® images (Figure 5.7 and 5.8) indicated strong 
apparent fluorescent signals in the tumor sites. The discrepancies could be caused by 
several reasons.  First, the fluorescent signal is a summation of the contributions by both 
entrapped and freely dissolved dyes.  When most nanocrystals remained un-dissolved, a 
fluorescent image corresponds closely to where nanocrystals reside. However, when 
hybrid nanocrystals dissolved, both free drug and dye molecules were released;   
consequently, the difference in biodistribution between PTX as measured by scintillation 
counting and fluorescence images is expected to become larger. It was observed that the 
majority of the hybrid nanocrystals had been distributed to the liver, spleen, and lungs, 
with only about 1% of the injection remained in blood by 11 minutes. Hence, the 
concentration of nanocrystals that were circulated in the blood was rapidly depleted, 
which might promote a shift in the concentration gradient towards the sink condition. 
From the calculation of complete dissolution for spherical particles under sink condition 
based on Hixson-Crowell presented in Table 1.1, a particle composed of paclitaxel  (i.e. 
assumed to have diffusion coefficient of 2×10-7 cm2/s, solubility of 1 μg/ml, and 100 nm 
radius) would have been dissolved within 4.2 minutes. If aggregation did occur upon 
injection, then the time to reach complete dissolution would be longer. Significant 
numbers of nanocrystals that remained in blood circulation may have dissolved within a 
few minutes, but the sequestered ones may remain in the organs for much longer period. 
Second, because PTX is hydrophobic and the dye is hydrophilic, the two different 
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molecules are expected to have drastically different biodistribution preferences and 
clearance pathways. At 30 minutes after injection, strong fluorescent signal started to 
appear in the urinary bladder area, indicating that free FPI-749 molecules were renally 
cleared and excreted through the bladder.  Meanwhile, the percent of 3H-PTX NCs found 
in the kidney was considerably lower (i.e. more than 50-fold lower than that in the liver).  
Third, planar optical images were collected by superimposing the photographic image 
acquired with white light illumination and emitted fluorescent light detected by highly 
sensitive and low noise charged-couple device (CCD) [311]. The epi-fluorescence signal 
detected by the photographic method can hardly be quantified accurately since the 
fluorophore depth and concentration cannot be clearly differentiated.  Light scattering 
and absorption by blood (oxyhemoglobin and deoxyhemoglobin) and water further 
attenuate the signal particularly emitted from internal organs (e.g. liver, spleen, lungs, 
heart) [339]. Conversely, accumulation of dye in the xenografted tumor (flank) sites, 
which are within surface proximity, appeared to be very strong. This pitfall can be 
partially avoided by using systems that rely on fluorescence tomography-based-imaging 
methods [234], where light-transport models are used as part of the reconstruction 
process aiming at recovering the position of the fluorescence source [312]. 
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Figure 5.7. IVIS® images of the dorsal view of athymic mice injected with 3H-PTX/FPI-
749 nanocrystals. 
 
 
Figure 5.8. IVIS® images of the ventral view of athymic mice injected with 3H-PTX/FPI-
749 nanocrystals. 
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5.3.5 Ex vivo IVIS® Imaging 
Subsequent to euthanization by CO2 asphyxiation, harvested tumor and major organs of 
mice administered with 3H-PTX NCs were imaged under IVIS® (Figure 5.9). In order to 
compare with the normalized tissue distribution of 3H-PTX (Figure 5.3), the total 
fluorescence intensities from individual organs and tumors were normalized by the 
weight of a tissue (Figure 5.10).  While the trends in the liver and spleen between the 
drug distribution and bioimaging were comparable, the fluorescent intensities in the 
tumor, heart, lungs, and kidneys were much elevated.  It is important to note that the 
fluorescence in heart, lungs, and kidneys dissipated rapidly – indicated by the steep 
slopes – implying that the dye molecules were cleared out of the system.  In contrast, a 
temporal delay of clearance in tumor was observed.   
The results further illustrate the limitation of using fluorescence imaging for 
biodistribution detections of drug delivery systems.  When the dye is released from the 
nanocrystals, discrepancy exists.  Still, coherence does exist, particularly in the liver in 
which 40-50% of the hybrid nanocrystals were sequestered by macrophages.  Strong 
fluorescent signals observed also in the spleen and lungs were most likely contributed by 
entrapped FPI-749 from nanocrystals.  The strong intensity in the tumor, nevertheless, 
likely came from released, free dye molecules – for example, from phagocytized 
nanocrystals – that re-entered the blood circulation. Hybrid nanocrystals or dye molecules 
that were trapped on the peripheral blood vasculatures of tumor gave off apparent strong 
fluorescent signals, which are heavily surface-weighted. Moreover, light absorption by 
hemoglobin in the NIR range can present an interference factor as well [340, 341]. 
Blood-rich organs (e.g., liver, spleen, and lungs) are known to attenuate the reflected 
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fluorescent signal the most [339], while tumor tissues, which contain much less 
hemoglobin, do not attenuate as much.  Divergences in the result of tissue distribution 
analyzed by radiolabeled material and optical imaging of excised tissues, especially in 
tumor, have been observed previously [229, 231, 309] .  Thus, extra caution should be 
taken when evaluating the tumor-targeting efficiency of novel therapies by using optical 
imaging.  The apparent high fluorescence signal observed in tumors may not necessarily 
mean that the treatment targets the tumor efficiently.  
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Figure 5.9. IVIS® images of ex-vivo tissues of animals administered with 3H-PTX/FPI-
749 nanocrystals 
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Figure 5.10. The fluorescence distribution (% total efficiency/gram of blood or tissue) of 
20 mg/kg 3H-PTX/FPI-749 nanocrystals. The term “asap” refers to 11 minutes post-
injection time. 
 
 
5.4 Conclusion 
The tissue distribution study showed that 3H-Taxol was extensively distributed to the 
major organs, which could impose systemic toxicity, as observed in the decrease of 
percent body weight change during the survival study (Chapter 4). The 3H-Taxol was 
extensively distributed to major organs, while 3H-PTX/FPI-749 nanocrystals were rapidly 
cleared from the blood circulation by the MPS with more than 40% of the injected dose 
found in the liver.  3H-Taxol was maintained in plasma longer and accumulated in the 
tumor at higher concentrations than 3H-PTX/FPI-749 nanocrystals. Yet, the concentration 
of 3H-PTX in tumor was maintained quite steadily from 8 to 72 hours, suggesting the 
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prolonged retention and possible release of 3H-PTX from engulfed nanocrystals in the 
macrophages.  Still, less than 1% of the injected dose by either Taxol or PTX 
nanocrystals was present in the tumor at any given time point. 
Discrepancies were found between the biodistribution of the drug and the fluorescent 
imaging of the whole body and excised tumor and tissues. Since tissues inherit different 
molecular compositions and structures, they are optically distinctive in light attenuation, 
which translated in consequential divergence in quantitative results. In addition, the 
observed strong fluorescent intensity in the tumor was likely contributed by dissolved 
free dyes that were accumulated in the region. The clearance of fluorescent molecules 
from the tumor was reduced, possibly resulting from the impaired lymphatic drainage.  
There are a few lessons that may be learned from this study regarding further 
development of nanocrystal-based delivery systems, and other systems in general, for 
cancer therapy and diagnosis.  First, the EPR effect for both the solubilized formulation 
and nanocrystals was similar and insignificant with regard to drug accumulation.  If the 
tumor can be regarded as an organ of its own, the drug concentration was much less than 
the concentration in other major organs, especially liver, lungs, spleen, and kidneys.  
Obviously, the results were affected by not just the delivery system, but also by the tumor 
type and its biology.  Still, such a low accumulation (less than 1%) could lead to tumor 
suppression and antitumor efficacy.  Therefore, for cancer therapy, the most critical is 
perhaps not to get more drugs to the tumor, but to reduce drug accumulation in major 
organs or at least to steer the biodistribution away from key organs (e.g., heart and brain) 
to reduce toxic effects.  Drug accumulation in heart following nanocrystal administration 
was significantly less than that achieved with the free Taxol formulation.  On the other 
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hand, the liver appeared to tolerate high accumulation of nanocrystals, and such 
accumulation acted as a depot of the drug and permitted the re-distribution of the drug to 
the plasma and consequently the tumor. 
Second, the difference in the biodistribution between the fluorescent dye and the drug 
indicates that using the optical imaging for the indication of drug distribution can be 
limited and misleading.  This is not only because of the limitation of light penetration by 
the IVIS® system, but also due to the variation in the physicochemical properties of the 
two molecules such as lipophilicity, which likely lead to the differences in 
biodistribution.  As the hybrid nanocrystals started to dissolve and release the dye, the 
observed optical signal was a contribution of both hybrid nanocrystals and free dye 
molecules.  The imaging probe could become more and more diverged from drug 
location as they further distributed. 
Consequently, future development of pure and hybrid nanocrystals for cancer 
theranostics will focus on the control of the biodistribution in major organs.  This may be 
achieved by chemical modification of the surface of nanocrystals.  Furthermore, when 
using hybrid nanocrystals for theranostic purposes, the biodistribution of the 
nanocrystals, free drug, and free probes need to be resolved and differentiated. 
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Chapter 6 - Conclusion and Future Outlook 
 
Nanocrystals have shown promising potentials for drug delivery, particularly for 
delivering poorly soluble anticancer drugs.  Major challenges still remain and must be 
overcome before nanocrystal-based formulation can reach the bench side.  Through the 
advancements in formulation development, nanocrystals with uniform particle size and 
morphology can be produced either via diminution or precipitation approach. However, 
there seems to be a lack of feasible means to minimize opsonization by MPS subsequent 
to intravenous injection. Due to the dynamic process of dissolution (refer to Section 
1.3.4.4), any stabilizer attached to the surface can be detached from the surface during 
blood circulation and extravasation. Also, the physical entrapment of stabilizer in the 
crystal lattice has not yielded significant progress in the past as the addition of stabilizer 
tends to reduce the product yield. The idea of creating a non-sheddable stabilizer for 
nanocrystals [342] could be adapted to the future development of drug nanocrystals.  
When compared to the conventional delivery, Taxol, at the same administration dose, 20 
mg/kg, paclitaxel nanocrystals exerted similar efficacy, but yet with much reduced 
toxicity. Although results of the biodistribution study showed that Taxol, due to the 
micellar encapsulation by Cremophor [320], had better tumor accumulation over PTX 
nanocrystals, the clearance of the latter was temporally delayed. When tested in colon 
cancer HT-29 xenograft, only less than 1% of the intravenously administered dose of 
either Taxol or PTX nanocrystals was recovered in the tumor, indicating limitation of the 
EPR effect [29]. Yet, at such a low drug concentration, treatment led to tumor 
suppression and antitumor efficacy. More than 40% of the injected nanocrystals were 
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being sequestered by the macrophages within the first 10 to 15 minutes and found in the 
liver. Interestingly, the engulfed nanocrystals were able to be re-distributed back to the 
systemic circulation. It is worth noting that the sequestration of intravenously injected 
nanocrystals remains in the specialized macrophages and does not affect the safety profile 
of the drug [129]. Hence, due to its low inherent toxicity, nanocrystal suspension can be 
administered at much higher doses to achieve better therapeutic efficacy. Yet, additional 
studies on various dosing scheme should be explored because frequent injections and/or 
high concentration dosing may not lead to the increase in drug concentration in the tumor 
but in healthy tissues and organs as well. 
In order to obtain an improved theranostic nanocrystals, imaging probes also need to be 
tightly secured, which may be achieved through means chemical modification of the 
surface of nanocrystals. Due to its practicality, optical imaging has been increasingly 
utilized as a tool to trace the distribution of administered nanotheranostics. When a 
fluorophore is being used as an imaging probe, it is crucial that the selected dye either 
stays encapsulated or conjugated with the main component of the particles (e.g. drug 
molecule) for an extended period of time – at least until the theranostic system reaches 
the target (e.g. tumor). If the probe started to dissociate from the carrier, then the 
observed optical signal may not fully reflect the true biodistribution of the system, as the 
physicochemical properties of the carrier and probe may differ. In the case of hybrid 
nanocrystals that were studied, as they started to dissolve and release the dye, the 
observed optical signal was contributed from both entrapped and free dye molecules.  
Although optical imaging can provide a convenient, easy, and rapid means of assessing 
the agent’s biodistribution in the excised organs [229, 231, 233, 309], complications and 
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discrepancies may arise due to the inherent tissue properties. Because different tissues 
inherit distinctive molecular compositions and structures, they are optically distinctive in 
attenuating the light source. Consequently, this translates to divergence in quantitative 
results [339]. One of the determining factors in this deviation is the light interference due 
to absorption by hemoglobin in the NIR range. Blood-rich organs (e.g. liver, spleen, 
lungs, and heart) are known to attenuate the reflected fluorescent signal the most, while 
tumor tissues, which contain much less hemoglobin, do not attenuate light as much. 
Additionally, further complications arise because the spatial resolution of planar imaging 
is limited as the produced imaging information from this system is surface-weighted, in 
that anything closer to the surface will appear brighter [37]. When using hybrid 
nanocrystals for theranostic purposes in the future studies, the biodistribution of the 
nanocrystals, free drug, and free probes need to be resolved and differentiated. 
 
 
 
 
 
 
 
 
 
\ 
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APPENDICES 
 
A.1 Hybrid Camptothecin/Gold Nanocrystals 
A.1.1 Introduction 
The development of multifunctional nanomedicine, which combines the therapeutic and 
diagnostic capabilities, has tremendous potential to revolutionize the future of cancer 
therapy.  By incorporating bio-imaging agent molecules, the delivery of therapeutic agent 
can be potentially monitored and traced in vivo.  Over the past decade, the application of 
fluorescent markers, both organic- and inorganic-based material, has been vastly explored 
[343, 344]. While organic dyes may suffer from limitations, such as photobleaching, 
biodegradation, and narrow excitation/broad emission spectra, the lack of 
biocompatibility and high toxicity hinders the utilization of the inorganic markers [345]. 
In addition, fluorescence imaging is still limited to in vivo studies due to low sensitivity 
and shallow optical path.  Current imaging modalities, including positron emission 
tomography (PET), computed tomography (CT), magnetic resonance imaging (MRI), and 
ultrasound, can provide anatomical patterns and basic information regarding tumor 
location, size, and progression and are still the standard clinical tools [346, 347]. 
Attributed to its availability, efficiency, and cost, X-ray based CT is among the most 
convenient imaging/diagnostic tools in hospitals today [65, 348]. Iodinated aromatic 
molecules are the most commonly contrast agent used in clinics and dominate the X-ray 
contrast media markets [349, 350]. Due to its rapid renal clearance, however, 
approximately 100 to 200 mL of highly concentrated iodinated contrast medium solution 
(ca. 600 mg/mL) are administered intravenously to achieve adequate contrast [349]. 
189 
 
Adverse reactions caused by excessive amount of chemicals have also been reported 
[349, 351, 352]. In the past few years, the feasibility of using gold nanoparticles as a CT 
contrasting agent has been tested in vivo, both through passive [353, 354] or active [65, 
353] targeting.  Within a CT image, one can distinguish the difference between tissues 
based on the degrees of the X-ray attenuation; more X-rays are attenuated in denser 
tissues.  The contrast of structure or fluid within the body can be enhanced by utilizing 
contrast agent, where its attenuation coefficient is determined by the atomic number and 
electron density.  Because gold’s atomic number and electron density (79 and 19.32 
g/cm3, respectively) are higher than iodine (53 and 4.9 g/cm3, respectively), gold gives a 
higher mass attenuation coefficient.  For instance, at 100 keV (a standard X-ray energy 
for diagnostic imaging), gold and iodine have attenuation coefficient of 5.16 and 1.94 
cm2/g, respectively; thus, gold provides about 2.7 times stronger contrast per unit weight 
than iodine.  In addition, the low toxicity and good biocompatibility [64] make gold 
(clusters and nanoparticles) an ideal contrast agent.  More importantly, regardless the 
shape of gold nanoparticles, the only important parameter in CT imaging is the total 
amount of gold per unit volume [65]. The utilization of gold as contrast agent in vivo was 
first reported in 2006 [353], and it is being continually explored. 
In the past two decades, colloidal drug delivery systems (CCDS), including liposomes, 
solid lipid nanoparticles, polymeric nanoparticles, and micelles, have been used to 
formulate highly insoluble antic drugs.  Despite the fact that these systems have been 
extensively studied, various inherent limitations remain.  They generally have limited 
drug loading capacity [16, 355]. Phospholipid-based structures, such as liposomes, may 
also suffer from drug leakage and instability during the preparation, storage, and 
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administration process that can compromise the therapeutic outcomes [24, 25]. As such, 
more physically stable and solvent-free nanocrystals-based formulation may be used for 
delivering antineoplastic drugs and reach the tumor site in the solid form.  This 
multifunctional design may lead to cancer theranostic systems, which can be passively 
targeted to tumor site via enhanced permeation and retention (EPR) effect [6]. The 
fundamental concept of such an integrated crystalline system lies in physical inclusion of 
a bioimaging substance in the crystal lattice of a host drug compound; no chemical 
conjugation is thereby needed.  Herein, the purpose of this report is to demonstrate 
successful incorporation of gold ions or atoms and their clusters in the crystal lattice of a 
chemotherapeutic drug, camptothecin (CPT).  The idea of this novel hybrid nanocrystal 
was inspired by the studies of “dyeing crystals” [235], where organic dyes are imbedded 
in organic crystals.  To the best of our knowledge, purported incorporation of an 
inorganic material into organic nanocrystal lattice for biomedical applications has not 
been previously reported. 
CPT was selected as the model drug because it has a broad spectrum of therapeutic 
activity against various cancer types [356, 357]. Similar to other chemotherapeutic 
agents, CPT has a low solubility in water (ca. 1.2 μg/mL at 25 °C).  It also has a well-
established clinical and been the focus of numerous drug delivery studies since its 
discovery in 1966 [358]. Specifically, the antitumor activity of CPT results from its 
ability to actively target and inhibit the DNA enzyme topoisomerase I (TOP1).  
Unfortunately, the clinical application of the drug remains greatly limited, largely due to 
its inherent instability in solution as well as protein binding in the plasma.  The native, 
biologically active compound may undergo hydrolysis and produce an inactive form 
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(Figure A.1.1).  The ring-open reaction, which converts the lactone to carboxylate, occurs 
above pH 7.  Despite the chemical instability of the molecule, pure CPT nanocrystals 
showed to accumulate in tumor and inflict the antitumor effect, as demonstrated in our 
recent study [168]. In our experiments reported here, preparation and storage of hybrid 
CPT nanocrystals were conducted in pH 4-water to maintain its active lactone form.  
 
 
Figure A.1.1. The two forms of camptothecin (CPT) 
 
A.1.2 Materials and Method 
A.1.2.1 Materials 
Camptothecin (>99%) was purchased from 21CECPharm (United Kingdom); all other 
chemicals and solvents were obtained from Sigma (St. Louis, MO) and Fisher Scientific 
(Pittsburgh, PA). 200-mesh-lacey carbon grids were from Electron Microscopy Sciences 
(Hatfield, PA). 
 
A.1.2.2 Preparation of Hybrid Camptothecin Nanocrystals 
Hybrid of gold nanoparticles and/or gold ions in camptothecin nanocrystals were 
produced by an anti-solvent precipitation method with a simultaneous reducing reaction.  
In detail, to produce hybrid camptothecin/gold nanoparticle nanocrystals, 40 ml of boiled 
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pH 4 water (adjusted with 0.25 M HCl), 3 mL of 1 mM hydrogen tetrachloroaurate, 
HAuCl4, were added in a three-neck-flask. The mixture was stirred at 500 rpm with a 
stirrer shaft and under intense sonication. The stirring speed was subsequently decreased 
in order to minimize bubbles formed and to encourage crystal growth. Next, 0.3 ml of 1% 
trisodium citrate dehydrate aqueous solution was added to the system. While the gold salt 
solution was being reduced, 2 ml of 1 mg/ml camptothecin/dimethyl sulfoxide 
(CPT/DMSO) was added. The system continued to be sonicated and stirred to encourage 
crystal growth and formation of gold nanoparticles. The suspension’s color changed from 
clear to pinkish. To produce hybrid camptothecin/gold ions nanocrystals, the same 
method was performed without the addition of 0.3 ml of 1% trisodium citrate dehydrate 
aqueous solution. In this case, the gold remained as a salt solution, not reduced, and may 
be entrapped to the crystal lattice more homogeneously. In contrast to the hybrid gold 
nanoparticles suspension, the solution and retentate for the gold salt solution remains 
colorless. Once hybrid nanocrystals formed, the crystals were harvested by vacuum 
filtering with a 50 nm polycarbonate nuclepore filter. With vacuum filtration system still 
intact, approximately 5 to 10 ml of pH 4 water was added to wash any gold nanoparticles 
that were not incorporated or attached to the crystals. The product harvested on the filter 
was then re-suspended in pH 4 water by sonicating the filter paper. For further removal of 
gold nanoparticles or ions that were not associated with the crystals, the filtration, 
washing and re-suspension by sonication were repeated three times. Following the final 
filtration process, the product collected on the filter paper was re-suspended in 1 ml of pH 
4 water and diluted with aqua regia mixtures for gold analysis with inductively coupled 
plasma (ICP). Filtrate from each filtration process was also collected for mass balance 
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calculation. Only trace amount of camptothecin and gold nanoparticles were present in 
the second and third filtrate; thus, only the first filtrate was analyzed by ICP. Before 
mixing with the digestion solution, filtrate was concentrated by boiling the water, leaving 
a total volume of 5 ml. The filtration and analysis process are depicted in Figure A.1.2. 
 
Figure A.1.2 The schematic of filtration and harvesting hybrid nanocrystals 
 
A.1.2.3 Chemical Analysis of Hybrid Camptothecin Nanocrystals 
Varian Vista-Pro ICP-OES was utilized to quantify the amount of the gold incorporated. 
1 ml of either the concentrated product or filtrate was digested with 1 ml of freshly mixed 
aqua regia (i.e. a mixture of concentrated nitric acid and hydrochloric acid (1:3 molar 
ratio)) and diluted with 3 ml of deionized water. Standard solutions were prepared by 
using ICP standard for gold (Fisher Scientific, Pittsburgh, PA) diluted with aqua regia at 
concentrations of 0.010, 0.050, 0.1, 0.5, 1, 5, 10, and 50 ppm. Analysis was performed at 
wavelength of 267.594 nm. Quantification of camptothecin was conducted by high-
Original batch 
(40 ml)
Nanocrystal concentrated 1
Filtrate 1 
(concentrated)
Filtrate 2
Filtrate 3
**Filtrate 1 will be concentrated by boiling the water off 
Resuspended (by sonication) 
and washed with pH 4 water  
(5-10 ml)
= analyzed by ICP 
Resuspended (by sonication) 
and washed with pH 4 water  
(5-10 ml)
Harvested product on filter 
paper
Harvested product on filter 
paper
Nanocrystal concentrated 2
Harvested product on filter 
paper
Nanocrystal concentrated 3
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performance liquid chromatography (HPLC, Waters Breeze) with UV detection (Waters 
2487 dual λ absorbance detector) at 256 nm.  A Waters’ Symmetry C18 5 ?m column 
(4.6 x 150 mm) was used at 33oC with a mobile phase of acetonitrile : 2% triethylamine 
aqueous solution adjusted to pH 5.5 with acetic acid (36:64) pumped at a rate of 0.5 
mL/min (Waters 1525 binary pump). 
 
A.1.2.4 Electron Microscopy Imaging and Energy Dispersive X-ray Spectroscopy 
(EDS)  
SEM images were obtained using Hitachi SEM 4300 at an accelerating voltage of 3 kV.  
Prior to visualization, samples were coated with conductive layers of gold palladium 
(Au/Pd) for 1 minute with current of 20 mA in a sputter coater, resulting in 
approximately 15 nm thick coating. The coating helped to reduce sample charging. The 
freeze-dried hybrid nanocrystal suspension was imaged by using JEOL 2010F TEM, 
which is equipped with the Oxford EDS detector. TEM was operated at 200 KeV. 
Scanning Transmission Electron Microscopy (STEM) was performed at high angle 
conditions of approximately 50 mrad, using a 1.7 angstrom high resolution probe.  EDS 
was performed under STEM conditions using a 1 nm analytic probe.  A small amount of 
the freeze dried hybrid nanocrystals were rubbed on the carbon lacey grid and placed in 
the sample holder for imaging. Samples obtained from one-time cycle of washing and re-
suspension was compared to that washed and re-suspended three times. 
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A.1.3 Result and Discussion 
Incorporation of gold in CPT nanocrystals was attempted in two forms, either as gold 
atoms or gold ions.  Both preparations were conducted in a single, physical step, 
eliminating typical multi-step chemical treatment of conjugating bio-imaging agents 
[359, 360]. For the hybrid nanocrystals of camptothecin and gold atoms (e.g. gold 
nanoparticles), chloroauric acid was being reduced at the same time when the nucleation 
of camptothecin nanocrystals started via the anti-solvent method.  The redox was based 
on a simple route developed by McFarland, et al. [361], where citrate aqueous solution 
was added to reduce the chloroauric acid.  Reduced gold was believed to be integrated 
into CPT nanocrystals as individual atoms and/or clusters.  As the reduction progressed, 
the solution changed from clear to pinkish.  Concurrently, a high concentration of 
dissolved CPT in dimethyl sulfoxide (DMSO) nucleated and crystallized as the DMSO 
solution was quickly added to the pH 4 water.  In the case of incorporating gold ions, 
citrate solution was not added.  Thus, without the reduction step, individual or clusters of 
chloroauric acid could be freely entrapped in the crystal lattice of the camptothecin 
nanocrystals.  At the end of each batch process, product was filtered and freeze-dried 
either with (Figure A.1.3) or without (Figure A.1.4) extra washing and resuspension step.  
The hybrid camptothecin nanocrystals had morphology of rectangular thin sheet, with the 
length ranged from approximately 300 nm to 1.5 μm (Figure A.1.3).  The TEM and 
STEM images (Figure A.1.3) clearly showed that gold clusters were incorporated and/or 
attached to the organic nanocrystals with high affinity, even after vigorous washing and 
sonicating (Figure A.1.4).  Visually, the hybrid nanocrystals seem to be aggregated, 
possibly due to the freeze drying process.  The size of the embedded gold atom clusters 
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was approximately 10 nm (Figure A.1.3 and A.1.4), consistent with the size reported by 
McFarland, et al [361]. EDS analysis of the gold clusters in the CPT nanocrystals 
revealed that the expected characteristic peaks of oxygen (O), carbon (C), gold (Au), and 
copper (Cu) were present.  The oxygen and carbon peaks were due to the organic 
material, CPT, and the copper peak was present because it was the material of the sample 
holder and grid. 
 
Figure A.1.3.  CPT/gold hybrid nanocrystals without vigorous washing and filtering: (A) 
TEM images, (B) STEM images. 
A1 A2
B1 B2
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Figure A.1.4.  CPT/gold hybrid nanocrystals with vigorous washing and filtering: (A) 
TEM image, (B) STEM image, (C) EDS analysis.   
 
In the absence of reduction of chloroauric acid during the nanocrystal preparation, 
individual or clusters of gold ions (chloroaurate) were incorporated in the camptothecin 
nanocrystals.  The clusters of these ions were approximately 1.4 nm in size (Figure A.1.5 
B and B*), and the individual gold ions seen as white spots were approximately 2Å in 
diameter (Figure A.1.5 C and C*) with a narrow size distribution.  The white spots are 
believed to be individual gold ions incorporated in the lattice of the camptothecin 
nanocrystals.  If these ions were not imbedded in the lattice, they would have been 
A B
C
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washed off.  The gold ions were also shown to be more homogenously distributed 
relative to that of the reduced gold atoms/clusters (Figure A.1.3 and A.1.4).   
 
Figure A.1.5.  CPT/chloroaurate hybrid nanocrystals with vigorous washing and 
filtering: (A) STEM image of overall structure, (B) high resolution STEM image of 
imbedded gold clusters, (B*) particle analysis of gold cluster, (C) high resolution STEM 
image of imbedded gold ions, (C*) particle analysis of gold ion.  
 
 
Fast Fourier Transform (FFT) image processing was utilized to get more a detailed and 
optimized structure image of the hybrid CPT nanocrystal (Figure A.1.6.).  In this analysis 
a Fourier transform was applied to Figure A.1.6.(A) producing the diffractogram, Figure 
A.1.6.(C)  The diffraction spots were then filtered as in Figure A.1.6.(D), and an inverse 
A B C
B* C*
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Fourier transform applied producing image 5b.  This brings out the CPT lattice planes 
giving a lattice spacing of approximately 4 Å. 
 
 
Figure A.1.6. (A) HR-TEM of hybrid CPT nanocrystals, (B) FFT filtered image using 
diffraction patterns (C and D) of a TEM image of hybrid camptothecin nanocrystals 
 
Moreover, the percent entrapment of gold in the CPT nanocrystals was quantified by 
inductively coupled plasma-optically emission spectrometry (ICP-OES) [362]. Relative 
to the amount of the starting material, 8.11 and 1.31% of gold atoms and chloroauric 
acid, respectively, were present in the hybrid nanocrystals.  The reduction process allows 
neutral gold clusters to form quickly and to be entrapped to the camptothecin 
A B
C D
200 
 
nanocrystals.  On the other hand, chloroaurate incorporation may be relatively limited 
due to its ionized state in the solution and the need to bind a counter ion (most likely, 
proton) prior to the entrapment.  As such, more gold atoms were integrated in the CPT 
nanocrystals.  It is important to note that these nanocrystals were vigorously washed 
under sonication for multiple times so the majority of gold atoms or ions that were 
quantified were embedded inside the nanocrystals as defects. 
 
A.1.4 Conclusion 
Nanocrystal composites of a therapeutic and inorganic contrast agent may have 
multifunctional application even at relatively low loadings of gold.  Because of the 
sensitivity of CT imaging and the high attenuation coefficient of gold, a good contrast-to-
noise images can be obtained at gold concentrations of 100 μg/ml [363, 364], which is 
approximately a hundred times lower than the cytotoxicity of gold nanoparticles. When 
operated at standard X-ray energy of 100 keV, same contrast obtained from iodine-based-
contrast agent can be achieved with one-third-less-dose of gold. It is also important to 
note that even at its low dosing, gold can exhibit longer blood retention (i.e. allowing 
prolonged imaging time) due to its inherent physical property of high molecular weight 
[353]. Additional advantages of maximizing integrity and minimizing clearance of gold 
may be established by its entrapment in nanocrystal structure.  
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A.2 Nanocrystals of ZSTK474 
A.2.1 Introduction 
Certain protein associated with the PI3K/Akt/mTOR signaling, which plays critical role 
in cell proliferation, angiogenesis, and metastasis, is substantially overexpressed in CRCs 
relative to the normal colonic tissue [365, 366]. The findings suggested a new therapeutic 
strategy to specifically target the PI3K/Akt/mTOR signaling pathway. A novel PI3K 
inhibitor, ZSTK474 [2-(2-Difluoromethylbenzimidazol-1-yl)-4,6-dimorpholino-1,3,5-
triazine] (Figure A.2.1), is more potent and stable compared to the two known precedent 
inhibitors, LY294002 and wortmannin [367]. When tested using the COMPARE analysis 
on a panel of 39 human cancer cell lines (termed JFCR39 [368]), ZSTK474 exhibited 
substantially lower mean GI50 (50% growth inhibition) of 0.32 μM than LY294002 and 
wortmannin with GI50 of 7.4 μM and 10 μM, respectively. Nonetheless, ZSTK474 is a 
poorly water soluble compound. Its solubility in water is approximately 1-5 ?M (MW: 
417.41 g/mol).  Thus, in order to achieve sufficient bioavailability, oral dosage form of 
ZSTK474 was administered at high dose (> 100 mg/kg). When ZSTK474 was given 
daily at 100 mg/kg from days 0 to 13 in mouse B16F10 melanomas, tumor growth 
suppression was observe. Further tumor growth inhibition in B16F10 melanomas, A549, 
PC-3, and WiDr xenografts was observed at 400 mg/kg oral administration [367].  
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Figure A.2.1. The chemical structure of ZSTK474. 
 
Although no noticeable toxicity was observed at 400 mg/kg oral dose, mice with WiDr 
colon cancer xenograft experienced significant body weight loss (p:0.009) from day 7 to 
14 during treatments [367]. The drug exposure can potentially be minimized by giving 
intravenous injection at much lower dose. However, the current approach of solubilizing 
poorly water soluble chemotherapeutics in solvents may also yield adverse side effects, 
due to solvent toxicity and non-specific distribution of dissolved molecules to rapidly 
growing cells. Various nano-encapsulation designs, such as liposomes [14, 15], micelles 
[16], solid lipid nanoparticles [17, 18], polymeric nanoparticles [19, 20], and dendrimers 
[21], have been developed to improve tumor-targeting efficiency. They do so by taking 
advantage of the tumor’s enhanced permeation and retention (EPR) effect [7], which 
signifies the poorly constructed blood vessel and ineffective drainage of the lymphatic 
system. However, the design of the aforementioned nanoconstructs can become overly 
complex, resulting in poor carrier stability [24, 25], low drug loading [26], and difficult 
scale-up production. 
With nanocrystal formulation, drug molecules are directly administered as solid, 
crystalline nanoparticles.  There are no solubilizing chemicals, nor encapsulating carriers.  
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The drug loading is nearly 100%; at times, a few percent of surfactants are used.  The 
physical integrity is also superior to other nanoparticle-based systems.  For a poorly 
soluble drug, it is expected that free drug molecules will be slowly dissolved from the 
nanocrystals. All these properties make nanocrystal extremely appealing for delivering 
poorly soluble anticancer drugs. In addition, hybrid nanocrystals [169] can be constructed 
from this nanotemplate by physically entrapping near infrared fluorophore in the crystal 
lattice, offering not only treatment but also non-invasive monitoring of the biodistribution 
in vivo. Thus, the objective of this research is to formulate and characterize both pure and 
hybrid nanocrystals of ZSTK474 nanocrystals. Further studies to evaluate the efficacy 
and performance both in vitro and in vivo models of colorectal cancer were conducted in 
collaboration with Dr. Mark Evers’ (Markey Cancer Center, University of Kentucky) 
laboratory. 
 
A.2.2 Materials and Method 
A.2.2.1 Materials 
ZSTK474 (MW: 417.41 g/mol) was purchased from LC Laboratories (Woburn, MA). 
FPR-648 fluorophore (maximum excitation wavelength, ?ex=648 nm; maximum 
emission, ?em=671 nm) was obtained from Polyscitech (West Lafayette, IN). Dimethyl 
sulfoxide (DMSO, HPLC grade) and acetonitrile (HPLC grade) were purchased from 
Fisher Scientific (Pittsburgh, PA). Saline (0.9% w/v sodium chloride) for injection was 
from Hospira (Lake Forrest, IL). Deionized (DI) water (by Milli-Q®, filtered through 0.2 
?m membrane) was used for all the experiments. 0.050 ?m (50 nm) Whatman® nuclepore 
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polycarbonate track-etched membranes used for filtration were purchased from Fisher 
Scientific (Pittsburgh, PA).   
 
A.2.2.2 Preparation of ZSTK474 Nanocrystals 
The pure and hybrid ZSTK474 nanocrystals were prepared by using the combination 
approach. Briefly, 1 mL of 2.5 mg/mL ZSTK474 (LC Laboratory, Woburn, MA) 
dissolved in dimethyl sulfoxide (DMSO, ACS grade, Fisher Scientific, Pittsburgh, PA) 
was added rapidly to 20 mL of deionized water in a three-neck round bottom flask. The 
mixture was being stirred at 1000 rpm and sonicated for 10 minutes. Ice was added to the 
sonication bath to maintain the water temperature between 12-18°C. The product was 
collected by using 0.05 μm Whatman® nuclepore polycarbonate paper (Fisher Scientific, 
Pittsburgh, PA) in vacuum filtration flask. The retentate was re-suspended in 2-3 mL 
deionized water by utilizing bath sonicator.  To further minimize the particle size, re-
suspended product of ZSTK474 pure nanocrystals was homogenized (Powergen 125, 
Fisher Scientific) for 10 minutes. Homogenized products from multiple batches were 
collected on using 0.05 μm Whatman® nuclepore polycarbonate paper. The retentate was 
resuspended in small volume of deionized water to create a concentrated stock and stored 
in 4°C. Some part of the batch was freeze-dried (LabConco Freeze Dryer 4.5) for further 
solid-state characterization. 
The procedure to prepare the hybrid nanocrystals was the same as that of the pure, except 
that Flamma Fluor FPR-648 (maximum excitation wavelength, ?ex=648 nm; maximum 
emission, ?em=672 nm) was added to deionized water prior to the addition of 
ZSTK474/DMSO solution. Fluorophore (FPR-648) that might adhere to the nanocrystal’s 
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surfaces was removed by subjecting the sample to filtration-resuspension-filtration cycle 
until observed filtrate was clear.  
 
A.2.2.3 Physical Characterization and Chemical Analysis of ZSTK474 
Nanocrystals 
Scanning electron microscope (SEM) images were obtained using Hitachi SEM 4300 at 
accelerating voltage of 3 kV.  Sample was sputter coated with gold palladium (Au/Pd) at 
20 mA for 1 minute prior to analysis. SigmaScan (Systat Software Inc.) software was 
used to obtain an estimate on the longest dimension of the nanocrystals. The average and 
standard deviation was derived from manual measurements of particle size from 
approximately one hundred particles. Particle size of the nanosuspension in deionized 
water was also measured using dynamic light scattering (DLS) Malvern Zetasizer Nano 
ZS. Zeta potential of nanocrystals in 10 mM sodium chloride was also obtained from the 
same instrument. Accumet pH meter 915 (Fisher Scientific) was utilized to measure the 
pH. To assess the crystallinity, X-ray power diffraction was collected on a powder X-ray 
diffractometer (Multiplex, Rigaku) with Cu KR radiation (40 kV, 44 mA). Scans were 
obtained from 5 to 40 2? with step size of 0.02 and scan rate of 0.5°/min. 
Quantitative analysis of ZSTK474 was conducted by high liquid chromatography (HPLC, 
Waters Breeze) with Waters’ Symmetry C18 5 μm column (4.6 x 150 mm) at 254 nm. 
Acetonitrile and water (65:35) were pumped at a total flow rate of 2 mL/min (Waters 
1525 binary pump). 
The entrapment of FPR-648 in hybrid nanocrystals was quantified using IVIS®. Triplicate 
of FPR-648 standard solutions in PBS (i.e. 1, 2, and 5 ?g/mL) were placed in 96-well 
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plate. The fluorescence intensity was plotted against concentration to obtain standard 
curve, and the amount of FPR-648 in hybrid nanocrystals was determined from the linear 
correlation. 
 
A.2.3 Result and Discussion 
A.2.3.1 Characterization and Analysis of ZSTK474 Nanocrystals 
Nanocrystals of ZSTK474, with average size of 400 nm, were produced by the 
combination approach. Nucleation process was initiated when the high concentration of 
the drug solution added to water, where drug was practically insoluble. Although 
ZSTK474 nanocrystals were produced with the same method as the PTX nanocrystals 
(Section 2.3.1), their crystal growth subsequent to nucleation were more substantial.  
Scanning electron microscope (SEM) was utilized to visualize the morphology and 
measure the size of ZSTK474 nanocrystals (Figure A.2.2). The mean of particles’ longest 
dimension in Figure A.2.2 was 395.45 ± 135.97 nm. Due to the elongated shape, DLS 
underestimated the hydrodynamic diameter of the particles, 304.0 ± 10.50 nm. The 
polydispersity index obtained from DLS measurement, 0.153±0.026, was between 0.1-
0.25, indicating that the particle size distribution was narrow [134] and the degree of 
flocculation or aggregation, if any, was minimal. When measured in 10 mM NaCl 
(concentration of 0.1 mg/mL, pH=5.33), the surface charge (zeta potential) of the 
ZSTK474 nanocrystals were slightly negative, -9.57±0.75 mV. Although higher absolute 
value may be more desirable to resist flocculation, the negative surface charge is 
favorable because it has lower probability in inducing hemolytic reaction compared to 
one with positive charge [191]. The sharp peaks in the PXRD diffractogram (Figure 
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A.2.3) indicated that the ZSTK474 nanocrystals were crystalline, which is the most stable 
form relative to that of amorphous. 
 
Figure A.2.2. SEM image of ZSTK nanocrystals. Scale bar represents 2 μm. 
 
Figure A.2.3. Powder x-ray diffractogram of freeze-dried ZSTK474 nanocrystals.  
 
As for the hybrid ZSTK474/FPR-648 nanocrystals, the mean longest dimension analyzed 
by SigmaScan was 492.4 ± 269.30 nm. There was 0.035% (w/w) entrapment of FPR-648 
in the crystal lattice of ZSTK474. Despite the minute percent of entrapment, the 
florescence signal should still be able to be detected by in vivo optical modality (e.g. 
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IVIS®). The hybrid nanocrystals were tested in vivo, in collaboration with Dr. Evers’ 
group.  
 
A.2.3.2 Stability of ZSTK474 Nanocrystals in Different Media 
The stability of ZSTK474 nanocrystals in different media was investigated. To achieve 
similar isotonicity, nanocrystals have to be re-suspended in saline prior to intravenous 
injection. Thus, the change in the particle size of nanocrystals suspension in saline at 
room temperature was evaluated (Table A.2.1 and A.2.2). Results revealed that there was 
no significant difference in the particle size during the three hour suspension period. This 
window should be sufficient as the amount of time taken for intravenous injection is far 
less than this. Based on the SEM images (Table A.2.1), there seem to be a minor 
interaction between nanocrystals and the components of cell culture media in the first 
hour when they were incubated at 37°C.  However, compared to PTX nanocrystals 
(Section 2.3.4), ZSTK474 nanocrystals were more stable as the particle size and 
morphology were not significantly altered during this period. Since there may not be 
strong interaction between ZSTK474 and the components of cell culture media, such as 
albumin, ZSTK474 molecules may be released at slower rate compared to PTX 
nanocrystals.  
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Table A.2.1. SEM images of ZSTK474 nanocrystals suspended in saline (at room 
temperature) and cell culture media (McCoy’s 5A + 10% fetal bovine serum + 1% 
penicillin streptomycin) at 37°C. Scale bars represent 2 ?m.  
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Table A.2.2. The stability study of ZSTK474 nanocrystals in different media. The 
particle size of the nanocrystals were analyzed from the SEM images by SigmaScan. 
Data represents means ± S.D. 
Time 
Particle Size (nm) Measurement 
DI Water  
(Room Remperature) 
Saline 
(Room Temperature) 
Cell Culture Media 
(37°C) 
0.5 hour 450  ?  180 450 ? 190 490 ? 160 
1 hour 460 ? 180 460 ? 220 540 ? 180 
2 hours 430 ? 180 450 ? 170 490 ? 210 
3 hours 430  ? 200 450 ? 170 460 ? 180 
 
 
A.2.4 Conclusion 
Colorectal cancer (CRC) overexpresses proteins that are associated with the 
PI3K/Akt/mTOR signaling. The administration of PI3K inhibitor, such as ZSTK474, can 
target more specifically the CRC site. Due to its low aqueous solubility and oral 
bioavailability, ZSTK474 has to be administered at high dose to achieve sufficient 
efficacy for tumor growth suppression. Here, a stable nanosuspension of pure and hybrid 
ZSTK474 was produced by the combination approach. The nanocrystals are expected to 
exert efficacy at much lower dose in vivo xenograft model.     
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